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ABSTRACT 
Mental illnesses are a substantial burden in Canada and worldwide. Early life conditions and 
experiences make individuals more susceptible to developing diseases. The primary goal of this 
thesis is to understand mental health issues in children and adolescents and to provide a basis for 
prevention planning and policy. The four core studies in this thesis utilize a variety of 
epidemiological methods and data sources. 
 The first study, a systematic review and meta-analysis of longitudinal studies, found that early 
childhood maltreatment is a strong risk factor for the latter onset of depression and anxiety 
disorders. Proportion attributable fractions (PAFs) indicated a very large reduction in depression 
and anxiety could result from reducing childhood maltreatment. 
The second study explored epigenetic changes (DNA methylation) linked to depression. This 
systematic review found inconsistent results for candidate genes (e.g. BDNF, SLC6A4, NR3C1, 
OXTR, and others) and genome-wide studies. There was high heterogeneity in terms of 
experimental and statistical methodologies among the studies. Future studies should apply 
standardized experimental and laboratory methodologies and adopt longitudinal designs to trace 
changes overtime.  
The third study using clinical administrative data examined whether current child and adolescent 
mental health services effectively improved clients’ psychosocial functioning. Treatment was 
found to be effective though the initial severity of the problem affected outcomes. While 
shortening the length of treatment might improve resource use efficiency, it would be detrimental 
to some clients. Personalized treatment is required to meet clients’ specific needs.  
Finally, the potential iatrogenic effects (Bipolar Disorder (BPAD)) of pharmacological treatment 
(stimulant) of children and adolescents for ADHD is examined using a cohort study design and 
provincial administrative data. After adjusting for psychiatric comorbidity, it was found that 
stimulant use by itself does not lead to the development of BPAD, but rather the severity of the 
initial disease and comorbidity are predictors of future BPAD. 
The clear message of this research is that early reduction in risk factor exposure in utero and in 
childhood and adolescence and the early treatment of mental health problems has a very positive 
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effect in reducing the onset and further development of psychiatric diseases and mental health 
problems. 
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CHAPTER 1 - INTRODUCTION 
1.1 Burden of Mental Illness 
Mental illnesses are defined as “alterations in thinking, mood or behavior (or some 
combination thereof) associated with significant distress and impaired functioning” (Government 
of Canada, 2006). Mental disorders have been a rising global burden for health systems from 
1990 to 2010 (Murray, et al., 2012). 
Mental illness is also a leading cause of disability in Canada (Mental Health Commission 
of Canada, 2014; Lim, Jacobs, Ohinmaa, Schopflocher, & Dewa, 2008). They account for nearly 
a quarter (23%) of Years of Life Lost (YLL) due to disability and 13% of YLL due to disability 
and premature mortality in Canada. It is estimated that 1 in 5 Canadians experiences a mental 
health or addiction problem every year (Smetanin, et al., 2011). By 40 years of age, 1 in 2 
Canadians have, or have had, at least one mental illness (Smetanin, et al., 2011). Mental illness 
also causes a heavy economic burden. The costs in Canada were estimated at $51 billion per 
year, which included health care costs, lost productivity, and reductions in health-related quality 
of life (Lim, Jacobs, Ohinmaa, Schopflocher, & Dewa, 2008; Smetanin, et al., 2011). 
People with mental illness and addictions are more likely to suffer from comorbidity of 
other mental or chronic health conditions. For example, people with early onset of depression 
and anxiety disorders are more likely to develop other chronic diseases in adult life, such as 
diabetes, heart disease, asthma, and chronic back pain (Scott, et al., 2011). Conversely, 
depression and anxiety disorders may be a concomitant consequence of the burden of chronic 
diseases or conditions, such as long-term medical conditions (Patten, 2001) and coronary heart 
disease (Frasure-Smith & Lesperance, 2005).
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1.2 A Public Health Perspective on Mental Illness 
In order to reduce the burden of mental and behavioural disorders, the World Health 
Organization (WHO, 2001) suggested that a public health approach would be the most 
appropriate method to respond to the multifaceted etiology, widespread stigma and 
discrimination, and significant treatment gap across the world. There are a number of actions that 
can be achieved, such as formulating policies, assuring universal access to mental health services 
(including health promotion and prevention), ensuring adequate care and protection of human 
rights, promoting healthy lifestyles and reducing risk factors, as well as enhancing research into 
the causes of mental disorders, the development of effective treatment, and the evaluation of 
mental health systems, etc. (WHO, 2001). 
The core of public health is the prevention of disease particularly primary and secondary 
prevention. In order to prevent and intervene in the development of mental illness, knowledge of 
its nature – risk factors, and course and outcome – is needed. While we don’t need a complete 
picture of a disease to effectively intervene to effectively intervene to alter the course of the 
disease, we do need knowledge of significant modifiable risk factors so we can intervene and 
alter the occurrence and trajectory of disease.  
Prevention should be assessable to all, acceptable to the general population and be 
therapeutically and cost effective. One of the principles of a public health perspective is to focus 
on the health of an entire population or population at risk. It aims to provide the maximum 
benefit for the largest number of people and reduce health inequities. Prevention programs based 
on the public health approach are designed to expose a broad segment of a population to 
prevention measures and to reduce and prevent mental disorders at a population-level (WHO, 
2017). The Public Health Agency of Canada (2013) suggested that the ultimate benefits of a 
population health approach should “extend beyond improved population health outcomes to 
include a sustainable and integrated health system, increased national growth and productivity, 
and strengthened social cohesion and citizen engagement”. 
Prevention should also not be harmful or iatrogenic. Iatrogenesis refers to injury or illness 
that result from the actions or activities of healthcare professionals or promoting products or 
services as beneficial to health, that potentially have untoward effects of people affected (Caplan 
& Caplan, 2001; Medical Dictionary, 2009; A Dictionary of Sociology, 1998). Some examples of 
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iatrogenesis include risk associated with medical interventions (e.g. adverse effects of 
prescription drugs, over-use of drugs, drug interaction), medical error, wrong prescription, 
negligence, nosocomial infections, and faulty procedures, techniques, information, methods, or 
equipment (Wikipedia, 2017). 
The psychiatric treatment of some conditions and populations have been considered as 
carrying significant risks for iatrogenesis, such as substance abuse and antisocial youths (Moos, 
2005; Weiss, et al., 2005). It was reported in a systematic review on substance use prevention 
programs that negative effects was found in 17 evaluation studies with 43 negative outcomes. 
Drug prevention programs led to increases in consumption of alcohol use, cigarette use, 
marijuana use, and multiple drug use (Werch & Owen, 2002). Additionally, poorly researched 
social marketing for the prevention of drug abuse may not only be ineffective, but it may also 
result in negative consequences (Sumnall & Bellis, 2007). For example, it was found that the 
higher exposure to the anti-drug advertisements in the US was associated with misperceptions of 
higher prevalence of drug use among young people which are strong predictors of intention to 
drug use (Donaldson, Graham, & Hansen, 1994; Rimal & Real, 2005). Finally, intervention 
programs for youth conduct problems, delinquency, and substance abuse applying group-delivery 
formats, such as group counseling, residential treatment, and school-based intervention 
programs, have been identified as producing iatrogenic effects. Evidence-based treatments were 
recommended to prevent and reduce the iatrogenic effects. Integrating research with clinical 
practice, including impressions, needs, and moderators of intervention outcomes, should also be 
required to guide prevention and treatment decisions (Rhule, 2005). 
1.3 Why Study Children and Adolescents? 
1.3.1 Epidemiology of Mental Illness in Children and Adolescents 
It is reported that 70% of mental health problems have their onset during childhood or 
adolescence (Government of Canada, 2006). Young people aged 15 to 24 are more likely to 
experience mental illness and/or substance abuse than any other age group (Pearson, Janz, & Ali, 
2015). In addition, the usage of health services for mental illness among children and adolescents 
increased from 1996/97 to 2009/10, which may be due to a real increase in the number of cases, 
but may also reflect an increased awareness, detection, and treatment of mental illness among 
children (Public Health Agency of Canada, 2015). 
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The development and diagnosis of mental health issues in children and adolescents are 
somewhat different from those in adults: behaviors that seem not to be a mental disorder at 
young age may develop a serious mental problem at older age; children’s behavior and wellness 
are vulnerable to be affected by their familial environment; and they also lack the cognitive and 
linguistic sophistication to accurately describe their feelings and symptoms (Smetanin, et al., 
2011). 
1.3.2 Life Course Perspective 
The life course perspective, as known as life course approach or life course theory, 
examines how an individual’s early events influence their future decisions and events, such as 
marriage and divorce (White & Klein, 2007), engagement in crime, or disease incidence (Kuh & 
Ben-Shlomo, 1997). Life course epidemiology links adult health and disease risk to physical or 
social exposures during gestation, childhood, adolescence, earlier in adult life, or across 
generations. Early life conditions and experiences, such as poverty, adverse experience, and poor 
early growth, may make individuals more susceptible to developing adult risk factors and/or 
chronic diseases. Therefore, the life course strategies for prevention of chronic conditions 
suggest to intervene as early as possible before damage and disability set in (Factor-Litvak & 
Susser, 2004). 
A population health approach directs investments to those areas that have the greatest 
potential to influence population health status positively. A population health approach is 
grounded in the notion that the earlier in the causal stream action is taken, the greater the 
potential for population health gains (Public Health Agency of Canada, 2013). 
1.3.2.1 Early origins of mental disorders 
A developmental model of the origins of disease, called fetal origins hypothesis, has been 
widely accepted and supported by various epidemiological and epi-genetic studies. The 
hypothesis proposes that the developmental health and wellbeing outcomes for an individual 
from infancy to adulthood are significantly impacted by the conditions in gestation period. For 
example, the association between low birthweight and coronary heart disease has been confirmed 
in longitudinal studies of men and women around the world (Barker, 2007). 
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Another example shows the importance of in-utero influences and the role of early 
attachment and emotional care. Maternal anxiety during pregnancy has been linked to problems 
of infant temperament, behavior, and cognitive development; emotional and behavioral problems 
in children and adolescents; and structural brain changes (Newman, et al., 2016). Newman et al. 
(2016) also indicated that epigenetic modifications, such as DNA methylation, can be one of the 
mechanisms underlying the in-utero effects on fetal development, and the association between 
childhood experience and quality of care and their regulation of psychological well-being. It was 
reported that epigenetic signatures may mediate the associations between childhood adversity 
and long-term alterations in an individual’s stress response and immune system trajectories 
(Bick, et al., 2012). Prenatal “unhealthy diet” was also found to be associated with higher IGF2 
methylation at birth which predicted ADHD symptoms (Rihlaarsdam, et al., 2016). 
1.3.3 Potential for Early Intervention and Public Mental Health Measures 
By understanding mental illnesses and conditions in children and adolescents, it is hoped 
that the potential of mental illness prevention can be maximized by intervening as early as 
possible, even during gestation; resilience from early-life adverse experiences can be promoted 
to reduce their impact in adulthood; and ultimately, the prevalence of mental disorders among 
both children and adults can be decreased, and the burden of health systems can be alleviated. 
1.4 Context of This Research 
The primary goal of this thesis study is to contribute to a further understanding of mental 
health issues in children and adolescents by applying various epidemiological methods, and to 
provide a possible basis for future health prevention planning and policy decision-making. 
This research consists of four major studies targeting primary and secondary levels of 
prevention (see Table 1-1). Two studies regarding as primary prevention identify the risk factors 
of mental disorders and promote prevention on the development of mental disorders. One 
(Chapter 3) is a systematic review on the association between childhood maltreatment (as a 
common psychosocial environmental risk factor for mental illness) and later-onset depression 
and anxiety disorders. Meta-analysis was used to generate a pooled statistical indicator of risk. 
Population attributable fractions were calculated to understand to what extent that depression and 
anxiety incidence can be attributable to child maltreatment. The other risk factor study targeting 
primary prevention examines the association between DNA methylation modifications (as an 
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important biological risk factor affecting gene expression) and depression (Chapter 4). This is a 
systematic review of epigenetic effects using qualitative methods to summarize and compare the 
results across different laboratory factors and methodologies, such as tissues, platform/methods, 
sample size, etc. 
The two other studies are conducted from a secondary prevention perspective controlling 
disease progression and recurrence. Chapter 5 examines the effectiveness of current outpatient 
therapy for children and adolescents with mental health issues in the Saskatoon Health Region, 
and identifies the factors that associated with favorable treatment outcomes. The second 
secondary prevention study examines the association between the use of stimulant medications 
as treatment for Attention Deficit Hyperactivity Disorder (ADHD), a major childhood and 
adolescent psychiatric disorder, and potential adverse outcomes (e.g. bipolar disorder) using a 
longitudinal administrative health data from the Province of Saskatchewan (Chapter 6). Studies 
on potential iatrogenic effects of treatment can be valuable for the prevention of comorbidity and 
other adverse outcomes due to early intervention and treatment. 
Finally, in Chapter 7 the major findings of this thesis are summarized, and strengths and 
weaknesses enumerated, as well implications for mental health policy and intervention in 
children and adolescents’ mental illness/health are identified. 
  
Table 1-1 Summary of major studies in this research 
Title of study Target area Method & analysis Level of prevention 
(Katz & Ali, 2009) 
Maltreatment in childhood substantially 
increases the risk of adult depression and 
anxiety in prospective cohort studies: 
systematic review, meta-analysis, and 
population attributable fractions (Chapter 3) 
Psychosocial & 
environmental risk 
factor; 
Prevention 
Systematic review & Meta-
analysis; 
Population Attributable Fraction 
(PAF) 
Primary - methods to 
avoid occurrence of 
disease either through 
eliminating disease 
agents or increasing 
resistance to disease 
DNA methylation and major depressive 
disorder: a systematic review (Chapter 4) 
Biological risk factor Systematic review - Qualitative 
method 
Predictors of functional improvement in 
children and adolescents treated at child and 
youth mental health and addictions services in 
the Saskatoon Health Region (Chapter 5) 
Outpatient treatment 
outcome 
Descriptive analysis; 
Logistic regression; 
Sign test; 
Confirmative Factor Analysis 
Secondary - methods 
to detect and address 
an existing disease 
prior to the appearance 
of symptoms. 
Stimulant use and adverse events among 
children and youth (Chapter 6) 
Medical treatment; 
Iatrogenic effects 
Descriptive analysis; 
Penalized Maximum Likelihood 
Estimation (the Firth Method) 
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CHAPTER 2 – METHODS AND PROCEDURES 
2.1 Study designs and level of evidence  
Different epidemiological study designs provide information with different quality (Study 
Designs, n.d.). Observational studies, including cross-sectional, cohort, and case-control studies, 
observe and systematically collect information without changing the subjects being observed (no 
intervention.  On the contrary, experimental studies, including randomized controlled trials 
(RCT) and quasi-experimental designs, intervene to change something (e.g., give some patients 
treatment) and observe what happens (Study Designs, n.d.). Figure 2-1 shows the summary and 
the advantages and disadvantages of each design. 
 
Figure 2-1 Summary of designs, showing advantages and disadvantages of each 1 
 
                                                 
 
1 https://www.med.uottawa.ca/sim/data/Study_Designs_e.htm 
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Different study designs also provide different levels of evidence which are integral to 
evidence-based medicine (EBM). Figure 2-2 shows the hierarchy of evidence ranking from 
systematic reviews and meta-analyses as the strongest evidence to case reports and expert 
opinions as the weakest (The Logic of Science, 2016). 
This thesis uses three basic study designs and several epidemiological techniques: 
population cohort design using clinical data (Chapter 5) and administrative data (Chapter 6), 
systematic reviews, both quantitative and qualitative, (Chapter 3 and 4), and population 
attributable fractions (Chapter 3) which is used to estimate the projected effect that reducing the 
prevalence of exposure would have on the incidence and prevalence of disease. 
 
Figure 2-2 Hierarchy of evidence 2 
 
  
                                                 
 
2 thelogicofscience.com 
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2.2 Data Sources 
Data used in this thesis research include both existing datasets, such as large-scale health 
administrative data from the Province of Saskatchewan (Chapter 6) and clinical data from 
Saskatoon Health Region (Chapter 5), and self-collecting data for review studies (Chapter 3 and 
4). 
For systematic reviews (Chapter 3 and 4), data has been collected via computerized 
search and manual search. Computerized search was conducted in various databases, such as 
PubMed, EMbase, Medline, and Cochrane Library etc., using search strategies. Inclusion and 
Exclusion criteria were applied to identify the eligibility of articles. Gray literature and reference 
lists in eligible articles were also be screened to include the most comprehensive articles. 
2.3 Statistical Analysis 
Descriptive analyses (Chapter 5 and 6) were applied to understand demographic and 
clinical characteristics of study populations, such as age, gender, living area, presenting mental 
health problem, referral source, prescription medication, etc. 
Multivariate statistics were also employed. For example, multivariate logistic regression 
models were used for dichotomous outcomes (Chapter 5); Penalized Maximum Likelihood 
Estimation (the Firth Method) which was designed for analyzing rare events with logistic 
regression was also used (Chapter 6). Other analyses utilized include confirmatory factor 
analysis (CFA) which is applied to verify the relationship between observed factors and 
underlying constructs, and sign test for paired data which is used to compare median differences 
when the observations are not normally distributed (Chapter 5). 
With regard to systematic reviews, both quantitative (meta-analysis, Chapter 3) and 
qualitative methods (Chapter 4) were applied respectively in the two studies. Meta-analysis was 
used to combine the results from two or more separate studies to answer a common question. It 
provides more power than separate studies, summarizes numerous and inconsistent findings, and 
investigate consistency of effect across different samples (Higgins & Green, 2011). Qualitative 
methods were used in Chapter 4 of the systematic review on the relationship between DNA 
methylation and depression due to the high heterogeneity existed among the studies included, in 
which case quantitative methods, such as meta-analysis, are not recommended by the Cochrane 
Guidelines.  
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CHAPTER 3 – MALTREATMENT IN CHILDHOOD SUBSTANTIALLY INCREASES THE 
RISK OF ADULT DEPRESSION AND ANXIETY IN PROSPECTIVE COHORT STUDIES: 
SYSTEMATIC REVIEW, META-ANALYSIS, AND POPULATION ATTRIBUTABLE 
FRACTIONS 
 
A version of this chapter has been published as: “Li, M., D'Arcy, C., & Meng, X. (2016). 
Maltreatment in childhood substantially increases the risk of adult depression and anxiety in 
prospective cohort studies: systematic review, meta-analysis, and population attributable 
fractions. Psychological Medicine, 46(4), 717-730. doi:10.1017/S0033291715002743”. My 
contributions to this study included contribution to study design, data collection, quality 
assessment, data synthesis and analysis, and manuscript writing and editing. This chapter also 
includes PAF estimates for Canada that were excluded in the published study. 
  
 15 
 
 
3.1 Abstract  
Literature supports a strong relationship between childhood maltreatment and mental illness but 
most studies reviewed are cross-sectional and/or use recall to assess maltreatment thus being 
prone to temporality and recall bias. Research on the potential prospective impact of 
maltreatment reduction on the incidence of psychiatric disorders is scarce. Electronic databases 
and grey literature from 1990 to 2014 were searched for English language cohort studies with 
criteria for depression and/or anxiety and non-recall measurement of childhood maltreatment. 
Systematic review with meta-analysis synthesized the results. Study quality, heterogeneity, and 
publication bias were examined. Initial screening of titles and abstracts resulted in 199 papers 
being reviewed. Eight high quality articles met eligibility criteria. Population attributable 
fractions (PAFs) estimated potential preventive impact. The pooled OR between any type of 
maltreatment and depression was 2.03 (95% CI 1.37-3.01) and 2.70 (95% CI 2.10-3.47) for 
anxiety. For specific types of maltreatment and depression or anxiety disorders, the ORs were: 
physical abuse OR=2.00 (95% CI 1.25-3.19), sexual abuse OR=2.66 (95% CI 1.88-3.75), and 
neglect OR=1.74, (95% CI 1.35-2.23). PAFs suggest that over one-half of global and one-third of 
Canadian depression and anxiety cases are potentially attributable to self-reported childhood 
maltreatment. A 10-25% reduction in maltreatment could potentially prevent 31.4 - 80.3 million 
depression and anxiety cases worldwide and 124,000 - 325,000 in Canada. This review provides 
robust evidence of childhood maltreatment increasing the risk for depression and anxiety, and 
reinforces the need for effective programs and policies to reduce its occurrence. 
Key words: child abuse, depression, anxiety disorders, projected effect, population 
attributable fraction. 
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3.2 Introduction 
Childhood maltreatment is a major public health and social welfare problem. 
Internationally, it is considered a serious public health, human rights, legal and social issue 
(Butchart et al. 2006). International studies estimate that 1 in 5 women and 1 in 13 of men have 
been sexually abused during childhood, while 25% of all adults report being physically abused 
(WHO, 2014).  
Childhood maltreatment also results in psychological and neurobiological sequelae, 
which may contribute to the emergence of psychopathology (McCrory et al. 2010). It may be 
related to many neurobiological mechanisms: 1) stress systems (Ciccetti & Toth, 2005); 2) 
structural brain differences (Herringa et al. 2013), e.g. hippocampus, amygdala, corpus callosum 
and other white matter tracts, and prefrontal cortex; 3) functional brain differences, e.g. 
hyperactivity of amygdala in response to negative facial affect; and 4) genetics and epigenetics 
of resilience and vulnerability. Maltreatment in childhood has also been found to threaten the 
optimal development of affective processing abilities, attachment relationships, self-system 
processes, peer relationships, and adaptation to school (Ciccetti & Toth, 2005).  
Depression and anxiety disorders are the major causes of morbidity worldwide. 
According to the report on the global burden of disease 2010 (Whiteford et al. 2013), depressive 
disorders contributed most of the burden of mental illness and substance use disorders (42.5%) 
followed by anxiety disorders (15.3%). Depressive disorders also accounted for 40.5% of 
disability-adjusted life years (DALYs) caused by mental illness and substance use disorders, with 
anxiety disorders accounting for 14.6%.  
Previously studies of child maltreatment have shown its significant impact on 
psychological and health outcomes. Child abuse, including physical abuse, sexual abuse, and 
exposure to intimate partner violence, has been associated with a large number of psychiatric 
disorders, including depression, bipolar disorder, generalized anxiety disorder, alcohol and drug 
abuse, suicidal ideation and attempts, etc. (Afifi et al. 2014). Children from abusive families are 
significantly more likely to report depressive symptoms than those from non-abusive homes 
(Toth et al. 1992). 
A number of reviews have also consistently shown the negative immediate and long-term 
psychological effects of the childhood maltreatment. Maniglio (2010, 2012) in systematic 
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reviews of reviews found that child sexual abuse was a significant risk factor for both depression 
and anxiety disorders. In addition, adults abused as children exhibited more posttraumatic stress 
symptoms, cognitive distortion, emotional distress (including depression and anxiety disorders), 
eating disorders, sleep disorders, substance abuse, and avoidance (Briere & Elliott, 1994; Chen et 
al. 2010; Nanni et al. 2012). 
Although previous reviews have shown a significant direct relation between childhood 
maltreatment and depression and anxiety, they either reviewed cross-sectional studies or studies 
that did not have external documentation on child abuse history. Abuse exposure has generally 
been measured via recall methods. Such recall is prone to bias and false memory (Robins et al. 
1985; Taylor & Brown, 1988; Coughlin, 1990; Maughan et al. 1995; Neumann et al. 1996; Hardt 
& Rutter, 2004). A substantial proportion of individuals known to have suffered 
abuse/maltreatment do not report such abuse when interviewed in adult life (Hardt & Rutter, 
2004). Taylor and Brown (1988) indicated that mental health is associated with a filtering out of 
negative memories and/or re-representing them in non-threatening terms. People with good 
functioning in adult life are apt to forget early parental negativity whereas there is a tendency for 
people with poor functioning to retrospectively exaggerate negativity that was not reported 
contemporaneously during childhood (Robins et al. 1985; Maughan et al. 1995). In addition, 
cross-sectional studies cannot identify the temporal relationship between risk factors and 
outcomes. Questions have also been raised concerning the use of rating scales as opposed to 
diagnostic instruments to measure mental illness outcomes. 
Little study can be found regarding the potential impact of reducing childhood abuse in 
decreasing the incidence of psychiatric disorders in a population. Population attributable 
fractions (PAFs) are used to indicate the proportional reduction in a population of a disease 
(incidence or mortality) that would occur if exposure to a risk factor were reduced to an 
alternative ideal exposure level (Rockhill et al. 1998). PAFs have been commonly recognized as 
effective tools to measure the potential effects of risk factors on psychiatric disorders (Sareen et 
al. 2008; Bolton & Robinson, 2010; Barnes & Yaffe, 2011; Meng & D’Arcy, 2013, 2014). 
Northridge (1995) believed that PAFs could help policymakers in judging priorities for public 
health action, intervention planning and decision-making. 
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This study aims to: 1) systematically review the evidence for the association between 
childhood maltreatment and depression and anxiety using longitudinal cohort studies and studies 
with external documented measures of child maltreatment and diagnostic measures of depression 
and/or anxiety; and 2) provide firm estimates of by how much the incidence of depression and 
anxiety in a population would be reduced if childhood maltreatment was reduced. 
3.3 Method 
The process and reporting of results systematic review and meta-analysis were guided by 
the PRISMA guidelines, 2009 revision (Moher et al. 2009), and the Meta-analysis of 
Observational Studies in Epidemiology recommendations (Stroup et al. 2000). 
3.3.1 Inclusion and Exclusion Criteria 
Prior to their inclusion in this review all articles were evaluated taking into account their 
internal validity and the following inclusion and exclusion criteria: 1) be published in English 
within the last 25 years (1990-2014); 2) be a cohort study; 3) did not use subject recall to assess 
maltreatment in childhood 4) gave clear information on the assessment of childhood abuse or 
adverse childhood experience (ACE) (e.g. types of abuse, years of age being abused, assessment 
and ascertainment tools, etc.); 5) use clear diagnosis criteria for depression or anxiety in 
adulthood, specifically DSM and its updates (American Psychiatric Association, 2013), ICD-10 
(World Health Organization, 1992) or other generally accepted diagnostic criteria; 6) provide 
statistical indicators (e.g. relative risk) or original data to estimate the relationship between child 
abuse and depression/anxiety. Most importantly studies that measured exposure to childhood 
maltreatment merely via recall methods or referrals without official documentary support (e.g. 
police records, records from social services, child protective services, and criminal court) were 
excluded because subject recall methods are prone to bias and false memory criticisms. 
3.3.2 Search Strategy 
We conducted computerized searches in the PubMed, PsychINFO, EMBASE, Medline, 
and Cochrane Library databases for the 25-year period from January 1990 to December 2014 for 
published articles. Search strategy is in Appendix 1. In addition, we manually searched other 
resources for other relevant studies. The reference lists of selected articles, review articles on 
relevant topic, and the gray literatures were screened. 
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3.3.3 Data Collection and Quality Assessment 
The full-text article was retrieved for all studies that initially appeared to meet the 
inclusion criteria for further examination. The two review authors (ML and XM) independently 
assessed the articles for eligibility. Any disagreements among reviewers were resolved through 
discussion. Data on author, publication year, journal, sample size, methods, indicators, outcomes, 
comorbidities, adjustments, study design and results were extracted independently by the two 
authors. The Newcastle Ottawa Scale criteria were used to characterize study quality (Wells et al. 
2012). Assessment of study quality is essential for a proper understanding of non-randomized 
studies. One author of the selected articles was contacted for further information. One eligible 
study was excluded because of replication of same sample population and outcomes of interest. 
3.3.4 Data Synthesis 
The reviewed articles were grouped for five analyses: (1) any maltreatment and 
depression, to examine the relationship between any specified and unspecified child 
maltreatment and depression; (2) any maltreatment and anxiety; (3) physical abuse and either 
depression or anxiety disorders; (4) sexual abuse and either depression or anxiety disorders; and 
(5) neglect and either depression or anxiety disorders. We report on each category of analysis 
separately. Studies were involved in multiple separate analyses as their available data dictated. 
3.3.5 Statistical Analyses 
3.3.5.1 Meta-analysis 
The analyses separately generated pooled estimates of the effects of child maltreatment in 
general and specific types of abuse on depression and/or anxiety. We also evaluated 
heterogeneity with DerSimonian and Laird I2 statistics for each category to determine the 
proportion of heterogeneity that is not due to chance (Higgins et al. 2003). Funnel plots and 
Egger’s tests were used to inspect for publication bias (Egger et al. 1997). Compared to funnel 
plot, the Egger’s test provides a more objective way to estimate the reliability of the results. If 
these tests show non-significant heterogeneity, we used fixed effects model, whereas a more 
conservative random effects model was used if we saw the possibility of heterogeneity. 
Sensitivity analysis assessed the influence of each individual study on overall estimates by 
recalculating ORs with each study being removed one at a time. The quality of each study was 
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rated according to the Newcastle-Ottawa Scale, and meta-regression analyses were used to 
examine the impact of study quality on results. STATA, version 12, statistical software was used 
for the analyses. 
3.3.5.2 Calculation of projected effects (PAFs) 
The definition of PAF is the proportional reduction in average disease risk that would be 
achieved by elimination of exposure of interest (Rockhill et al. 1998). It indicates that the 
proportion of people with a disease in a population is potentially attributable to a given risk 
factor by assuming that there is a causal relationship (Benichou 2001). The PAF takes into 
account the strength of the association between the risk factor and the outcome as well as the 
prevalence of the risk factor. It was calculated by the following formula based on previous 
literature (Barnes & Yaffe, 2011; Rockhill et al. 1998; Sareen et al. 2008):  
PAF = 
𝑝(𝑂𝑅−1)
𝑝(𝑂𝑅−1)+1
 
Where p is the population prevalence of the exposure, and OR is the pooled odds ratio of 
outcomes given different categories of child maltreatment. In the present study, worldwide and 
Canadian PAFs were calculated for specific types of abuse. Present worldwide prevalence 
estimates were obtained by the most recent review of a series of meta-analysis (Stoltenborgh et 
al. 2015). Both self-reported and informant prevalence estimates were used to generate self-
reported and informant PAFs, respectively. Informant estimates are from studies collecting data 
from police records, social services, child protective services (CPS), child welfare workers, or 
teachers. Canadian prevalence estimates were obtained by searching journal databases (e.g. 
PubMed, etc.), World Health Organization, and Statistic Canada’s websites. The most recent 
estimates were used. 
Finally, we estimated the total number of depression and/or anxiety cases attributable to 
different categories of child maltreatment by multiplying PAF estimates and the present number 
of cases across the world and in Canada. We also calculated the number of cases that could 
potentially have been prevented if the prevalence of exposure to childhood maltreatment were 
10% or 25% lower than present levels. We also calculated confidence ranges for PAF estimates, 
number of attributable cases, and number of cases potentially prevented by using the 95% CIs 
from the pooled OR estimates. 
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3.4 Results 
3.4.1 Mata-Analysis 
3.4.1.1 Selection of articles 
Figure 3-1 shows the process of study selection. The initial search produced 5,340 titles, 
from which 392 abstracts were reviewed. After reviewing abstracts 199 articles were retrieved 
for full evaluation. Full-text articles were reviewed. The eight articles that met our inclusion and 
exclusion criteria are fully referenced in Appendix 2. 
Table 3-1 presents the detailed data on characteristics of the reviewed articles. Articles 
included in the analysis were assessed for quality using the Newcastle-Ottawa Quality 
Assessment Criteria as well as for the external ascertainment of child to exposure as opposed to 
reliance on self-report measures. All the included studies rated highly in terms of quality (See 
Appendix 3). 
The quality of the data is evident in the fact that none of the study characteristics 
examined had any impact on observed odds ratios in any of the analyses reported here. Nor was 
there any publication bias observed. 
3.4.1.2 Relationship between any maltreatment and depression 
Five articles (Brown et al. 1999; Widom et al. 2007; Danese et al. 2009; Scott et al. 
2012; Cutuli et al. 2013) were included in the analysis to examine the relationship between any 
child maltreatment and depression. Figure 3-2a presents the individual study, pooled estimates, 
and funnel plots that were used to visually assess the presence of publication bias. A random 
effects model was used. 
The pooled OR overall for depression for individuals with any type of child maltreatment 
compared to those without maltreatment history was 2.03 (95% CI 1.37 - 3.01, χ2 = 10.94, I2 = 
63.4%, p = 0.027), indicating those with a child abuse history were 2.03 times more likely to 
have depression than those without such history.  
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5,340 citations 
retrieved from search
3,510 titles reviewed
392 potentially 
relevant study 
abstracts retrieved
199 full text articles 
retrived
8 studies met criteria 
for meta-analysis
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the general 
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Figure 3-1 PRISMA flow diagram – Childhood maltreatment and later depression and/or anxiety 
  
 
 
Table 3-1 Summary of the Studies Attributes 
First 
Author Year Setting Sample Source 
Sample 
Size Type of Exposure 
Age of 
Exposure 
(Year) Ascertainment of Exposure Health Outcome 
Age of 
Outcome 
Assessed (Year) 
Assessment of 
Health Outcome 
Cutuli et 
al. 
2013 USA Children of 
primiparous women 
157 Maltreatment in general Birth to 
17.5 
Observation, caregiver 
interviews, reviews of 
child protection & medical 
records 
Depression 18 – 28 ASCID 
Cutajar 
et al. 
2010 Australia Victoria residents 5,365 Sexual abuse Birth to 16 Official records from 
VIFM 
Anxiety & PTSD 18 and above Diagnosed using 
DSM, then 
transferred Codes 
using WHO-ICD  
Widom 1999 USA General population 1,196 Child abuse in general, 
physical abuse, sexual 
abuse, & neglect 
Birth to 11 Official records from the 
county juvenile or adult 
criminal court 
PPTSD 18 and above NDIS 
Scott et 
al. 
2012 New 
Zealand 
National population 1,413 Maltreatment in general Birth to 17 Official records from CYF  Major depressive 
disorder & anxiety 
16 – 27 WCIDI 
Widom 
et al. 
2007 USA General population 1,196 Child abuse in general, 
physical abuse, sexual 
abuse, neglect 
Birth to 11 Official records from the 
county juvenile or adult 
criminal court 
Major depressive 
disorder 
18 & above N DIS-III-Revised 
Spataro 
et al. 
2004 Australia Victoria residents 3,141,357 Child sexual abuse Birth to 16 Official records from 
VIFM 
Anxiety 18 & above Registered cases 
on the Victorian 
Psychiatric Case 
Register 
Brown et 
al. 
1999 USA General population 776 Child maltreatment in 
general, neglect, physical 
abuse, sexual abuse 
Non-
specify 
(“Youth”) 
Official records from 
NYSCR & retrospective 
self-report 
Depressive 
disorder 
Non-specify 
(“Young adult”) 
N DISC 
Danese 
et al. 
2009 New 
Zealand 
Members of the 
Dunedin Multi-
disciplinary Health 
and Development 
Study 
1,037 Childhood maltreatment 
in general 
Birth to 10 Retrospectively self-report 
& assessment from 
cumulative index 
Major depressive 
disorder 
32 DDSM-IV 
VIFM, Victorian Institute of Forensic Medicine; CYF, Child, Youth and Family Agency; NYSCR, New York State Central Registry for Child Abuse and neglect; PTSD, Post-traumatic stress disorder; SCID, 
Structured Clinical Interview for DSM disorders; DSM, Diagnostic and Statistical Manual of Mental Disorders;  WHO-ICD, WHO International Diagnostic Interview; DIS, National Institute of Mental Health 
Diagnostic Interview Schedule; CIDI, WHO Composite International Diagnostic Interview; DISC, National Institute of Mental Health Diagnostic Interview Schedule for Children 
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Figure 3-2 Odds ratios between childhood maltreatment and depression and/or anxiety and 
funnel plots. 
In the funnel plots, the X-axis shows the logarithmic scale of odds ratio estimate for each study 
and Y-axis is standard error of the logarithmic function of the odds ratio. The dashed line 
represents the 95% confidence interval and the point estimate of logarithmic transition of odds 
ratio illustrates as the solid line. OR = odds ratio. 
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c. Relationship between physical abuse and depression and/or anxiety 
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As shown in the funnel plot in Figure 3-2a, all the studies were within the domain, which 
represents 95% confidence interval limits around the estimate. No asymmetry was shown in the 
funnel plot. There was no evidence of publication bias in this meta-analysis (Egger’s test, p = 
0.46). 
Sensitivity analysis was also used to assess the influence of each study on overall 
estimates by omitting one study at a time. The analysis yielded with/without childhood 
maltreatment ORs ranging from 1.69 (95% CI 1.09 -2.64) to 2.24 (95% CI 1.33 - 3.79). The 
combined OR was 1.91 (95% CI 1.27 - 2.85), which clearly indicates the experience of 
childhood maltreatment was a risk factor for depression. 
3.4.1.3 Relationship between general maltreatment and anxiety 
Four articles (Widom, 1999; Spataro et al. 2004; Cutajar et al. 2010; Scott et al. 2012) 
were used to examine the relationship between any type of child maltreatment and anxiety 
disorders. Figure 3-2b shows the individual study and pooled estimates, and funnel plots. A 
random effects model was used. 
The pooled OR overall for anxiety for individuals who experienced any type of child 
maltreatment compared to those who did not was 2.70 (95% CI 2.10-3.47, χ2 = 6.65, I2 = 54.9%, 
p = 0.084), indicating that those who experienced child abuse were 2.70 times more likely to 
have anxiety disorders in adulthood than those who did not experience. 
The funnel plot in Figure 3-2b showed that all the studies were within the domain of 95% 
confidence interval limits around the estimate. No asymmetry was found in the funnel plot. No 
evidence of publication bias was found in this meta-analysis (Egger’s test, p = 0.26). 
Sensitivity analyses found that with/without childhood maltreatment ORs ranging from 
2.65 (95% CI 1.91 - 3.68) to 3.11 (95% CI 2.34 - 4.13). The combined OR was 2.84 (95% CI 
2.19 - 3.68), clearly indicating that childhood maltreatment experience was a risk factor for 
anxiety disorders. 
3.4.1.4 Relationship between physical abuse and depression or anxiety 
Three articles (Brown et al. 1999; Widom, 1999; Widom et al. 2007) were used to 
examine the relationship between physical abuse and either depression or anxiety disorders. 
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Figure 3-2c presents the individual study, pooled estimates, and funnel plots. A random effects 
model was used. Analysis using a fixed effects model did not affect the results. 
The pooled OR for depression and/or anxiety for individuals who were physically abused 
in childhood compared to those who were not was 2.00 (95% CI 1.25 -3.19, χ2 = 2.98, I2 = 
32.9%, p = 0.225), indicating that children who were physically abused were 2 times more likely 
to develop depression or anxiety in adulthood than those who were not. 
The funnel plot in Figure 3-2c indicated that all the studies were within the domain of 
95% confidence interval limits around the estimate. No asymmetry was found in the funnel plot. 
No evidence of publication bias found in this meta-analysis (Egger’s test, p = 0.449). 
Sensitivity analysis produced with/without physical abuse ORs ranging from 1.71 (95% 
CI 0.83 - 3.53) to 2.41 (95% CI 1.05 - 5.54). The combined OR was 1.96 (95% CI 1.02 - 3.78), 
indicating that childhood experience of physical abuse was an important risk factor for 
depression and anxiety disorders. 
3.4.1.5 Relationship between sexual abuse and depression or anxiety 
Five articles (Brown et al. 1999; Widom, 1999; Spataro et al. 2004; Widom et al. 2007; 
Cutajar et al. 2010) were included in the analysis of the relationship between sexual abuse and 
depression and anxiety disorders. Figure 3-2d presents the individual study and pooled estimates, 
and funnel plots. A random effects model was used. 
The pooled OR overall for depression and anxiety for individuals sexually abused in 
childhood compared to those who were not was 2.66 (95% CI 1.88 - 3.75, χ2 = 9.06, I2 = 55.9%, 
p = 0.06), indicating that children experienced sexually abuse were 2.66 times more likely to 
develop depression or anxiety in adulthood than those without such experience. 
As shown in Figure 3-2d, the funnel plot indicated that all the studies were within the 
domain of 95% confidence interval limits around the estimate. No asymmetry was found in the 
funnel plot. No evidence of publication bias found in this meta-analysis (Egger’s test, p = 0.417). 
Sensitivity analysis yielded with/without sexual abuse ORs ranging from 2.75 (95% CI 
1.81- 4.16) to 3.16 (95% CI 2.35- 4.27). The combined OR was 2.96 (95% CI 2.22 - 3.95), 
showing that childhood experience of sexual abuse was a strong risk factor for depression and 
anxiety disorders. 
 28 
 
3.4.1.6 Relationship between neglect and depression or anxiety 
Three articles (Brown et al. 1999; Widom, 1999; Widom et al. 2007) contributed to the 
analysis of the relationship between neglect and depression and anxiety disorders. Figure 3-2e 
presents the individual study and pooled estimates, and funnel plots. A fixed effects model was 
used. 
The pooled OR overall for depression and anxiety for individuals experienced neglect 
compared to those did not experience neglect was 1.75 (95% CI 1.37 - 2.24, χ2 = 1.08, I2 = 0.0%, 
p = 0.58), indicating that children who experienced neglect were 1.75 times more likely to 
develop depression or anxiety in adulthood than those who were not neglected. 
As shown in Figure 3-2e, the funnel plot indicated that all the studies were within the 
domain of 95% confidence interval limits around the estimate. No asymmetry was found in the 
funnel plot. There was no evidence of publication bias found in this meta-analysis (Egger’s test, 
p = 0.284). 
Sensitivity analysis for with/without neglect ORs ranged from 1.70 (95% CI 1.07 - 2.70) 
to 1.91 (95% CI 1.04 - 3.51). The combined OR was 1.76 (95% CI 1.13 - 2.75), pointing to 
childhood experience of neglect as a significant risk factor for depression and anxiety disorders.  
3.4.2 Projected Effects (PAFs) 
3.4.2.1 World wide 
3.4.2.1.1 Self-reported prevalence of child maltreatment and PAFs 
 In 2014, the worldwide self-reported prevalence of physical abuse is 22.6% (Stoltenborgh 
et al. 2015). Worldwide depression and anxiety disorders are estimated to affect 350 million 
(WHO, 2012) and 273 million adults (Vos et al. 2012), respectively. The PAF estimate used here 
for the effect of physical abuse on the incidence of depression and anxiety disorders was 18.4%, 
which indicates that nearly 115 millions of depression and anxiety cases are potentially 
attributable to childhood physical abuse (Table 3-2). If the global prevalence of physical abuse 
was reduced by 10%, we estimated that there would be 9.5 million fewer depression and anxiety 
cases worldwide, whereas a 25% reduction could reduce prevalence by 24.6 million cases 
(Figure 3-3). The numbers of cases attributable to any specific type of abuse and any specific 
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mental disorder maybe an overestimate due to the existence of co-morbidity among mental 
disorders and the potential for an individual to suffer multiple types of abuse. 
The self-reported prevalence of sexual abuse is 12.7% based on the Stoltenberg et al. 
(2011 & 2015) meta-analysis. Approximately 17.4% (over 108 million) of depression and 
anxiety cases in the world are potentially attributable to sexual abuse in childhood. If the 
prevalence of sexual abuse was reduced by 10%, about 9.1 million cases could potentially be 
prevented; a 25% reduction in sexual abuse prevalence could potentially prevent about 23.4 
million cases worldwide. 
It was estimated that 16.3% and 18.4% of worldwide population respectively have been 
exposed to physical and emotional neglect (Stoltenborgh et al. 2015). Our meta-analysis suggests 
about 10.8% (67 million) and 12.0% (75 million) of depression and anxiety cases respectively 
are potentially attributable to physical and emotional neglect. A 10% of reduction in the 
prevalence of physical neglect could potentially lower the number of cases of depression and 
anxiety by 6.1 million globally; this number would increase to 15.4 million if the prevalence 
physical neglect were reduced by 25%. Similarly, around 6.7 and 16.9 millions of cases of 
depression and anxiety, respectively could be prevented by a 10% and a 25% reduction in the 
prevalence of emotional neglect. 
Adding up specific types of maltreatment, over half (58.59%) of depression and anxiety 
cases worldwide were potentially attributable to childhood maltreatment. A 10% reduction in 
child maltreatment could potentially prevent 31.36 million depression and anxiety cases, and a 
25% reduction could potentially prevent 80.28 million cases. 
 
  
 
Table 3-2 Depression and anxiety disorders cases attributable to specific types of childhood maltreatment worldwide 
 
Pooled OR (95% 
CI) 
 Self-report  Informant 
Population 
Prevalence 
of 
maltreatment 
PAF (confidence range) 
Number of cases 
attributable – millions 
 (Confidence range) 
Population 
Prevalence 
of 
maltreatment 
PAF (confidence range) 
Number of cases 
attributable – 
millions 
 (Confidence range) 
Physical abuse vs. Anxiety 
and/or depression 
2.00 (1.25, 3.19) 22.60% 18.43% (5.35%, 33.11%) 114.84 (33.32, 206.26) 0.30% 0.30% (0.07%, 0.65%) 1.86 (0.47, 4.07) 
Sexual abuse vs. Anxiety 
and/or depression 
2.66 (1.88, 3.75) 12.70% 17.41% (10.05%, 25.88%) 108.47 (62.63, 161.26) 0.40% 0.66% (0.35%, 1.09%) 4.11 (2.19, 6.78) 
Physical neglect vs. Anxiety 
and/or depression 
1.74 (1.35, 2.23) 16.30% 10.76% (5.40%, 16.70%) 67.06 (33.62, 104.05) -- -- -- 
Emotional neglect vs. 
Anxiety and/or depression 
1.74 (1.35, 2.23) 18.40% 11.98% (6.05%, 18.46%) 74.66 (37.69, 114.98) -- -- -- 
OR, odds ratio; PAF, Population Attributable Fraction. 
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Figure 3-3 Potential depression and anxiety cases that could be prevented through child 
maltreatment reduction worldwide 
 
 
 
Figure 3-4 Potential depression and anxiety cases that could be prevented through child 
maltreatment reduction in Canada 
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3.4.2.1.2 Informant prevalence of child maltreatment and PAFs 
The informant prevalence of physical abuse was 0.3% (Stoltenborgh et al. 2015). It is 
estimated that 0.3% (nearly 1.9 million) of depression or anxiety cases are potentially 
attributable to childhood physical abuse. A 10% to 25% reduction of the prevalence could 
potentially prevent 190,000 to 460,000 of depression and anxiety cases. 
It reported that 0.4% of the worldwide population have been exposed to sexual abuse 
based on informant studies (Stoltenborgh et al. 2015). The PAF estimate is 0.66%, which 
indicates that 4.1 millions of depression and anxiety cases are potentially attributable to the 
exposure of sexual abuse in childhood. If the prevalence of sexual abuse was reduced by 10%, 
about 410,000 cases could potentially be prevented; a 25% reduction could potentially prevent 
about 1,020,000 cases. 
3.4.2.2 Canada 
As of 2008, the Canadian prevalence of child maltreatment in general was estimated at 
36% (Public Health Agency of Canada, 2010). There are 3.2 million people aged 15 years and 
above in Canada suffering from depression in 2012 (Statistics Canada, 2013). The PAF estimate 
for child maltreatment leading to depression was about 27.1%, corresponding to nearly 870,000 
depression cases potentially attributable to childhood maltreatment (Table 3-3). If the prevalence 
of child abuse was 10% lower than at present, we estimated that there would be 60,000 fewer 
depression cases across Canada, whereas a 25% reduction could result in 170,000 fewer cases 
(Figure 3-4). 
It was reported that 2.4 million people aged 15 years and above in Canada were affected 
by anxiety disorders in 2012 (Statistics Canada, 2013). Approximately 38.0% (910,000) of 
anxiety disorders in Canada are potentially attributable to some form of child abuse. If the 
prevalence of child abuse was reduced by 10%, about 60,000 anxiety disorder cases could 
potentially be prevented, while a 25% deduction in prevalence could potentially prevent about 
160,000 cases. 
The prevalence of physical abuse in Canada is estimated at 7.3% (Public Health Agency 
of Canada, 2010). We calculated that 6.8% (380,000) of depression and anxiety cases are 
potentially attributable to physical abuse. A 10% of reduction in the prevalence of physical abuse 
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could result in 40,000 fewer cases and a 25% of reduction could lead to a further decrease of 
50,000 cases.  
The prevalence of childhood sexual abuse in Canada was estimated at 1.11% as of 2008 
(Public Health Agency of Canada, 2010). The PAF estimate indicated that around 1.8% 
(100,000) of depression and anxiety cases are potentially attributable to sexual abuse in 
childhood. Ten thousand cases could be potentially prevented by reducing the prevalence of 
sexual abuse by 10%; and the number of prevented cases could be more than doubled if the 
prevalence reduced by 25%. 
It was estimated that approximately 12.3% of people in Canada experienced neglect in 
childhood (Public Health Agency of Canada, 2010). PAF estimates indicate about 8.3% 
(470,000) of depression and anxiety cases are potentially attributable to neglect. If the prevalence 
of neglect reduced by 10%, about 40,000 cases could potentially be prevented, while a 25% 
deduction of prevalence could potentially prevent about 110,000 cases. 
Together, 31.79% of depression and anxiety cases in Canada are potentially attributable 
to child maltreatment in general. If the prevalence of child maltreatment reduced by 10%, 
123,656 depression and anxiety cases could potentially be prevented, while a 25% reduction of 
prevalence could potentially prevent 325,442 cases in Canada.
  
 
Table 3-3 Depression and anxiety disorders cases attributable to specific types of childhood maltreatment in Canada 
 
Population 
Prevalence 
of maltreatment 
Pooled OR 
(95% CI) 
PAF (confidence range) 
Number of cases 
attributable – millions 
 (Confidence range) 
Any Maltreatment vs. Depression 36% 2.03 (1.37, 3.01) 27.05% (11.75%, 41.98%) 0.87 (0.38, 1.34) 
Any Maltreatment vs. Anxiety 36% 2.70 (2.10, 3.47) 37.97% (28.37%, 47.07%) 0.91 (0.68, 1.13) 
Physical abuse vs. Anxiety and/or depression 7.30% 2.00 (1.25, 3.19) 6.80% (1.79%, 13.78%) 0.38 (0.10, 0.77) 
Sexual abuse vs. Anxiety and/or depression 1.11% 2.66 (1.88, 3.75) 1.81% (0.97%, 2.96%) 0.10 (0.05, 0.17) 
Neglect vs. Anxiety and/or depression 12.27% 1.74 (1.35, 2.23) 8.32% (4.12%, 13.11%) 0.47 (0.23, 0.73) 
OR, odds ratio; PAF, Population Attributable Fraction. 
3
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3.5 Discussion 
This meta-analyses consistently showed significant relationships between various types 
of maltreatment and depression and/or anxiety outcomes. The pooled OR between any type of 
maltreatment and depression was 2.03 (95% CI 1.37-3.01) and 2.70 (95% CI 2.10-3.47) for 
anxiety. For specific types of maltreatment and depression or anxiety disorders, the ORs were: 
physical abuse OR=2.00 (95% CI 1.25-3.19); sexual abuse OR=2.66 (95% CI 1.88-3.75); and 
neglect OR=1.75 (95% CI 1.37-2.24). 
Consistent with previous reviews, our results show childhood maltreatment is a risk 
factor for depression and anxiety disorders. Several meta-analyses, using less rigorous criteria for 
the measurement of maltreatment exposure, evaluating the short- and long-term effects of 
various types of childhood maltreatment on mental health support our finding that all types of 
child maltreatment are associated with an elevated risk of developing psychological disorders, 
including depression and anxiety disorders (Maniglio, 2009; Paolucci et al. 2010; Nanni et al. 
2012; Norman et al. 2012). 
To the best of our knowledge, this is the first paper to provide quantitative estimates on 
the projected reduction of mental disorders cases that could result from a reduction in child 
maltreatment. The PAFs estimate that over half of depression and anxiety cases worldwide and 
approximately 32% of cases in Canada are potentially attributable to self-reported childhood 
maltreatment. A 10% to 25% reduction in child maltreatment could potentially prevent 31.36 to 
80.28 million depression and anxiety cases worldwide and 123,656 to 325,442 cases in Canada. 
Approximately 9 million cases are attributable to informant child physical or sexual abuse. A 
10% to 25% of reduction in the informant prevalence of child abuse could potentially prevent 0.4 
to 1 million cases.  
Both self-reported and informant worldwide prevalence have strengths and limitations. 
An obvious drawback of self-reported is the reliance on retrospective memory, which is often 
seen as unreliable and could be biased; whereas informant reports are often reflecting the most 
severe cases of maltreatment. Informant measures could better assess the continuity and 
circumstances of maltreatment experiences, such as neglect or emotional abuse; while self-
reported measures work better for some types of maltreatment, such as sexual abuse, which may 
be more invisible to informants. Additionally, the prevalence from informant studies is 
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considered as an underestimate since they are substantially based on reports by professionals to 
Child Protection Services and cover shorter periods of childhood (usually a one-year period), 
compared to self-report studies. However, a conclusion as to whether self-report prevalence rates 
are over- or underestimates is less clear-cut. It could overestimate when emotional abuse or 
neglect is measured without taking into account the chronicity of the maltreated behaviors; it 
could also underestimate when abuse is measured at a single time point (Fergusson et al. 2000; 
Stoltenborgh et al. 2015). 
  PAFs estimates provide quantitative measures of the impact that could be achieved by 
reducing the prevalence of child maltreatment on depression and anxiety. Our study strongly 
suggests that decreasing the amount of maltreatment in childhood should be the target for mental 
illness prevention and mental health promotion. This is not only because adverse experiences in 
childhood significantly increase the risk of adult depression and anxiety, but also its own threats 
to children’s psychological and neurobiological sequelae. Interventions and services for 
maltreatment should also promote resilience to further improve the mental health of general 
populations. 
3.5.1 Strength and Limitations of the Current Study  
The strengths of this study come from the pooled the findings from longitudinal cohort 
studies with the external proof of documented child maltreatment, thus avoiding the issue of 
recall bias, effort after meaning and potential false memories. The studies reviewed here used 
strong mental health measures, are relatively recent, and were of good quality. PAF estimates 
show how the incidence of depression and anxiety could be decreased by reducing childhood 
abuse. 
There are several limitations. Firstly, the small numbers of articles reviewed is an 
obvious limitation. It is unfortunate that more studies did not meet our stringent 
inclusion/exclusion criteria. Secondly, the studies reviewed are not representative of large 
sections of world’s population with the study samples coming from the USA (4), Australia (2), 
and New Zealand (2). Studies from developing countries are lacking. PAFs measures used the 
global prevalence of child abuse (in general and individual type), which is more generalizable. 
Therefore, PAFs measures may be influenced by the inconsistent measures between global 
prevalence of maltreatment and associations between maltreatment and depression and anxiety. 
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Thirdly, heterogeneity was found to be high in the studies reviewed indicating substantial 
variation in the degree of association between child maltreatment and mental health outcomes 
reported in the various studies. This reinforces the need for standardization in the measurement 
of child maltreatment and its various types. It also may indicate that there are significant 
moderators that influence the maltreatment and mental health relationship. There is a need for 
better tracking of potential moderators in future studies of the effects of childhood abuse. 
Fourthly, this review only included studies without subject recall bias in maltreatment 
assessment. The nature of these abuse reports often deals with more severe cases. Because the 
prevalence of child abuse was not provided for severity levels, we used the crude prevalence to 
calculate PAF. The estimates of PAFs may be influenced by the severity levels of child abuse. 
Finally, most selected studies did not report whether outcome of interest was present at baseline, 
except one study. No randomized clinical trials can be performed for the relationship between 
maltreatment and depression and anxiety. This systematic review is an observational study to 
explore the association between child abuse and adulthood depression and anxiety. No causality 
could be inferred, as there is a lack of data on baseline depression and anxiety.  
Using externally documented measure of maltreatment thus avoiding potential recall 
biases, this systematic review provides robust evidence about the effects of childhood 
maltreatment on the subsequent incidence of depression and anxiety in adulthood. The calculated 
PAFs showed the large reduction in the incidence of depression and anxiety that could result 
from reducing the prevalence of child maltreatment. This analysis reinforces the need for legal, 
health and social services programs and policies aimed at reducing the prevalence of childhood 
maltreatment. 
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Appendix 1  Search Strategy 
To get maximum number of relevant citations, we used the following search strings: ‘child’ 
AND (depress* OR anxiet* OR phobi* OR panic OR PTSD OR post-trauma* OR posttrauma* 
OR OCD OR obsessive* OR agraphobi*) AND (abus* OR maltreat* OR neglect OR abandon* 
OR illtreat* OR ill-treat* OR mal-treat* OR advers* OR trauma* OR ACE*)’ as the keywords 
for study retrieval. 
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Appendix 3 Assessment of Studies Quality Characteristics 
First Author Year 
Represen-
tativeness1 
Selection of 
control2 
Ascertainment 
of exposure to 
child abuse3 
Assessment of 
exposure4 
Assessment of 
outcome5 
Temporality6 
Adequacy of 
follow-up of 
cohorts or 
response rate7 
Was 
follow-up 
long 
enough8 
Appropriate 
analysis9 
Appropriate 
confounding 
control10 
TOTAL 
Cutuli et al. 2013 0 1 1 1 1 0 1 1 1 0 7 
Cutajar et al. 2010 1 1 0 2 1 1 1 1 1 0 9 
Widom 1999 1 1 1 2 1 0 1 1 1 1 10 
Scott et al. 2012 1 1 0 2 1 0 1 1 1 0 8 
Widom et al. 2007 1 1 0 2 1 0 1 1 1 1 9 
Spataro et al. 2004 1 1 0 2 1 0 1 1 1 1 9 
Brown et al. 1999 1 1 0 1 1 0 1 1 1 1 8 
Danese et al. 2009 1 1 0 1 1 0 1 1 1 1 8 
1Representativeness of the population: population-based representative = 1; Not representative, selected group, volunteers, or no description = 0. 
2Selection of the non-exposed cohort/control: drawn from the same population =1; drawn from a different source or no description =0. 
3Assertainment of exposure to child abuse: data on child abuse collected prospectively, or collected retrospectively although the official reports were generated in real-time = 1; data on child abuse collected 
retrospectively = 0.  
4Assessment of exposure: all cases from secure official record (court-substantiated abuse) = 2; cases partially from secure official record = 1; self-reported or structured interview or self-administered 
questionnaire or no description = 0. 
5Assessment of outcome: use of structured clinical interview for DSM-III/IV (DIS, DISC, CIDI) = 1; questions from published health surveys/screening instruments, own system, symptoms described, no system, 
not specified, or self-reported = 0. 
6Demonstration that outcome of interest was not present at start of study: yes = 1; no = 0. 
7Adequacy of follow-up of cohorts or response rate: completeness good (>= 80%), with description of those lost to follow-up = 1; completeness poor (< 80%) or no statement = 0. 
8Was follow-up long enough for outcomes to occur: yes = 1; no = 0. 
9Appropriate statistical analysis: yes = 1; no = 0. 
10Appropriate methods to control confounding: yes (multivariable adjusted OR including SES, education, or family dysfunction in models) = 1; no (univariate analysis or controls for age/sex only) = 0. 
CIDI, Composite International Diagnostic Interview; DIS, Diagnostic Interview Schedule; DISC, Diagnostic Interview Schedule for Children; SES, socioeconomic status. 
doi:10.1371/journal.pmed.1001349.t002 
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CHAPTER 4 – WHAT DO DNA METHYLATION STUDIES TELL US ABOUT 
DEPRESSION: A SYSTEMATIC REVIEW  
 
A revised version of this chapter will be submitted for publication. The target journal initially is 
Molecular Psychiatry.  
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4.1 Abstract 
Background. While there has been a few reviews conducted to explore the association between 
DNA methylation modification and the etiology of depression, there has  been no comprehensive 
review of epigenetic studies of depression critically exploring experimental methodologies and 
verification of laboratory testing factors that  may significantly affect the accuracy and validity 
of results. This systematic review corrects for this knowledge deficit. 
Methods. Electronic databases and grey literatures up to June 2016 were searched for English-
language studies with clear criteria for diagnosis of depression. Fifty seven articles met our 
eligibility criteria and included in this review along with a summary of study characteristics. We 
grouped the findings into etiological and treatment studies according to the following genomic 
attributes: (1) BDNF; (2) SLC6A4; (3) NR3C1; (4) OXTR; (5) other candidate genes; (6) 
genome-wide; and, (7) treatment response. 
Results. Majority of the studies were recently published and from developed countries. Whole 
blood and saliva samples were the most common tissues used in study analyses. Bisulfite 
conversion, along with pyrosequencing, were widely used to test DNA methylation level across 
all studies. High heterogeneity existed among the studies in terms of experimental and statistical 
methodologies and study designs. Given such heterogeneity it is recommended that a systematic 
review without meta-analysis be undertaken.  Inconsistent findings were identified in each study 
subgroup. The majority of the studies on BDNF (10/11) and nearly half of studies on SLC6A4 
(5/11) showed that an increased DNA methylation was associated with depression. Significant 
(with both hyper- and hypo-methylation) and insignificant relationships were found in all other 
subgroups. 
Conclusion. This review generally supported that DNA methylation changes is associated with 
depression. It is suggested that more longitudinal studies using standardized experimental and 
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laboratory methodologies are needed in future epigenetic studies to enable more systematical 
comparisons and quantitative synthesis. 
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4.2 Introduction 
A number of systematic reviews on susceptible genes and gene by environment 
interactions provide a comprehensive list of putative genetic and environmental risk factors for 
major depressive disorder (MDD) (Levinson, 2006; Lohoff, 2010; Shyn & Hamilton, 2010; 
Saveanu & Nemeroff, 2012; Cohen-Woods, Craig, & McGuffin, 2013; Dunn, et al., 2015). 
However, there has been little compilation of our knowledge of DNA methylation and 
depression. Furthermore, there has been no comprehensive review of epigenetic studies in 
depression critically exploring experimental methodologies and verification of laboratory testing 
in humans, which may significantly affect the accuracy and validity of results.  
To fill this information gap, and provide a critical update on recent findings of DNA 
methylation in depression, we aimed to: 1) systematically synthesize major findings on DNA 
methylation and depression; 2) compare similarities and differences across different studies, 
including experimental and laboratory factors and statistical analyses, which might partially 
explain some inconsistencies in results; and, 3) comment on the challenges and opportunities for 
future studies. 
4.3 Background  
4.3.1 The Ubiquity of Depression 
Major depressive disorder (MDD) is one of the most prevalent mental disorders. The 
Global Burden of Disease 2012 systematic review of 291 diseases and injuries in 21 world 
regions from 1990 to 2010 concluded that MDD accounted for 2.5% of global DALYs and its 
ranking increased from 15th to 11th (Murray, et al., 2012). MDD is not only commonly known 
for its impact on health and wellbeing, but also has an economic impact on absenteeism, loss of 
productivity, unemployment, and health care expenditure.  
Studies have consistently found that genetic and psychosocial environment substantially 
contribute to the risk of depression (Saveanu & Nemeroff, 2012; Silberg, et al., 1999; Rice, 
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Harold, & Thapar, 2001). However, replications of these research findings have been hampered 
by phenotypic and genetic heterogeneities, thus even occurs in large-scale genome wide 
association studies (Lewis, et al., 2010; Shi, et al., 2011; Akula, et al., 2010; Muglia, et al., 
2010). It is now generally accepted that the pathogenesis of MDD not only includes genetic, 
psycho-socio environmental factors and their interactions, but also involves epigenetic 
modifications, especially those altered by DNA methylations. DNA methylation has been 
identified in a number of studies as an etiological and diagnostic biomarker for many mental 
disorders (Dempster, et al., 2011; Fuchikami, et al., 2011; Walker, et al., 2016; Kaminsky, et al., 
2012). Both genetic and environmental factors can affect the extent of DNA methylation. DNA 
methylation also integrates the impact of both genetic and environmental factors on the potential 
downstream functional outcomes on a phenotype (Lienert, et al., 2011; Schadt, 2009).  
4.3.2 Gene Expression and Epigenetics 
A number of gene have been putatively linked to major depression. A gene is a string of 
DNA encoding information and hiding in a cell’s nucleus. Gene expression refers to the process 
of synthesizing the information in a gene to produce functional gene products which can be 
proteins or non-proteins, such as transfer RNA (tRNA) or small nuclear RNA (snRNA). Gene 
expression consists from several steps, including transcription, RNA splicing, translation, and 
post-translational modification. Genes are expressed by being transcribed into messenger RNA 
(mRNA), and then be translated into protein via tRNA (Wikipedia, 2016). 
The regulation of gene expression is crucial to an organism’s development. It ensures the 
genetic information in DNA is properly interpreted and allows the genotype to give rise to 
organism’s phenotype. Genes can interact with and respond to organism’s environment. External 
environmental factors or endocrine signals (Nguyen, Nioi, & Pickett, 2009) may cause 
modification of regulatory proteins (Paul, 2008) and intracellular signals (Los, Maddika, Erb, & 
Schulze-Osthoff, 2009), thus further affecting regulation of gene expression. 
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Epigenetics refers to the external changes in a chromosome, which affects transcription 
and gene expression, and alters the heritable phenotype. Epigenetic modifications of gene 
expression include alterations in DNA methylation – the addition of a methyl group which 
prevents certain genes from being expressed, and histone modifications (Dalton, Kolshus, & 
McLoughlin, 2014; Rettner, 2013; Ennis, 2014). Histones are proteins that DNA wraps around. 
Modifications that squeeze DNA tightly making the DNA unable to be “read” by the cell; on the 
contrary, relaxed histones can make the DNA accessible to be “read” (Rettner, 2013). Epigenetic 
modifications can be potentially caused by many outside stimulus from chemicals to lifestyle 
factors, such as Bisphenol A (BPA), exercise, and child abuse and other forms of early trauma 
(Ennis, 2014). DNA methylation is the most studied epigenetic modification, and can change the 
activity of a DNA segment turning genes “on” or “off” without change in the DNA’s sequence 
(Dalton, Kolshus, & McLoughlin, 2014). 
4.3.2.1 DNA methylation 
DNA methylation is the reversible and heritable attachment of a methyl group to a 
nucleotide. The most common form of DNA methylation occurs at the 5´carbon of cytosine in 
CpG dinucleotides, creating 5-methylcytosine. CpG dinucleotides are often located in CpG 
islands (clusters of CpG sites) within the promoter region or first exon of genes, or upstream 
from genes within CpG island shores (DNA regions within 2 Kb of CpG islands) or shelves 
(within 2 Kb of shores) (Jones, 2012). Two of DNA's four bases, cytosine and adenine, are found 
to be able to be methylated. Figure 4-1 shows an example of cytosine methylation which is 
widespread in both eukaryotes and prokaryotes (Wikipedia, 2017). DNA methylation is a key 
epigenetic mechanism in developmental regulation of gene expression, and plays an important 
role in transcriptional regulation of genes and miRNAs (Lopez-Serra & Esteller, 2012), control 
of alternative promoter usage (Laurent, et al., 2010), and alternative splicing (Laurent, et al., 
2010). 
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Figure 4-1 Cytosine methylation 
 
4.3.3 The Mediating Role of DNA Methylation Modification in the Relationship between 
Early Life Experience and Later On Psychiatric Disorders 
Significant associations between early life exposure and psychiatric disorders have been 
consistently reported by various epidemiological and epigenetic studies (Moffitt & Tank, 2013; 
Danese, et al., 2008; Vythilingam, et al., 2002; Kessler, et al., 2010). Early life conditions and 
experiences, such as poverty, adverse experience, and poor early growth, can make individuals 
more prone to developing physical and psychiatric diseases. A developmental model of the 
pathogenesis of disease - fetal origins hypothesis, proposes that the developmental health and 
wellbeing outcomes for an individual from infancy to adulthood are significantly impacted by 
the conditions during gestation, as in the association between low birth weight and coronary 
heart disease that has been confirmed in longitudinal studies of men and women around the 
world (Barker, 2007). 
Various studies have demonstrated that early life exposures are also associated with DNA 
methylation modifications, such as the history of childhood abuse (McGowan, et al., 2009), 
exposure to intimate partner violence during pregnancy (Radtke, et al., 2011), prenatal maternal 
depressive symptoms (Oberlander, et al., 2008), poor maternal care (Unternaehrer, et al., 2015), 
and early life socioeconomic status (Lam, et al., 2012). Early life, as an especially sensitive 
period, critically affects the structure and function of the genome, and this effect is not limited to 
the brain or susceptible genes, but is more genome- and system-wide (Szyf & Bick, 2013). 
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Animal findings have provided the evidence to support that early life stress is linked to persistent 
modifications of DNA methylation in the central nervous systems, by changing gene expressions 
throughout the life span and passing the changes to offspring (Roth, Lubin, Funk, & Sweatt, 
2009; Murgatroyd, et al., 2009).  
In addition, epigenetic mechanisms have been found to contribute to the establishment 
and maintenance of regular gene expressions (Xu, et al., 2010). Modifications of DNA 
methylation are associated with either gene silencing for hypermethylation or the inducement of 
gene transcription for hypomethylation, both of which are assumed to increase vulnerability of 
psychiatric disorders (Kosztolany, 2011; Ptak & Petronis, 2010). Both inherited and acquired 
epigenetic dysregulations may play a role in the etiology of MDD and other psychiatric disorders 
(D'Addario, et al., 2013; Oh, et al., 2015; Kahl, et al., 2016). A prospective cohort study 
indicated that lower DNA methylation levels of seven candidate genes assessed at birth were 
associated with more attention deficit hyperactivity disorder (ADHD) symptoms in children at 
the year of six (van Mil, et al., 2014).  
Furthermore, epigenetic alterations could mediate the relationship between early life 
exposures and psychiatric disorders. Prenatal “unhealthy diet” was associated with higher ADHD 
symptoms, indirectly via hypermethylation of insulin-like growth factor 2 (IGF2), which plays 
an essential role in growth and development before birth (Rihlaarsdam, et al., 2016). Similarly, 
epigenetic signatures probably mediate associations between early adverse events and long-term 
alterations in human stress and immune systems response (Bick, et al., 2012). Newman et al. 
(2016) in their review summarizing the early origins of psychiatric disorders suggest that 
epigenetic modifications, such as DNA methylation, could be one of the mechanisms underlying 
the in-utero effects on fetal development, and the association between early childhood 
experiences and quality of parental care provided and emotional regulation. 
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4.3.4 The Development of DNA Methylation Arrays  
Harrison and Parle-McDermott reviewed the major developments in the methodologies 
used for DNA methylation analysis over the past 30 years (Harrison & Parle-McDermott, 2011). 
The earliest techniques were based on the separation of methylated and unmethylated cytosines 
using reversed-phase high performance liquid chromatography (RP-HPLC), which was further 
improved throughout the 1980s (Kuo, McCune, Gehrke, Midgett, & Ehrlich, 1980; Gomes & 
Chang, 1983; Patel & Gopinathan, 1987) and thin-layer chromatography (TLC). In the following 
years, molecular techniques were then applied to indirectly examine DNA methylation levels at 
both a genome-wide and gene-specific context, such as immunoprecipitation via anti-
5′methylcytosine (anti-5mC) antibody (Oakeley, A, & Jost, 1997), and methylation-sensitive 
restriction enzymes, which cut DNA via recognition of digested fragments (Santos, Hendrich, 
Reik, & Dean, 2002). The advent of sodium bisulfite treatment of DNA, a deamination reaction 
converts cytosine to uracil when unmethylated but remains cytosine when methylated. Various 
approaches can detect conversions, such as bisulfite sequencing (Frommer, et al., 1992), 
methylation-specific polymerase chain reaction (MS-PCR) (Herman, Graff, Moyhanen, Nelkin, 
& Baylin, 1996), and methylation-specific high resolution melting (MS-HRM) (Wojdacz & 
Dobrovic, 2007). In recent years, these three techniques, immunoprecipitation, methyl-sensitive 
RE, and bisulphite treatment, have become principal methods for DNA methylation 
differentiation and have been applied to DNA microarrays/beadchips and next-generation 
sequencing platforms (Harrison & Parle-McDermott, 2011). The microarrays separate and 
analyze methylated and unmethylated DNA fragments; whereas next generation sequencing is a 
newly developed parallel sequencing, which allows the sequencing of DNA and RNA more 
quickly and cheaply compared with the previously used Sanger sequencing. Although all these 
recent techniques have their strengths and weaknesses, new methodologies and analytical tools 
will be developed in the near future to lower the cost of genome-wide sequencing and improved 
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consistency of laboratory testing. These evolutions promote epigenetic studies and bring us 
closer to exploring a complete human epigenetic profile (Harrison & Parle-McDermott, 2011). 
4.3.5 What Have Been Found by Previous Reviews on This Topic? 
To our knowledge, there are five reviews including only one systematic review so far on 
the general topic of DNA methylation and depression (Lockwood, Su, & Youssef, 2015; Uddin, 
Sipahi, Li, & Koenen, 2013; Dalton, Kolshus, & McLoughlin, 2014; Bakusic, Schaufeli, Claes, 
& Godderis, 2017; Chen, Meng, Pei, Zheng, & Leng, 2017). Generally they suggest that altered 
DNA methylations may be associated with the etiology of depression. Lockwood, Su, and 
Youssef in their narrative review of epigenetic findings in both animal models and human studies 
concluded epigenetics could play an important role in depression and suicide in humans 
(Lockwood, Su, & Youssef, 2015). Again, Uddin et al. (2013) using a same approach studied the 
role of sex in DNA methylation and post-traumatic stress disorder (PTSD) and MDD, and 
suggested that sex differences in DNA methylation among genes known to influence brain 
development may explain the sexually dimorphic risk for developing PTSD and MDD. Another 
narrative review found the inverse association between adverse environmental factors, i.e. early 
life stress, and the epigenetic modification of gene expression (Dalton, Kolshus, & McLoughlin, 
2014). A recent review examined the association between DNA methylation of seven candidate 
genes and depression and found that BDNF and NR3C1 gene methylation levels may be related 
to depression, whereas the relationship between SLC6A4 and depression was inconsistent (Chen, 
Meng, Pei, Zheng, & Leng, 2017). 
In contrast to a sufficient number of systematic reviews on susceptible genes and gene by 
environment interactions, that provide a list of putative genetic and environmental risk factors for 
MDD (Levinson, 2006; Lohoff, 2010; Shyn & Hamilton, 2010; Saveanu & Nemeroff, 2012; 
Cohen-Woods, Craig, & McGuffin, 2013; Dunn, et al., 2015), there has been a limited progress 
in systematically reviewing DNA methylation in depression. There has been no comprehensive 
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review(s) of epigenetic studies in depression critically exploring the role of experimental 
methodologies and verification of laboratory testing factors, which may significantly affect the 
accuracy and validity of results. One recent systematic review assessed both animal and human 
studies and identified the correlation between burnout/depression and global and candidate-gene 
DNA methylation (Bakusic, Schaufeli, Claes, & Godderis, 2017). However, the review in 
question did not examine the influence of experimental and statistical methodologies and 
analyses on the findings. 
This systematic review aims to: 1) systematically synthesize major findings on DNA 
methylation and depression; 2) compare similarities and differences across different studies, 
including experimental and laboratory factors and statistical analyses, which might partially 
explain some inconsistencies of results; and, 3) note the challenges and opportunities for future 
studies. 
4.4 Methods 
The processing and reporting of results of this systematic review were guided by the 
PRISMA 2009 guidelines (Moher, Liberati, Tetzlaff, & Altman, 2009).  
4.4.1 Search Strategy 
Two methods were used to retrieve all studies with relevant topics. First, we conducted a 
search of the computerized bibliographic databases PubMed, Web of Science, EMBASE, 
Medline, and Cochrane Library. The search strategy is detailed in Supplementary Appendix 1. 
The literature search comprised articles up to June, 2016. Second, a snowball technique was then 
applied to identify further studies. We manually searched other resources for other relevant 
studies. The reference lists of selected articles, review articles on relevant topic, and the gray 
literatures were screened. Figure 4-2 presents the process of study selection.  
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Figure 4-2 PRISMA flow diagram – DNA methylation and depression  
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4.4.2 Inclusion and Exclusion Criteria 
All suitable articles were evaluated with regards to their internal validity and four 
selection criteria as follows: 1) used a clear diagnosis criteria for depression, specifically DSM 
and its updates (APA, 2013), ICD-10 (WHO, 1992) or other generally accepted diagnostic 
criteria; 2) examined the association between DNA methylation and depression; and, 3) provided 
a statistical indicator (i.e. coefficient) or original data to estimate the relationship between DNA 
methylation and depression. 
Articles were excluded if they 1) did not specify the “depressed” patients as patients 
suffering from major depression, major depressive disorder, unipolar depression, or other types 
of depression; 2) were not written in English.  
4.4.3 Data Collection 
1. Selection of studies. Two authors (M Li & X Li) independently screened all the retrieved 
articles. Inconsistencies in interpretation were resolved through group discussions (X Li, 
M Li & Meng). Endnote and RefWorks were used as bibliographic software. 
2. Data extraction and management. Data on author(s), year of publication, sample size, 
study designs, study cohort, experimental methods, type of tissues, target genes/genome, 
DNA purification method (a method of DNA isolation from a sample to assess the purity 
of the extracted DNA), DNA methylation method, DNA methylation validation 
(verification of methylation patterns), genotyping, gene expression, experimental factors, 
statistical methods, and major findings were extracted independently. For those studies 
with multiple reports, a single record denoted one study with information extracted from 
multiple reports. Group discussions dealt with all the inconsistent interpretations. 
3. Dealing with missing data. The reviewers endeavored to contact the original authors of 
the studies with missing information in order to gather complete and consistent study 
information. Open-ended questions were used to prevent misleading answers. 
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4. Data synthesis. Because the divergence of targeted genes/genomes, we grouped the 
summarized findings as follows: (1) BDNF; (2) SLC6A4; (3) NR3C1; (4) OXTR; (5) other 
candidate genes; (6) genome-wide; and, (7) treatment response. Some studies were 
involved in multiple separate analyses as their data permitted. Because the different 
experimental study designs and various statistical methods used, we first summarized the 
overall review findings and then discussed factors/characteristics could confound the 
review findings. Findings for each subgroup analysis are also provided.  
4.5 Results 
Some 4, 273 citations were initially retrieved from the title search. A total of 1, 643 
abstracts were reviewed with 323 full text articles being retrieved for review. Finally, 57 articles 
met our eligibility criteria and are included in this review (see Figure 4-2). Appendix 2 lists all 
the selected articles by analysis group. 
Supplementary Appendix 3 presents details on the study characteristics of the selected 
studies. We did notice a significant heterogeneity in terms of study characteristics across studies. 
Most studies were published between 2008 and 2016, especially in the past six years. The 
selected studies mainly focused on adult and senior age groups (49/57), covered a total number 
of 10,857 subjects worldwide (North America: 16/57, Asia: 16/57, Europe: 22/57, and Australia: 
5/57). We also evaluated study quality covering from design (study design, sample size, and type 
of subject), implementation (biological sample, DNA methylation method, purification of DNA 
extraction, and validation of methylation), analysis (analytical method, batch effect, genotyping 
and gene expression), to results interpretation (major findings and their implications). The 
majority of the studies in this review were case-control or longitudinal studies with hospital or 
general population-based cohort. There was a wide variety in terms of sample size ranging from 
11 to 1,024. Blood and saliva were most commonly used as biological samples analyzed by 
generally accepted DNA methylation methods, such as bisulfite conversion with pyrosequencing. 
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Both parametric and non-parametric statistics were used. Importantly, most of these studies did 
not analyze the influence of batch effect on their results (55/57), except two genome-wide 
studies. 
This review was designed to apply evidence-based approaches to evaluate the findings of 
studies on the relationship between DNA methylation and depression. High heterogeneity existed 
among the studies reviewed, in such a case the Cochrane guidelines does not recommend using 
quantitative methods, such as meta-analysis. As a consequence, qualitative methods were used. 
We present our review results divided into the major categories of etiological-genome-
wide studies, etiological-candidate genes studies, and treatment response studies. Table 4-1 
summarizes study characteristics. 
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Table 4-1 Summary of study characteristics 
Genomic Category BDNF SLC6A4 
Number of articles 11 11 
Years 2011-2016 2008-2016 
Country/continent Asia (7); Europe (3); North America (1); 
not mentioned (1) 
Asia (3); Europe (2); North America (4); 
Australia (2) 
Age group Adult to senior Adult to senior (9); adolescent (2) 
Sample size 4,184 (38-1024) 2,188 (43-954) 
Diagnostic standard DSM-IV (9); Hamilton Depression Rating 
Scale (1); GMS AGECAT & Geriatric 
Depression Scale (1) 
DSM-IV (8); SCID (1); CIDI (1); Beck 
Depression Inventory (BDI-II) (2); 
AAGA-II (1); CIS-R (clinical interview 
schedule-revised) (1) 
Study design case-control (7); longitudinal study (4) 
followed-up for 1 to 2 years 
case-control (7); longitudinal study (3) 
followed-up for 6 weeks to 1 years; 
twins study (1) 
Cohort Hospital-based (5); general population (4) Cases were hosptal- or population-based; 
controls from general population or 
hospital (1) 
Biological sample blood (9); buccal tissue (1); saliva (1) blood (9); saliva (1); buccal cell (1) 
Purification of DNA 
extraction 
Yes (7) - QIAamp DNA Blood Mini Kit 
(5); PUREGENE DNPurification Kit (1); 
Dneasy Blood & Tissue Kit (1); No (4) 
Yes (5) - QIAamp DNA Blood Mini Kit 
(3); Dneasy Blood & Tissue Kit (1); cold 
protein precipitation (1); No (6) 
DNA methylation 
method /kit 
All used bisulfite conversion (11) - 
EpiTect Bisulfite Kit (4); EZ-96 DNA 
Methylation Kit (3).  Methylation-specific 
quantitativePCR (1), PCR and sequencing 
(1), pyrosequencing (7) using PSQ 96M 
System(5) and PyroMark ID System with 
Pyro Gold Reagents Kit(2) 
All used bisulfite conversion (11) -  
EpiTect kit (2); EZ DNA methylation 
kits (3). Pyrosequencing (6) using 
PyroMark Software (3); PSQ 96 System 
(2). PCR and sequencing (2). Analyzed 
using EpiTYPER analysis (3) and 
MassARRAY  (3) 
Methylation 
validation 
Yes (1) - Bisulfite-modified universal 
methylated DNA was used as negative 
control (1); No (10) 
Yes (4) - mean of methylation 
percentage (1); bisulfite conversion (1); 
pyrosequencing on duplicate samples 
(2); No validation (6) 
Genotyping Yes (7); No (4) Yes (9); No (2) 
Gene expression All No (11) Yes (4); No (7) 
Analytical method Pearson's correlation coefficient test (1); 
ANOVA (1); hierarchical clustering 
analyses (1); t-test (5); multivariate logistic 
regression (4); linear regression (2); 
Wilcoxon-MannWhitney test (1) 
Regression analyses (6) - linear (2); 
logistic (2); both (1). MannWhitney U 
test (1). ANOVA (2). T-test (2).   
Major finding Higher level of BDNF DNA methylation 
were associated with depression (CpG 
1,2,3,4,5,9) or poststroke depression (10); 
No significant difference (CpG 1,2,3,4) 
(1). 
No significant association (6); SLC6A4 
methylation level was independently 
associated with poststroke depression/ 
depressive symptoms (3); Higher 
methylation is associated with lifetime 
depression, compared with alcohol 
dependence (1) and depression patients 
compared with controls (1); 
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Genomic Category NR3C1 OXTR 
Number of articles 5 4 
Years 2014-2016 2015-2016 
Country/ continent Asia (2); Europe (2); North America (1) North America (3); Europe (1) 
Age group Adult to senior (5); adolescent (1) Adult to senior 
Sample size 1,292 (12-954) 1,025 (43-545) 
Diagnostic standard DSM-IV (2); CIDI (1); Patient Health 
Questionnaire (PHQ-9) consistent with 
DSM-IV (1); diagnosed by psychiatrist (1) 
DSM-IV (2); SCID-I/II (1); Edinburgh 
Postnatal Depression Scale (EPDS) (1) 
Study design Case-control (4); longitudinal study (1) Case-control (3); longitudinal study (1) 
Cohort Participants recruited from hospital- or 
population-based studies (4); hospital 
outpatients (1) 
participants recruited from population-
based studies/databases (3); hospital 
inpatients, controls from advertisement (1) 
Biological sample blood (4); post-mortem brain tissues (1) blood (3); saliva (1) 
Purification of DNA 
extraction 
Yes (4) - EZ DNA Methylation-Gold kit, 
Prep Mini Spin Kit, QIAamp DNA Blood 
Mini Kit (2) & LifeSciences's Quickgene 
DNA Whole Blood Kit; No (1);  
Yes (2) - QIAamp DNA Blood Mini Kit 
(2); No (2) 
DNA methylation 
method /kit 
All used bisulfite conversion (5) using 
EpiTect Bisulfite Kit (1) or EZ DNA 
Methylation Kit (1). Pyrosequencing using 
PyroMark kit (4). PCR (1). Analyses using 
EpiTYPER method (1) 
All used bisulfite treatment (4) using 
EpiTect Bisulfite Kit (1) or EZ DNA 
methylation Gold kit (1). Pyrosequencing 
analysis using PyroMark system (3). PCR 
and sequencing using BigDye Terminator 
Cycle Sequencing Kit (1) 
Methylation 
validation 
Yes (2) - bisulfite treatment using EpiTect 
bisulfite kit or pyrosequencing using 
PyroMark; No validation (3) 
No (4) 
Genotyping Yes (1); No (4) Yes (4) 
Gene expression Yes (3); No (2) Yes (1); No (3) 
Analytical method Analysis of covariance (ANCOVA) (1); T-
test (2); linear and logistic regression (1);  
Mann-Whitney U-test (1) 
T-test (1); linear mixed effect model (1); 
logistic regression (1); linear regression (1) 
Major finding Depression /depressive symptom was 
associated with higher methylation level 
(NR3C1_1, CpG 7 in female) (2); 
depression was related to lower 
methylation level (CpG 3,4, 5-13) (2); no 
significant findings (1) 
Greater methylation levels were found in 
cases compared with controls (1); 
decreased methylation levels were found 
in depressed female patients (1) or serum 
estradiol levels in postpartum depression 
(1); no significant association with 
postpartum depression(1) 
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Genomic Category Genome 
Number of articles 15 
Years 2011-2016 
Country/ continent Asia (2); Europe (4); North America (6); Australia (1); mixed UK & Australia & 
Canada (2) 
Age group Adult to senior (13); not mentioned (2) 
Sample size 1,952 (12-454) 
Diagnostic standard DSM-III/IV (10); SCIDI (1); Patient Health Questionnaire (PHQ-9) (1); Beck 
Depression Inventory (BDI) & BDI-II (1); Hamilton Depression Rating Scale (HDRS) 
(1);  Edinburgh Postnatal Depression Scale (1); not mentioned (1) 
Study design Case-control (11); longitudinal study (2); twin study (3); discovery/pilot-replication (5) 
Cohort Participants recruited from hospital- or population-based studies or databases (Twin 
Registry, Brain Bank) (12); not mentioned (3) 
Biological sample blood (11); post-mortem brain (3); postmortem frontal cortex (3); sperm (1) 
Purification of DNA 
extraction 
Yes (6) - Nucleon Genomic DNA Extraction Kit (2), salt extraction method (AU) (1), 
MasterPure DNA Purification kit (1), QIAamp DNA Blood Maxi Kit (2), Qiagen DNA 
mini kit (1); No (9) 
DNA methylation 
method /kit 
Bisulfite conversion (12) using EZ DNA methylation Kit (4), ZymoResearch bisulfite 
kit (1), EpiTect Bisulfite Kit (1). Bead array using Infinium Human Methylation 
Beadchips (10). CHARM assay platform (1). Enrichment for methylated regions using 
methylated DNA immunoprecipitation combined with ultra-deep sequencing (MeDIP-
seq) (1). Pyrosequencing (2) using Gold Q96 Reagents (1) and Pyromark system (2). 
PCR and sequencing (1). ELISA-based for global DNA methylation profiling (1) - 
MethylFlash methylated DNA quantification kit (for 5-mc), MethylFlash 
hydroxymethylated DNA quantification kit (for 5-hmc). 
Methylation 
validation 
Yes (10) - next generation sequencing (1),  pyrosequencing (4), Bisulfite conversion 
(2), replicates (2), high-resolution melting and bisulfite Sanger sequencing (1), ; No (5) 
Genotyping Yes (1); No (14) 
Gene expression Yes (7); No (8) 
Analytical method Mann-Whitney U-test (2); linear mixed effect model (2); linear regression (1); logistic 
regression (1); t-test (5); ANOVA (1); pairwise comparisons (1); linear modelling 
using Limma and methyAnalysis package (1); ranking analysis (1); functional 
annotation cluster analyses (1) 
Major finding Significant differential modifications were found in depression, but can be increase or 
decrease (15) - Lower DNA methylation in depressive patients than in controls (5); 
hypermethylation was found in depressive /postpartum depressive patients (5); 
increased methylation found in pilot, not in replication (1); significant difference in 
mean methylation found in females, not in males (1); both directions were found (1): 
some processes (e.g. brain development, tryptophan metabolism) showed patterns 
suggestive of increased methylation among individuals with depression whereas others 
(e.g. lipoprotein) showed patterns suggestive of decreased methylation among 
individuals with depression. No difference among severe MDD and remitted patient at 
5-hmc and 5-mc levels (1). 
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Genomic Category Others 
Number of articles 10 
Years 2012-2016 
Country/continent Asia (1); Europe (6); North America (3); 
Age group Adult to senior (7); adolescent (1); not mentioned (2) 
Sample size 888 (34-174) 
Diagnostic standard DSM-IV (7); SCID-I/II (1);  Composite International Diagnostic Interview (CIDI) (1); 
MDI (1); Brief Symptom Inventory (BSI) 
Study design Case-control (8); longitudinal study (1); twin's study (1) 
Cohort hospital inpatients /outpatients & controls from general population (3); population-
based study (5); not mentioned (2) 
Biological sample blood (7); saliva (3) 
Purification of DNA 
extraction 
Yes (6) - QIAamp DNA Blood Mini Kit (2), Wizard Genomic DNA Purification kit 
(1), Invisorb Blood Giga Kit (1), Qiagen DNA mini kit (1), Puregene whole blood 
DNA-extraction kit (1); No (4) 
DNA methylation 
method /kit 
Bisulfite convertion (9) using EpiTect Bisulfite Kit (3), EZ DNA methylation Kit (2). 
Analyzed using EpiTYPER platform (3). Methylation-specific PCR (1). PCR and 
sequencing (5) using BigDye Terminator Cycle Sequencing Kit (1). Bead array using 
the Illumina Infinium HumanMethylation450 (450K) BeadChip (2). Pyrosequencing 
(1) using PyroMark Q96 MD (1). Not mentioned (1) 
Methylation 
validation 
Yes (2) - circle sequencing (1), pyrosequencing & replication (1); No (8) 
Genotyping Yes (4); No (6) 
Gene expression Yes (2); No (8) 
Analytical method Mixed linear models (1); linear regression (2); Pearson's correlation coefficient test (2); 
Fisher's exact test (1); t-test (2); ANCOVA (2); non-parametric analyses (1) 
Major finding Increased methylation was found in depression (GLUT1, CpG 1,5,12 of ACE, Elovl5, 
FKBP5) (4); lower level of methylation found in depression (Fads2, MAOA(2), 
DEPDC7) (4); No difference found (GLUT4, APOE) (2); The TPH2 promoter was 
methylated in 36.0% of MDD + suicide patients, as compared with in 13.0% of MDD 
patients (1); HP1BP3 and TTC9B predicted PPD, In a replication analysis, these 
biomarkers also functioned to segregate PPD status in women who developed 
depression during the antenatal period with 88% accuracy; however the prediction was 
in the opposite direction. 
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Genomic Category Treatment response 
Number of articles 11 
Years 2014-2016 
Country/ continent Asia (3); North America (1); Europe (5); mixed UK & Australia (1); not mentioned (1) 
Age group Adult to senior (9); not mentioned (2) 
Sample size 1,740 (11-554) 
Diagnostic standard DSM-IV (8); SCID-I/II (1); BDI-I/II (3); CSID-I (2); HAM-D-21 (2); GAF (2); 
Hamilton Depression Rating Scale-21 (1) 
Study design Case-control (4); longitudinal study (7) 
Cohort Hospital-based cohort (5); population-based database (1); controls from general 
population (1); not mentioned (3) 
Biological sample blood (11) 
Purification of DNA 
extraction 
Yes (8) - PUREGENE DNPurification Kit (1), Nucleon BACC Genomic DNA 
Extraction Kit (2), QIAamp DNA Blood Mini Kit (3), DNeasy Blood and Tissue Kits 
(1), FlexiGene DNA Kit (2); No (3) 
DNA methylation 
method /kit 
Bisulfite convertion (10) using EpiTect Bisulfite Kit (2), EZ DNA methylation kits (4). 
Analyzed using EpiTyper software (1). Pyrosequencing (3) using PyroMark system 
(2), PSQ 96M System (1). PCR and sequencing (5) using BigDye Terminator (4). 
Methylation-specific quantitativePCR following the MethyLight protocol using SYBR 
green (1). Methylated DNA immunoprecipitation combined with ultra-deep sequencing 
(MeDIP-seq) (1) 
Methylation 
validation 
Yes (3) - bisulfite conversion for negative controls (1), fully methylated and fully non-
methylated DNA was used in all experiments (3); No (8) 
Genotyping Yes (6); No (5) 
Gene expression Yes (3); No (8) 
Analytical method Linear regression (4); linear mixed effect model (3); Pearson's correlation coefficient 
test (2); ANOVA (1); Wilcoxon signed-rank test (1) 
Major finding Greater methylation levels were associated with SSRIs at 2 CpG, anti-depressant 
therapy (2); hypomethylation of the 5-HTT & MAOA transcriptional control region 
might impair antidepressant treatment response in Caucasian patients with MDD (2); 
Remitters had a significantly lower mean BDNF promoter methylation rate than non-
remitters (exon I) (1); No significant methylation (e.g. MAOA, BDNF) change related 
to antidepressant use (6); The pre-treatment methylation rate(CpG3) of SLC6A4 is 
associated with therapeutic responses to antidepressants in unmedicated patients with 
MD (1); lithium and valproate tended to decrease, even though not significantly, DNA 
methylation level at BDNF gene promoter, when compared to other classes of 
medications (e.g. antidepressants and atypical antipsychotics). 
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4.5.1 Etiological Studies  
4.5.1.1 Whole genome-wide studies 
There were 15 studies, published from 2013 to 2016, using whole-genome wide 
approaches to examine the relationship between DNA methylation and depression. Study sample 
sizes ranged from 12 to 454 subjects, and over half (53.3%, 8/15) of the studies contained 
relatively small sample sizes of <100. Subjects were recruited from existing hospital, or 
population-based studies or databases. The study designs of this category consisted of 11 case-
control studies, 3 twins’ studies, and 2 cohort studies, and 5 studies applied the discovery/pilot-
replication method. Most of biological specimens were whole blood samples, followed by post-
mortem brains, and sperm. Most studies included methylation validation procedure (66.7%, 
10/15), but no DNA purification in their arrays (60.0%, 9/15). The majority (80.0%, 12/15) of 
these studies used bisulfite conversion. Bead arrays were widely applied using Infinium Human 
Methylation Beadchips (10/15), followed by pyrosequencing, and methylated DNA 
immunoprecipitation combined with ultra-deep sequencing (MeDIP-seq). Almost half of the 
studies (46.7%, 7/15) also did gene expression afterwards. 
Although all these studies did find significant modifications in the level of DNA 
methylation among depression cases, both positive (hypermethylation) and negative 
(hypomethylation) correlations were noted. Inconsistent results were also identified. For 
instance, increased methylation that was previously shown in a pilot study was not present in its 
replication (Sabunciyan, et al., 2012); a significant decrease in mean methylation was observed 
among females, but not for males (Byrne, et al., 2013); lower methylation levels were found 
among severe MDD patients vs. healthy controls, but no difference between severe vs. remitted 
patients (Tseng, et al., 2014); one study found both hypermethylations in some processes (e.g. 
brain development and tryptophan metabolism), and hypomethylations in other tissues (e.g. 
lipoprotein) (Uddin, et al., 2011). 
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Although studies with both large and small sample sizes did not show significant 
differences in terms of study design and major findings, studies with large sample sizes were 
more likely to use DNA purification methods and examine gene expression than those with 
smaller samples. Thus results from studies with large sample sizes may be considered to be more 
reliable. 
4.5.1.2 BDNF 
There were 11 articles published from 2011 to 2016, studying the relationship between 
DNA methylation on BDNF gene and depression. Their sample sizes ranged from 38 to 1,024 
subjects. Studies in this  group used case-control (63.6%, 7/11) and short-term longitudinal 
cohorts (36.4%, 4/11) designs. Subjects were from both hospitals and general populations. The 
whole blood samples were the primary choice (81.8%, 9/11) for biological testing, followed by 
buccal cells and saliva samples. DNA methylation was mostly tested using bisulfite 
pyrosequencing (63.6%, 7/11), followed by methylation-specific quantitative PCR. Most studies 
checked DNA purification (63.6%, 7/11), but did not included methylation validation (90.9%, 
10/11). Seven studies also did genotyping (63.6%, 7/11), but none conducted gene expression. 
Most of studies in this group had the relatively large sample sizes (>200, 6/11) and majority of 
studies with large sample size performed DNA purification (5/6).  
Consistently, most studies (90.9%, 10/11) found that subjects with depression or post-
stroke depression were more likely to have hypermethylation on multiple BDNF CpG sites. Only 
one study did not replicate this finding, but it had a small sample size and did not report on 
laboratory factors in their analyses (Choi, et al., 2015).  
4.5.1.3 SLC6A4 
There were 11 studies examined the relationship between DNA methylation on SLC6A4 
and depression. The sample sizes in this group ranged from 43 to 286 subjects, except for one 
study had 954 subjects. Seven of the studies were case-control studies, three were longitudinal 
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studies with less one-year follow-up, and one was a “twins” study. Subjects were from hospitals 
and population databases or from general population. Whole blood was the primary biological 
sample (9/11), followed by buccal cells and saliva. Less than half studies tested for both DNA 
purification and methylation validation. More than half of studies (54.5%, 6/11) applied 
pyrosequencing followed by EpiTYPER or MassARRAY analysis, for DNA methylation. Most 
of the studies (9/11) also tested genotyping, but only four (4/11) examined gene expression. 
The three longitudinal studies which together represented 65.4% of the group subjects 
consistently found that SLC6A4 hypermethylation was significantly associated with depression 
and depressive symptoms (Kim, et al., 2013; Philibert, et al., 2008; van der Knaap, van Oort, 
Verhulst, Oldehinkel, & Riese, 2015). This finding was supported by a twins study (Zhao, 
Goldberg, Bremner, & Vaccarino, 2013) and a case-control study that had a most comprehensive 
consideration of laboratory factors and statistical analysis (Iga, et al., 2016). Five studies with 
relatively large sample sizes consistently found that SLC6A4 hypermethylation were linked to the 
risk of depression, depressive symptoms, or post-stroke depression, but other six small sample-
sized studies did not replicate this finding. 
4.5.1.4 NR3C1 
In this group there was a great variation in terms of sample size, which ranged from 12 to 
954 subjects. Most of studies were case-control, except for one longitudinal cohort study. 
Subjects were from hospital or the general population. Whole blood was the primary choice as 
the biological sample. However, one study used post-mortem brains. Most of studies tested for 
DNA purification and methylation validation. Pyrosequencing, followed by EpiTYPER analysis, 
were used to test the level of DNA methylation. Most studies did also tested gene expression and 
one did genotyping.  
The major findings of the five studies were inconsistent with both hypo- and hyper-
methylated CpG sites on NR3C1 gene reported. However, studies with longitudinal study 
 69 
 
 
designs, more reliable laboratory arrays and statistical analyses consistently showed that people 
with NR3C1 hypermethylation were more likely to report depression and/or depressive 
symptoms. (Nantharat, Wanitchanon, Amesbutr, Tammachote, & Praphanphoj, 2015; van der 
Knaap, van Oort, Verhulst, Oldehinkel, & Riese, 2015). 
4.5.1.5 OXTR 
Four articles met the criteria to explore the relationship between DNA methylation on 
OXTR gene and depression. Sample sizes ranged from 43 to 545 subjects. Most studies in this 
group of them were case-control designs (3/4), one was a longitudinal cohort study. Subjects 
were mainly recruited from the general population (91.7%), with the remaining being inpatients 
and controls recruited from advertisements (8.3%). Again, the whole blood was the primary 
tissue choice (75%), followed by saliva. DNA purification was tested by half of these studies. 
None tested for methylation validation. Bisulfite treatment and pyrosequencing were used for 
methylation arrays. All the studies did also test genotyping, while only one study examined gene 
expression. 
Due to the defects in study design (i.e. small sample sizes), and lab factors (lack of DNA 
purification, or methylation validation), findings from these four studies are difficult to interpret. 
Two case-control studies had small sample sizes (N<100) found inconsistent results. The third 
case-control failed to apply valid lab arrays and found a non-significant association. The 
longitudinal cohort study with 353 subjects did not perform DNA purification or methylation 
validation. 
4.5.1.6 Other candidate genes 
Ten studies met the eligibility criteria for the relationship between DNA methylation on 
other candidate genes and depression. They included: Glucose transporter 1 (GLUT1), Glucose 
transporter type 4 (GLUT4), Tryptophan hydroxylase 2 (TPH2), Angiotensin Converting Enzyme 
(ACE), Apolipoprotein E (APOE), Fatty acid desaturase 1 (Fads1), Fatty acid desaturase 2 
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(Fads2), Elongation of very long chain fatty acid elongase 5 (Elovl5), Heterochromatin protein 
1, binding protein 3 (HP1BP3), tetratricopeptide repeat domain 9B (TTC9B), FK506 binding 
protein 5 (FKBP5), monoamine oxidase A (MAOA), and DEP domain containing 7 (DEPDC7). 
This group of studies had a relatively small sample sizes ranging from 34 to 174 subjects. Case-
control study designs were more frequently used, followed by longitudinal cohort design and 
twins’ studies designs. Subjects were hospital inpatients or outpatients or from the general 
population, or from an existing population-based study. Two studies in this group did not 
mention the source of their samples. Most studies (7/10) used whole blood as the biological 
sample for arrays, the rest of the studies used saliva. Most of studies tested DNA purification, but 
only two examined methylation validation. Consistently, DNA methylation was measured via 
bisulfite conversion and pyrosequencing and then analyzed by EpiTYPER. A few studies did 
genotyping and/or gene expression. Notably, in one study the same outcomes were obtained from 
the initial study on MAOA and its replication study using an independent sample (Melas & 
Forsell, 2015; Melas, et al., 2013).  
Hypermethylation was found in depressed cases in four studies (GLUT1, CpG 1,5,12 of 
ACE, Elovl5, FKBP5)  (Kahl, et al., 2016; Zill, et al., 2012; Haghighi, et al., 2015; Hohne, et al., 
2015); in contrast, hypomethylation was found in depression in four studies (Fads2, MAOA, 
DEPDC7) (Haghighi, et al., 2015; Melas, et al., 2013; Melas & Forsell, 2015; Cordova-
Palomera, et al., 2015); and no significant difference in methylation levels was found between 
depressed patients and their healthy controls in two studies (GLUT4, APOE) (Kahl, et al., 2016; 
Chagnon, Potvin, Hudon, & Preville, 2015). In addition, one study found that patients who were 
both depression and suicidal had hypermethylation in the TPH2 promoter region, as compared 
with in depression-only patients (Zhang, et al., 2015). Finally, one study found methylated 
HP1BP3 and TTC9B predicted postpartum depression. In their replication analysis, these 
biomarkers were able to accurately segregate postpartum depression status in women, but the 
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prediction was in the opposite direction to that found in a pilot analysis (Kaminsky & Payne, 
2014). 
Due to the fact that many genes were studied in this group and most studies failed to 
apply strong study designs, or better laboratory and analyses factors in their execution, it is hard 
to weigh the value of their findings.  
4.5.2 Treatment Studies 
There were 11 articles published from 2013 to 2016, included in this analysis to explore 
the association between DNA methylation modification and treatment. The sample sizes in this 
category ranged widely from 11 to 554 subjects, with most of the studies having relatively small 
sample sizes (<100). Most of the studies’ subjects were adults and seniors were from hospital-
based cohorts, followed by population-based databases and general population. Study 
characteristics, such as study design, applying DNA purification, and genotyping and gene 
expression did not vary between small and large sample sized studies. The only tissue used in 
this group of studies was the whole blood. Most studies (72.7%, 8/11) tested for DNA 
purification, but not methylation validation. DNA methylation was mostly for tested by bisulfite 
conversion and pyrosequencing. Over half (6/11) of these studies also included genotyping and 
gene expression in their arrays.  
More than half studies (6/11) did not identify significant methylation modifications 
related to antidepressants use, including the only study on MAOA, one of three studies on 
SLC6A4, three of five studies on BDNF, and one genome-wide study (Dell'Osso, et al., 2014; 
Davies, et al., 2014; Kang H.-J. , et al., 2013; Na, et al., 2016; Domschke, et al., 2015; Tadic, et 
al., 2014). One of five studies on BDNF and one of three studies on SLC6A4 at 2 CpG sites 
hypermethylations were associated with antidepressant therapy (Booij, et al., 2015; Carlberg, et 
al., 2014). Whereas, the only study on 5-HTT transcriptional control region indicated that its 
hypomethylation might impair antidepressant response in Caucasians patients with MDD, and 
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one of five studies on BDNF promoter region hypomethylations were linked to antidepressant 
treatment response in remitters compared with non-remitters (Kleimann, et al., 2015; Domschke, 
et al., 2014). Okada, et al. (2014) identified the positive correlation between pre-treatment DNA 
methylation on SLC6A4 CpG3 and antidepressants in un-medicated patients (Okada, et al., 
2014). In addition, one study tested the association between methylation modifications and 
classes of antidepressants, and demonstrated that lithium and valproate tended to decrease, 
though not significantly, DNA methylation level on BDNF promoter, compared with other 
classes of medications, such as antidepressants and atypical antipsychotics (Dell'Osso, et al., 
2014). Only the small sample sized studies in this group did methylation validation. The only 
two negative correlations between methylation levels on BDNF and 5-HTT gene and 
antidepressants were found by studies with relatively small samples (Kleimann, et al., 2015; 
Domschke, et al., 2014). 
4.6 Discussion 
To the best of our knowledge, this is the first review comprehensively exploring the role 
of DNA methylation in depression taking into account of both laboratory and analytic factors that 
could confound findings. A total of 57 articles were included in this review. The majority of the 
studies reviewed were recently published and were from developed countries. Whole blood and 
saliva samples were the most common tissues used in these analyses. Bisulfite conversion along 
with pyrosequencing, were widely used to test DNA methylation level. There was a high 
heterogeneity among the studies in terms of laboratory and statistical methodologies used and 
study designs. Larger sample size and laboratory verification (DNA purification and DNA 
methylation validation) are the major characteristics important for accurate results.  
Due to the high level of heterogeneity in studies reviewed, qualitative analyses were used three 
subgroup analyses were done, including etiological-genome-wide studies, etiological-candidate 
genes studies, and treatment response studies.   
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4.6.1 Findings on Etiological-Whole-Genome Studies 
We found that the level of DNA methylation were significantly different between 
depression patients and controls in the whole genome-wide association studies. 
Hypermethylations were observed in six studies on the following genes as zinc finger and BTB 
domain containing 20 (ZBTB20), Heterochromatin protein 1, binding protein 3 (HP1BP3), 
Tetratricopeptide repeat domain 9B (TTC9B), and Glutamate Ionotropic Receptor NMDA Type 
Subunit 2A (GRIN2A) (Davies, et al., 2014; Guintivano, Arad, Gould, Payne, & Kaminsky, 2014; 
Osborne, et al., 2016; Kaut, et al., 2015; Haghighi, et al., 2014; Walker, et al., 2016). 
ZBTB20 exists hippocampal neurons and cerebellum granule cells (Mitchelmore, et al., 2002) 
and plays a role in many processes including neurogenesis, glucose homeostasis, and postnatal 
growth (ZBTB20 gene, 2017). It may also have an impact on the development and 
regionalization of the human hippocampus, which has been found to be related to depression by 
many studies (Sheline, Mittler, & Mintun, 2002; Bremner, et al., 2000; Sheline, Wang, Gado, 
Csernansky, & Vannier, 1996).  
Both HP1BP3 and TTC9B are linked to estrogen signaling. HP1BP3 is highly expressed 
in brain and related to a number of physical and behavioral phenotypes for mice, such as 
dwarfism, impaired bone mass, impaired maternal behavior, and anxiety (Garfinkel, et al., 2015; 
Garfinkel, et al., 2016). Lower HP1BP3 has been found to be associated with postpartum 
depression and Alzheimer's disease in humans (Guintivano, Arad, Gould, Payne, & Kaminsky, 
2014; Neuner, et al., 2016). TTC9B has been identified to be related to gonadal hormones (Cao, 
Iyer, & Lin, 2006) and may be linked to hippocampal synaptic plasticity, which is critical for 
hippocampal long-term potentiation and depression (Gerges, et al., 2004). These markers in 
peripheral blood may indicate estrogen-mediated epigenetic changes in hippocampus and in turn 
potentially raise the vulnerable phenotypes based on their actions in brain (Guintivano, Arad, 
Gould, Payne, & Kaminsky, 2014). 
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The GRIN2A gene provides instructions for making a protein called glutamate receptor 
subunit epsilon-1- in human encoded GluN2A, which is one component (subunit) of a subset of 
NMDA receptors. They are involved in normal brain development, changes in the brain in 
response to experience (synaptic plasticity), learning, and memory (GRIN2A gene, 2017). 
Methylation modifications in GRIN2A may play a key role in determining the function of NMDA 
receptors. Generally, gene promoter region methylation could repress the gene expression, but 
the methylation on gene body can be positively correlated with expression activity (Hellman & 
Chess, 2007). This suggests that the hypermethylation of the GRIN2A gene body may result in 
the overexpression of NR2A, and thus promote vulnerability for MDD via up-regulating NMDA 
receptor-dependent glutamatergic signaling (Calabrese, et al., 2012). 
Hypomethylations among depression patients were also observed on the following genes: 
WD repeat domain 26 (WDR26), 5-hydroxymethylcytosine (5-hmc), and 5-methylcytosine (5-
mc) (Numata, et al., 2015; Kaut, et al., 2015; Cordova-Palomera, et al., 2015; Khulan, et al., 
2014; Nagy, et al., 2015; Tseng, et al., 2014). Consistent with our findings on WDR 26, previous 
studies have found that the hypomethylation of WDR26 in depressed individuals may be related 
to lower gene expression levels (Pajer, et al., 2012). Additionally, the decreased blood 
transcription levels of WDR26 were associated with depression-related phenotypes (Pajer, et al., 
2012; Karanges, et al., 2013; Wray, et al., 2012; Lee, et al., 2005). 
5-Methylcytosine (5-mc) is a methylated form of the DNA base cytosine, which could be 
involved in the regulation of gene transcription. Its presence is important for the maintenance of 
the active chromatic state and for neurogenesis at non-promoter CpG islands (Wu, et al., 2010), 
and is associated with stable and long-term transcriptional silencing of promoters (Butler, 2009). 
5-mc is also found as the critical mechanism mediating genomic imprinting. This process has 
been identified to be a key for normal development, and its abnormal imprinting can result in 
disorders such as Prader-Willi, Angelman, and Beckwith-Wiedemann syndrome (Butler, 2009). 
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5-Hydroxymethylcytosine (5-hmc) is a product of conversion of 5-mc. It is related to the 
regulation of gene expression and prompting DNA demethylation. The three Ten-eleven 
translocation (TET) enzymes oxidize each step in the demethylation of 5-mc. 5-mc is converted 
to 5hmC, then 5-formylcytosine (5fC), then 5-carboxylcytosine (5caC), each by TET1-3 (Ito, et 
al., 2011). Reduced level of TET1 and subsequently 5hmC cause impaired self-renewal of stem 
cells (Freudenberg, et al., 2012). 
Notably, inconsistent results were identified within the same studies among different 
subgroups, for example, different sexes (Byrne, et al., 2013), processes (e.g. brain development, 
tryptophan metabolism, lipoprotein) (Uddin, et al., 2011), tissues (white blood cells, brain and 
sperm) (Oh, et al., 2015), or between pilot and replication studies (Sabunciyan, et al., 2012). 
4.6.2 Findings on Etiological-Candidate Genes Studies  
For candidate genes studies, we selected 11 studies on BDNF gene, with the majority 
(10/11) of them indicating that BDNF hypermethylation links with depression. Most of studies 
had the relatively large sample sizes and examined DNA purification. This is consistent with 
recent reviews on BDNF and depression (Chen, Meng, Pei, Zheng, & Leng, 2017; Bakusic, 
Schaufeli, Claes, & Godderis, 2017). Chen et al. (2017) indicated that more than half of the 
studies showed an increased BDNF methylation in depressed patients. Bakusic et al. (2017) 
concluded in their review that hypermethylation was consistently found in MDD subjects across 
three reviewed studies (Bakusic, Schaufeli, Claes, & Godderis, 2017). The BDNF gene provides 
instructions for making a protein found in the brain and spinal cord, and promotes the survival of 
nerve cells (neurons). It is actively involved in the growth, maturation, maintenance of these 
neurons, and regulation of synaptic plasticity, which is important for learning and memory 
(BDNF gene, 2017; Malcangio & Lessmann, 2003). It is reported that changes in the methylation 
level of the BDNF promoter is associated with its lower expression in prefrontal cortex 
(Zheleznyakova, Cao, & Schioth, 2016) and activity in the hippocampus in animal studies (Lee 
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& Kim, 2010). Similar decrease in BDNF levels were also found in serum and plasma in MDD 
patients, thus it is hypothesized that MDD is related to impaired neuronal plasticity (Lee & Kim, 
2010). 
Positive associations between SLC6A4 methylation modifications and depression have 
also been identified in many studies in this review and previous reviews (Chen, Meng, Pei, 
Zheng, & Leng, 2017; Bakusic, Schaufeli, Claes, & Godderis, 2017). All longitudinal studies in 
this review and studies with more comprehensive considerations of lab and statistical work 
consistently found depression patients had SLC6A4 hypermethylation compared to controls. 
SLC6A4 gives instructions for making a protein in the brain involving in the regulation of 
serotonergic signaling by transporting 5-HT from synaptic spaces into presynaptic neurons (Tao-
Cheng & Zhou, 1999) and the regulation of emotional behaviors (Meyer-Lindenberg, 2009). The 
alterations of SLC6A4 play an important role in the brain development and function in human 
(Booij, Wang, Levesque, Tremblay, & Szyf, 2013). It has been hypothesized that DNA 
hypermethylation may result in the reduction of SLC6A4 expression and 5-HT reuptake, which 
in turn increase the vulnerability to affective disorder at critical stages of development (Gaspar, 
Cases, & Maroteaux, 2003; Olsson, et al., 2010). 
The results of NR3C1, OXTR, and other target genes studies were controversial. Both 
hypo- and hyper- methylation levels were noted in depressive patients compared to controls. No 
significant associations between DNA methylation on these genes and depression were also 
reported by some studies. The similar findings were also found by previous reviews (Chen, 
Meng, Pei, Zheng, & Leng, 2017; Bakusic, Schaufeli, Claes, & Godderis, 2017). NR3C1 is the 
receptor of cortisol and glucocorticoids bind. It regulates gene transcriptions and links to the 
development, metabolism, and immune response (Lu, et al., 2006; Rhen & Cidlowski, 2005). 
OXTR is a receptor of the hormone and neurotransmitter oxytocin (Gimpl & Fahrenholz, 2001; 
Zingg & Laporte, 2003). It presents in the central nervous system and plays an important role in 
modulating various behaviors, such as stress and anxiety, social memory and recognition, sexual 
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and aggressive behaviors, bonding/affiliation and maternal behavior (Caldwell & Young, 2006; 
Kiss & Mikkelsen, 2005; Veenema & Neumann, 2008). We found some of NR3CI and OXTR 
studies reviewed here had limitations in terms of type of study design, sample size, and range of 
laboratory work and statistical analyses. Due to the high heterogeneity across studies, this review 
could not provide more conclusive results on these genes in terms of relationships between DNA 
methylation modifications on these genes and depression. 
4.6.3 Findings on Treatment Studies  
Inconsistent results were also identified in treatment studies on anti-depressant therapy in 
this review. Consistently, another recent review on DNA methylation and clinical response to 
anti-depressant medication in MDD patients was unable to find consistent support for such a 
relationship (Lisoway, Zai, Tiwari, & Kennedy, 2017). Both increased and decreased DNA 
methylation levels on SLC6A4 and BDNF genes were associated with the use of anti-depressant 
medications, whereas MAOA methylation modification was not linked to anti-depressant 
response. The relationship between antidepressant treatment and DNA methylation of certain 
genes has been reported, i.e. BDNF DNA methylation modification was associated with the 
decreased gene expression, which can lead to MDD (Duman, 2002). The use of antidepressants 
can restore the decreased BDNF up to the normal level and alleviate depressive symptoms 
(Duman, 2002; Lee & Kim, 2010). Inconsistencies across all these findings may be explained by 
different ethnicities, duration of treatments, and pharmacogenetic heterogeneities (Kang H. , et 
al., 2013; Domschke, et al., 2014). It was suggested to investigate anti-depressant response 
across different treatment modalities since the level of DNA methylation may be altered during 
the treatment (Roberts, et al., 2014). 
4.6.4 Strengths and Limitations 
This review was the first study to apply the evidence-based approach to summarize an 
overall profile of the relationship between DNA methylation and depression. We critically 
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reviewed various study characteristics that can significantly impact on this association, including 
study design, study population, targeted gene/genome, methylation arrays, type of tissue, DNA 
purification, methylation validation, appropriate statistical methods, and the consideration of 
downstream analyses, e.g. genotyping and gene expression. We found that DNA methylation 
level was associated with depression, including both hypo- and hyper-methylations. Many genes 
are involved in the epigenetic changes of depression. In addition, study characteristics are also 
critical in this exploration. We suggest that results from more carefully crafted studies were more 
reliable and more likely to be replicated. 
However, there are several limitations of this review to be noted. First, this review aimed 
to provide an overview of the cutting edge findings on the relationship between DNA 
methylation and depression. Therefore, all eligible studies with a wide range of genomic 
coverage, i.e. targeted genes or whole-genome and different types of study designs were 
included. No pooled results were made to simply estimate this relationship, as many factors were 
involved. Second, although we used a systematic approach and subgroup analysis to retrieve all 
relevant studies and analyze more homogeneous studies, heterogeneity still exist in this review. 
Different types of tissues, study designs, depressive phenotypes (including MDD, depressive 
symptoms, postpartum depression, and post-stroke depression), comparison groups (depressive 
patients vs. healthy controls, severe patients vs. remitted patients), analytic methods, and sample 
sizes could be sources of heterogeneity and may lead to inconsistent results. Finally, most of the 
studies in this review were cross-sectional. Given that DNA methylation level is dynamic and 
potentially reversible, and can be affected by a number of environmental factors (such as 
chemical exposure, drug use, stress, aging, gender, diet, and lifestyle), cross-sectional DNA 
methylation measures may not be able to reveal the true relationship between this epigenetic 
modification and depression. 
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4.7 Conclusion 
Even though this review identified a high heterogeneity across studies on the relationship 
between DNA methylation and MDD, we did find in this overview a rising tide in the 
recognition of DNA methylation modification in depression, and generally that DNA methylation 
changes are associated with the disease. But there are some inconsistencies across studies 
because of the wide range of study characteristics, which directly influence the results. Most of 
studies have applied the widely acceptable lab techniques and statistical analyses for this 
relationship, which makes the pooled results more likely to reach a consistent findings. Future 
epigenetic studies should also adopt longitudinal study designs to trace the change of 
methylation levels at different phases of disease, for example pre- and post-treatment stages.  To 
allow for a systematic comparison of studies there should be an agreed upon consistent set of 
standards involving a minimum set for items for the execution and reporting of methylation 
studies similar to what is required for the reporting of clinical trials and systematic reviews and 
meta-analysis (Schulz, Altman, Moher, & The CONSORT Group, 2010; Moher, Liberati, 
Tetzlaff, & Altman, 2009). This would advance the field and provide a firm base for evidence on 
the relationship between DNA methylation and major depressive disorder.  
  
 80 
 
 
4.8 References 
Akula, N., Schulze, T. G., Muglia, P., Tozzi, F., Detera-Wadleigh, S. D., Steele, C. J., . . . 
McMahon, F. J. (2010). Meta-analysis of genome-wide association data identifies a risk 
locus for major mood disorders on 3p21.1. Nature Genetics, 42(2), 128-131. 
APA. (2013). Diagnostic and Statistical Mannual of Mental Disorders (5th ed.). Washington: 
American Psychiatric Association. 
Bakusic, J., Schaufeli, W., Claes, S., & Godderis, L. (2017). Stress, burnout and depression: a 
systematic review on DNA methylation mechanisms. Journal of Psychosomatic Research, 
92, 34-44. 
Barker, D. J. (2007). The origins of the developmental origins theory. Journal of Internal 
Medicine, 261, 412-417. 
BDNF gene. (2017, August 2). Retrieved August 7, 2017, from Genetics Home Reference: 
https://ghr.nlm.nih.gov/gene/BDNF 
Bick, J., Naumova, O., Hunter, S., Barbot, B., Lee, M., Luthar, S. S., . . . Grigorenko, E. L. 
(2012). Childhood adversity and DNA methylation of genes involved in the hypothalamus-
pituitary-adrenal axis and immune system: whole-genome and candidate-gene associations. 
Development and Psychopathology, 24(4), 1417-1425. 
Booij, L., Szyf, M., Carballedo, A., Frey, E.-M., Morris, D., Dymov, S., . . . Frodl, T. (2015). 
DNA methylation of the serotonin transporter gene in peripheral cells and stress-related 
changes in hippocampal volume: a study in depressed patients and healthy controls. PLoS 
ONE, e0119061. doi:10.1371/journal.pone.0119061 
Booij, L., Wang, D., Levesque, M. L., Tremblay, R. E., & Szyf, M. (2013). Looking beyond the 
DNA sequence: the relevance of DNA methylation processes for the stress-diathesis model 
of depression. Philosophical Transactions of the Royal Society of London. Series B, 
Biological Sciences, 368(1615), 20120251. 
Bremner, J. D., Narayan, M., Anderson, E. R., Staib, L. H., Miller, H. L., & Charney, D. S. 
(2000). Hippocampal Volume Reduction in Major Depression. The American Journal of 
Psychiatry, 157(1), 115-118. 
Butler, M. G. (2009). Genomic imprinting disorders in humans: a nimi-review. Jounal of Assisted 
Reproduction and Genetics, 26, 477-486. 
Byrne, E. M., Carrillo-Roa, T., Henders, A. K., Bowdler, L., McRae, A. F., Heath, A. C., . . . 
Wray, N. R. (2013). Monozygotic twins affected with major depressive disorder have 
greater variance in methylation than their unaffected co-twin. Translational Psychiatry, 3, 
e269. doi:10.1038/tp.2013.45 
Calabrese, F., Guidotti, G., Molteni, R., Racagni, G., Mancini, M., & Riva, M. A. (2012). Stress-
induced changes of hippocampal NMDA receptors: modulation by duloxetine treatment. 
PLoS One, 7(5), e37916. 
 81 
 
 
Caldwell, H. K., & Young, W. S. (2006). Oxytocin and Vasopressin: Genetics and Behavioral 
Implications. In A. Lajtha, & L. Ramon, Handbook of Neurochemistry and Molecular 
Neurobiology (3rd ed., pp. 573-607). Berlin: Springer. 
Cao, S., Iyer, J. K., & Lin, V. (2006). Identification of tetratricopeptide repeat domain 9, a 
hormonally regulated protein. Biochemical and Biophysical Research Communications, 
345, 310-317. 
Carlberg, L., Scheibelreiter, J., Hassler, M. R., Schloegelhofer, M., Schmoeger, M., Ludwig, 
B., . . . Schosser, A. (2014). Brain-derived neurotrophic factor (BDNF) - epigenetic 
regulation in unipolar and bipolar affective disorder. Journal of Affective Disorders, 168, 
399-406. 
Chagnon, Y. C., Potvin, O., Hudon, C., & Preville, M. (2015). DNA methylation and single 
nucleotide variants in the brain-derived neurotrophic factor (BDNF) and oxytocin receptor 
(OXTR) genes are associated with anxiety/depression in older women. Frontiers in 
Genetics, 6, 230. doi:10.3389/fgene.2015.00230 
Chen, D., Meng, L., Pei, F., Zheng, Y., & Leng, J. (2017). A review of DNA methylation in 
depression. Journal of Clinical Neuroscience. Retrieved from 
http://dx.doi.org/10.1016/j.jocn.2017.05.022 
Choi, S., Han, K.-M., Won, E., Yoon, B.-J., Lee, M.-S., & Ham, B.-J. (2015). Association of 
brain-derived neurotrophic factor DNA methylation and reduced white matter integrity in 
the anterior corona radiata in majordepression. Journal of Affective Disorders, 172, 74-80. 
Cohen-Woods, S., Craig, I. W., & McGuffin, P. (2013). The current state of play on the molecular 
genetics of depression. Psychological Medicine, 43(4), 673-687. 
Cordova-Palomera, A., Fatjo-Vilas, M., Gasto, C., Navarro, V., Krebs, M.-O., & Fananas, L. 
(2015). Genome-wide methylation study on depression: differential methylation and 
variable methylation in monozygotic twins. 5, e557. doi:10.1038/tp.2015.49 
D'Addario, C., Dell'Osso, B., Galimberti, D., Palazzo, M. C., Benatti, B., Francesco, A. D., . . . 
Maccarrone, M. (2013). Epigenetic modulation of BDNF gene in patients with major 
depressive disorder. Biological Psychiatry, 73(2), e6-7. 
Dalton, V. S., Kolshus, E., & McLoughlin, D. M. (2014). Epigenetics and depression: return of 
the repressed. Journal of Affective Disorders, 155, 1-12. 
Danese, A., Moffitt, T. E., Pariante, C. M., Ambler, A., Poulton, R., & Caspi, A. (2008). Elevated 
inflammation levels in depressed adults with a history of childhood maltreatment. Archives 
of General Psychiatry, 65(4), 409-415. 
Davies, M. N., Krause, L., Bell, J. T., Gao, F., Ward, K. J., Wu, H., . . . Wang, J. (2014). 
Hypermethylation in the ZBTB20 gene is associated with major depressive disorder. 
Genome Biology, 15, R56. 
Dell'Osso, B., D'Addario, C., Palazzo, M. C., Benatti, B., Camuri, G., Galimberti, D., . . . 
Altamura, A. C. (2014). Epigenetic modulation of BDNF gene: differences in DNA 
 82 
 
 
methylation between unipolar and bipolar patients. Journal of Affective Disorders, 166, 
330-333. 
Dempster, E. L., Pidsley, R., Schalkwyk, L. C., Owens, S., Georgiades, A., Kane, F., . . . Mill, J. 
(2011). Disease-associated epigenetic changes in monozygotic twins discordant for 
schizophrenia and bipolar disorder. Human Molecular Genetics, 20(24), 4786-4796. 
Domschke, K., Tidow, N., Schwarte, K., Deckert, J., Lesch, K., Arolt, V., . . . Baune, B. (2014). 
Serotonin transporter gene hypomethylation predicts impaired antidepressant treatment 
response. International Journal of Neuropsychopharmacology, 17(8), 1167-1176. 
doi:https://doi.org/10.1017/S146114571400039X 
Domschke, K., Tidow, N., Schwarte, K., Ziegler, C., Lesch, K.-P., Deckert, J., . . . Baune, B. T. 
(2015). Pharmacoepigenetics of depression: no major influence of MAO-A DNA 
methylation on treatment response. Journal of Neural Transmission, 122, 99-108. 
doi:10.1007/s00702-014-1227-x 
Duman, R. S. (2002). Pathophysiology of depression: the concept of synaptic plasticity. 
European Psychiatry, 17, 306-310. 
Dunn, E. C., Brown, R. C., Dai, Y., Rosand, J., Nugent, N. R., Amstadter, A. B., & Smoller, J. W. 
(2015). Genetic determinants of depression: recent findings and future directions. Harvard 
Review of Psychiatry, 23(1), 1-18. 
Ennis, C. (2014, April 25). Epigenetics 101: a beginner's guide to explaining everything. 
Retrieved September 11, 2017, from The Guardian: 
https://www.theguardian.com/science/occams-corner/2014/apr/25/epigenetics-beginners-
guide-to-everything 
Freudenberg, J. M., Ghosh, S., Lackford, B. L., Yellaboina, S., Zheng, X., Li, R., . . . Jothi, R. 
(2012). Acute depletion of Tet1-dependent 5-hydroxymethylcytosine levels impairs 
LIF/Stat3 signaling and results in loss of embryonic stem cell identity. Nucleic Acids 
Research, 40, 3364-3377. 
Frommer, M., McDonald, L., Millar, D. S., Collis, C., Watt, F., Grigg, G., . . . Paul, C. (1992). A 
genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in 
individual DNA strand. Proceedings of National Academy of Sciences of United States of 
America, 89, 1827-1831. 
Fuchikami, M., Morinobu, S., Segawa, M., Okamoto, Y., Yamawaki, S., Ozaki, N., . . . Terao, T. 
(2011). DNA methylation profiles of the Brain-Derived Neurotrophic Factor (BDNF) gene 
as a potent diagnostic biomarker in major depression. PLOS One, 6(8), e23881. 
Garfinkel, B. P., Arad, S., Le, P. T., Bustin, M., Rosen, C. J., Gabet, Y., & Orly, J. (2015). 
Proportionate dwarfism in mice lacking Heterochromatin Protein 1 Binding Protein 3 
(HP1BP3) is associated with alteration in the endocrine IGF-1 Pathway. Endocrinology, 
156(12), 4558-4570. 
 83 
 
 
Garfinkel, B. P., Arad, S., Neuner, S., Netser, S., Wagner, S., Kaczorowski, C. C., . . . Orly, J. 
(2016). HP1BP3 expression determines maternal behavior and offspring survival. Genes, 
Brain, and Behavior, 15, 678-688. 
Gaspar, P., Cases, O., & Maroteaux, L. (2003). The developmental role of serotonin: news from 
mouse molecular genetics. Nature Reviews Neuroscience, 4, 1002-1012. 
doi:10.1038/nrn1256 
Gerges, N. Z., Tran, I. C., Backos, D. S., Harrell, J. M., Chinkers, M., Pratt, W. B., & Esteban, J. 
A. (2004). Independent functions of hsp90 in neurotransmitter release and in the 
continuous synaptic cycling of AMPA receptors. The Journal of Neuroscience, 24, 4758-
4766. 
Gimpl, G., & Fahrenholz, F. (2001). The oxytocin receptor system: structure, function, and 
regulation. Physiological Reviews, 81(2), 629-683. 
Gomes, J. D., & Chang, C. J. (1983). Reverse-phase high-performance liquid chromatography of 
chemically modified DNA. Analytical Biochemistry, 129(2), 387-391. 
GRIN2A gene. (2017, August 2). Retrieved August 5, 2017, from Genetics Home Reference: 
https://ghr.nlm.nih.gov/gene/GRIN2A 
Guintivano, J., Arad, M., Gould, T. D., Payne, J. L., & Kaminsky, Z. A. (2014). Antenatal 
prediction of postpartum depression with blood DNA methylation biomarkers. Molecular 
Psychiatry, 19, 560-567. 
Haghighi, F., Galfalvy, H., Chen, S., Huang, Y.-Y., Cooper, T. B., Burke, A. K., . . . Sublette, M. 
E. (2015). DNA methylation perturbations in genes involved in polyunsaturated fatty acid 
biosynthesis associated with depression and suicide risk. Frontiers in Neurology, 6, 92. 
doi:10.3389/fneur.2015.00092 
Haghighi, F., Xin, Y., Chanrion, B., O'Donnell, A. H., Ge, Y., Dwork, A. J., . . . Mann, J. J. 
(2014). Increased DNA methylation in the suicide brain. Dialogues in Clinical 
Neuroscience, 16(3), 430-438. 
Harrison, A., & Parle-McDermott, A. (2011). DNA methylation: a timeline of methods and 
applications. Frontiers in Genetics, 2, 74. 
Hellman, A., & Chess, A. (2007). Gene body-specific methylation on the active X chromosome. 
Science, 315, 1141-1143. 
Herman, J., Graff, J., Moyhanen, S., Nelkin, B., & Baylin, S. (1996). Methylation-specific PCR: 
a novel PCR assay for methylation status of CpG islands. Proceedings of National 
Academy of Sciences of United States of America, 93, 9821-9826. 
Hohne, N., Poidinger, M., Merz, F., Pfister, H., Bruckl, T., Zimmermann, P., . . . Ising, M. (2015). 
FKBP5 genotype-dependent DNA methylation and mRNA regulation after psychosocial 
stress in remitted depression and healthy controls. International Journal of 
Neuropsychopharmacology, 1-9. doi:10.1093/ijnp/pyu087 
Hoopes, L. (2008). Introduction to the gene expression and regulation topic room. Nature 
Education, 1(1), 160. Retrieved from ene expression and regulation. 
 84 
 
 
Iga, J., Watanabe, S., Numata, S., Umehara, H., Nishi, A., Kinoshita, M., . . . Ohmori, T. (2016). 
Association study of polymorphism in the serotonin transporter gene promoter, 
methylation profiles, and expression in patients with major depressive disorder. Human 
Psychopharmacology: Clinical and Experimental, 31, 193-199. 
Ito, S., Shen, L., Dai, Q., Wu, S. C., Collins, L. B., Swenberg, J. A., . . . Zhang, Y. (2011). Tet 
proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. 
Science, 333, 1300-1303. 
Jones, P. A. (2012). Functions of DNA methylation: islands, start sites, gene bodies and beyond. 
Nature Reviews Genetics, 13(7), 484-492. 
Kahl, K. G., Georgi, K., Bleich, S., Muschler, M., Hillemacher, T., Hilfiker-Kleinert, D., . . . 
Frieling, H. (2016). Altered DNA methylation of glucose transporter 1 and glucose 
transporter 4 in patients with major depressive disorder. Journal of Psychiatric Research, 
76, 66-73. 
Kaminsky, Z., & Payne, J. (2014). Seeing the future: Epigenetic biomarkers of postpartum 
depression. Neuropsychopharmacology Reviews, 39, 233-234. doi:10.1038/npp.2013.238 
Kaminsky, Z., Tochigi, M., Jia, P., Pal, M., Mill, J., Kwan, A., . . . Petronis, A. (2012). A multi-
tissue analysis identifies HLA complex group 9 gene methylation differences in bipolar 
disorder. Molecular Psychiatry, 17(7), 728-740. 
Kang, H., Kim, J., Stewart, R., Kim, S., Bae, K., Kim, S., . . . Yoon, J. (2013). Association of 
SLC6A4 methylation with early adversity, characteristics and outcomes in depression. 
Progress in Neuro-Psychopharmacology and Biological Psychiatry, 44(1), 23-28. 
Kang, H.-J., Kim, J.-M., Stewart, R., Kim, S.-Y., Bae, K.-Y., Kim, S.-W., . . . Yoon, J.-S. (2013). 
Association of SLC6A4 methylation with early adversity, characteristics and outcomes in 
depression. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 44, 23-28. 
Karanges, E. A., Kashem, M. A., Sarker, R., Ahmed, E. U., Ahmed, S., Van Nieuwenhuijzen, P. 
S., . . . McGregor, I. S. (2013). Hipocampal protein expression is differentially affected by 
chronic paroxetine treatment in adolescent and adult rats: a possible mechanism of 
"paradoxical" antidepressant responses in young persons. Frontiers in Pharmacology, 4, 
86. 
Kaut, O., Schmitt, I., Hofmann, A., Hoffmann, P., Schlaepfer, T. E., Wullner, U., & Hurlemann, 
R. (2015). Aberrant NMDA receptor DNA methylation detected by epigenome-wide 
analysis of hippocampus and prefrontal cortex in major depression. European Archives of 
Psychiatry and Clinical Neuroscience, 265, 331-341. 
Kessler, R. C., McLaughlin, K. A., Green, J. G., Gruber, M. J., Sampson, N. A., Zaslavsky, A. 
M., . . . Williams, D. R. (2010). Childhood adversities and adult psychopathology in the 
WHO World Mental Health Surveys. The British Journal of Psychiatry: The Journal of 
Mental Science, 197(5), 378-385. 
Khulan, B., Manning, J. R., Dunbar, D. R., Seckl, J. R., Raikkonen, K., Eriksson, J. G., & Drake, 
A. J. (2014). Epigenomic profiling of men exposed to early-life stress reveals DNA 
 85 
 
 
methylation differences in association with current mental state. Translational Psychiatry, 
4, e448. doi:10.1038/tp.2014.94 
Kim, J.-M., Stewart, R., Kang, H.-J., Kim, S.-W., Shin, I.-S., Kim, H.-R., . . . Yoon, J.-S. (2013). 
A longitudinal study of SLC6A4 DNA promoter methylation and poststroke depression. 
Journal of Psychiatric Research, 47, 1222-1227. 
Kiss, A., & Mikkelsen, J. D. (2005). Oxytocin - anatomy and functional assignments: a 
minireview. Endocrine Regulations, 39(3), 97-105. 
Kleimann, A., Kotsiari, A., Sperling, W., Groschl, M., Heberlein, A., Kahl, K. G., . . . Frieling, H. 
(2015). BDNF serum levels and promoter methylation of BDNF exon I, IV and VI in 
depressed patients receiving electroconvulsive therapy. Journal of Neural Transmission, 
122, 925-928. 
Kosztolany, G. (2011). Hypothesis: epigenetic effects will require a review of the genetics of 
child development. Journal of Community Genetics, 2(2), 91-96. 
Kuo, K. C., McCune, R. A., Gehrke, C. W., Midgett, R., & Ehrlich, M. (1980). Quantitative 
reversed-phase high performance liquid chromatographic determination of major and 
modified deoxyribonucleosides in DNA. Nucleic Acids Research, 8(20), 4763-4776. 
Lam, L. L., Emberly, E., Fraser, H. B., Neumann, S. M., Chen, E., Miller, G. E., & Kobor, M. S. 
(2012). Factors underlying variable DNA methylation in a human community cohort. 
PNAS, 109, 17253-17260. 
Laurent, L., Wong, E., Li, G., Huynh, T., Tsirigos, A., Ong, C. T., . . . Wei, C. L. (2010). Dynamic 
changes in the human methylome during differentiation. Genome Research, 20(3), 320-
331. 
Lee, B. H., & Kim, Y. K. (2010). The roles of BDNF in the pathophysiology of major depression 
and in antidepressant treatment. Psychiatry Investigation, 7(4), 231-235. 
Lee, H. C., Chang, D. E., Yeom, M., Kim, G. H., Choi, K. D., Shim, I., . . . Hahm, D. H. (2005). 
Gene expression projiling in hypothalamus of immobilization-stressed mouse using cDNA 
microarray. Molecular Brain Research, 135(1-2), 293-300. 
Levinson, D. F. (2006). The genetics of depression: a review. Biological Psychiatry, 60(2), 84-
92. 
Lewis, C. M., Ng, M. Y., Butler, A. W., Cohen-Woods, S., Uher, R., Pirlo, K., . . . McGuffin, P. 
(2010). Genome-wide association study of major recurrent depression in the UK 
population. American Journal of Psychiatry, 167(8), 949-957. 
Lienert, F., Wirbelauer, C., Som, I., Dean, A., Mohn, F., & Schubeler, D. (2011). Identification of 
genetic elements that autonomously determine DNA methylation states. Nature Genetics, 
43(11), 1091-1097. 
Lisoway, A., Zai, C., Tiwari, A., & Kennedy, J. (2017). DNA methylation and clinical response 
to antidepressant medication in major depressive disorder: a review and recommendations. 
Neuroscience Letters. Retrieved from http://dx.doi.org/10.1016/j.neulet.2016.12.071 
 86 
 
 
Lockwood, L. E., Su, S., & Youssef, N. A. (2015). The role of epigenetics in depression and 
suicide: A platform for gene-environment interactions. Psychiatry Research, 228(3), 235-
242. 
Lohoff, F. W. (2010). Overview of the genetics of major depressive disorder. Current Psychiatry 
Report, 12(6), 539-546. 
Lopez-Serra, P., & Esteller, M. (2012). DNA methylation-associated silencing of tumor-
suppressor microRNAs in cancer. Oncogene, 31(13), 1609-1622. 
Los, M., Maddika, S., Erb, B., & Schulze-Osthoff, K. (2009). Switching Akt: from survival 
signaling to deadly response. BioEssays, 31(5), 492-495. 
Lu, N. Z., Wardell, S. E., Burnstein, K. L., Defranco, D., Fuller, P. J., Giguere, V., . . . Cidlowski, 
J. A. (2006). International Union of Pharmacology. LXV. The pharmacology and 
classification of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid, 
progesterone, and androgen receptors. Pharmacological Reviews, 58(4), 782-797. 
Malcangio, M., & Lessmann, V. (2003). A common thread for pain and memory synapses? 
Brain-derived neurotrophic factor and TRKB receptors. Trends in Pharmacological 
Sciences, 24, 116-121. 
McGowan, P. O., Sasaki, A., D'Alessio, A. C., Dymov, S., Labonte, B., Szyf, M., . . . Meaney, M. 
J. (2009). Epigenetic regulation of the glucocorticoid receptor in human brain associates 
with childhood abuse. Nature Neuroscience, 12, 342-348. 
Melas, P. A., & Forsell, Y. (2015). Hypomethylation of MAOA's first exon region in depression: 
A replication study. Psychiatry Research, 226, 389-391. 
Melas, P. A., Wei, Y., Wong, C. C., Sjoholm, L. K., Aberg, E., Mill, J., . . . Lavebratt, C. (2013). 
Genetic and epigenetic associations of MAOA and NR3C1 with depression and childhood 
adversities. International Journal of Neuropsychopharmacology, 16, 1513-1528. 
doi:10.1017/S1461145713000102 
Meyer-Lindenberg, A. (2009). Neural connectivity as an intermediate phenotype: brain networks 
under genetic control. Human Brain Mapping, 30(7), 1938-1946. 
Mitchelmore, C., Kjaerulff, K. M., Pedersen, H. C., Nielsen, J. V., Rasmussen, T. E., Fisker, M. 
F., . . . Jensen, N. A. (2002). Characterization of two novel nuclear BTB/POZ domain zinc 
finger isoforms. Association with differentiation of hippocampal neurons, cerebellar 
granule cells, and macroglia. Journal of Biological Chemistry, 277, 7598-7609. 
Moffitt, T. E., & Tank, t. K.-G. (2013). Childhood exposure to violence and lifelong health: 
clinical intervention science and stress biology research join forces. Development and 
Psychopathology, 25, 4 0 2. doi:10.1017/S0954579413000801 
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. (2009). Preferred reporting items for 
systematic reviews and meta-analysis: the PRISMA statement. PLoS Medicine, 6, 
e1000097. 
 87 
 
 
Muglia, P., Tozzi, F., Galwey, N. W., Francks, C., Upmanyu, R., Kong, X. Q., . . . Roses, A. D. 
(2010). Genome-wide association study of recurrent major depressive disorder in two 
European case-control cohorts. Molecular Psychiatry, 15(6), 589-601. 
Murgatroyd, C., Patchev, A. V., Wu, Y., Micale, V., Bockmuhl, Y., Fischer, D., . . . Spengler, D. 
(2009). Dynamic DNA methylation programs persistent adverse effects of early-life stress. 
Nature Neuroscience, 12(12), 1559-1566. 
Murray, C. J., Vos, T., Lozano, R., Naghavi, M., Flaxman, A. D., Michaud, C., . . . Bridgett, L. 
(2012). Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 
1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancent, 
380(9859), 2190-2223. 
Na, K.-S., Won, E., Kang, J., Chang, H. S., Yoon, H.-K., Tae, W. S., . . . Ham, B.-J. (2016). 
Brain-derived neurotrophic factor promoter methylation and cortical thickness in recurrent 
major depressive disorder. Scientific Reports. doi:10.1038/srep21089 
Nagy, C., Suderman, M., Yang, J., Szyf, M., Mechawar, N., Ernst, C., & Turechi, G. (2015). 
Astrocytic abnormalities and global DNA methylation patterns in depression and suicide. 
Molecular Psychiatry, 20, 320-328. 
Nantharat, M., Wanitchanon, T., Amesbutr, M., Tammachote, R., & Praphanphoj, V. (2015). 
Glucocorticoid receptor gene (NR3C1) promoter is hypermethylated in Thai females with 
major depressive disorder. Genetics and Molecular Research, 14(4), 19071-19079. 
Neuner, S. M., Garfinkel, B. P., Wilmott, L. A., Ignatowska-Jankowska, B. M., Citri, A., Orly, 
J., . . . Kaczorowski, C. C. (2016). Systems genetics identifies HP1BP3 as a novel 
modulator of cognitive aging. Neurobiology of Aging, 46, 58-67. 
Newman, L., Judd, F., Olsson, C. A., Castle, D., Bousman, C., Sheehan, P., . . . Everall, I. (2016). 
Early origins of mental disorder- risk factors in the perinatal and infant period. BMC 
Psychiatry, 16, 270. 
Nguyen, T., Nioi, P., & Pickett, C. B. (2009). The Nrf2-Antioxidant response element signaling 
pathway and its activation by oxidative stress. Journal of Biological Chemistry, 284(20), 
13291-13295. 
Numata, S., Ishii, K., Tajima, A., Iga, J., Kinoshita, M., Watanabe, S., . . . Ohmori, T. (2015). 
Blood diagnostic biomarkers for major depressive disorder using multiplex DNA 
methylation profiles: discovery and validation. Epigenetics, 10(2), 135-141. 
Oakeley, E. J., A, P., & Jost, J. P. (1997). Developmental changes in DNA methylation of the two 
tobacco pollen nuclei during maturation. Proceedings of the National Academy of Sciences 
of the United States of America, 94(21), 11721-11725. 
Oberlander, T. F., Weinberg, J., Papsdorf, M., Grunau, R., Misri, S., & Devlin, A. M. (2008). 
Prenatal exposure to maternal depression, neonatal methylation of human glucocorticoid 
receptor gene (NR3C1) and infant cortisol stress responses. Epigenetics, 3, 97-106. 
 88 
 
 
Oh, G., Wang, S.-C., Pal, M., Chen, Z. F., Khare, T., Tochigi, M., . . . Petronis, A. (2015). DNA 
modification study of major depressive disorder: beyond locus-by-locus comparisons. 
Biological Psychiatry, 77(3), 246-255. 
Okada, S., Morinobu, S., Fuchikami, M., Segawa, M., Yokomaku, K., Kataoka, T., . . . Mimura, 
M. (2014). The potential of SLC6A4 gene methylation analysis for the diagnosis and 
treatment of major depression. Journal of Psychiatric Research, 53, 47-53. 
Olsson, C. A., Foley, D. L., Parkinson-Bates, M., Byrnes, G., McKenzie, M., Patton, G. C., . . . 
Saffery, R. (2010). Prospects for epigenetic research within cohort studies of psychological 
disorder: a pilot investigation of a peripheral cell marker of epigenetic risk for depression. 
Biological Psychology, 83(2), 159-165. 
Osborne, L., Clive, M., Kimmel, M., Gispen, F., Guintivano, J., Brown, T., . . . Kaminsky, Z. 
(2016). Replication of epigenetic postpartum depression biomarkers and variation with 
hormone levels. Neuropsychopharmacology, 41, 1648-1658. 
Pajer, K., Andrus, B. M., Gardner, W., Lourie, A., Strange, B., Campo, J., . . . Redei, E. E. 
(2012). Discovery of blood transcriptomic markers for depression in animal models and 
pilot validation in subjects with early-onset major depression. Translational Psychiatry, 2, 
e101. 
Patel, C. V., & Gopinathan, K. P. (1987). Determination of trace amounts of 5-methylcytosine in 
DNA by reverse-phase high-performance liquid chromatography. Analytical Biochemistry, 
164(1), 164-169. 
Paul, S. (2008). Dysfunction of the ubiquitin-proteasome system in multiple disease conditions: 
therapeutic approaches. BioEssays, 30(11-12), 1172-1184. 
Philibert, R. A., Sandhu, H., Hollenbeck, N., Gunter, T., Adams, W., & Madan, A. (2008). The 
relationship of 5HTT (SLC6A4) methylation and genotype on mRNA expression and 
liability to major depression and alcohol dependence in subjects from the Iowa Adoption 
Studies. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 0(5), 
543-549. doi:10.1002/ajmg.b.30657 
Ptak, C., & Petronis, A. (2010). Epigenetic approaches to psychiatric disorders. Dialogues in 
Clinical Neuroscience, 12(1), 25-35. 
Radtke, K. M., Ruf, M., Gunter, H. M., Dohrmann, K., Schauer, M., Meyer, A., & Elbert, T. 
(2011). Transgenerational impact of intimate partner violence on methylation in the 
promoter of the glucocorticoid receptor. Translational Psychiatry, 1, 1-6. 
Rettner, R. (2013, June 24). Epigenetics: Definition and Examples. Retrieved September 1, 2017, 
from Live Science: https://www.livescience.com/37703-epigenetics.html 
Rhen, T., & Cidlowski, J. A. (2005). Antiinflammatory action of glucocorticoids - new 
mechanisms for old drugs. The New England Journal of Medicine, 353(16), 1711-1723. 
Rice, F., Harold, G. T., & Thapar, A. (2001). Assessing the effects of age, sex and shared 
environment on the genetic aetiology of depression in childhood and adolescence. The 
Journal of Child Psychology and Psychiatry, 43(8), 1039-1051. 
 89 
 
 
Rihlaarsdam, J., Cecil, C. A., Walton, E., Mesirow, M. S., Relton, C. L., Gaunt, T. R., . . . Barker, 
E. D. (2016). Prenatal unhealthy diet, insulin-like growth factor 2 gene (IGF2) methylation, 
and attention deficit hyperactivity disorder symptoms in youth with early-onset conduct 
problems. Journal of Child Psychology and Psychiatry. doi:10.1111/jcpp.12589 
Roberts, S., Lester, K., Hudson, J., Rapee, R., Creswell, C., Cooper, P., . . . Eley, T. (2014). 
Serotonin transporter methylation and response to cognitive behaviour therapy in children 
with anxiety disorders. Translational Psychiatry, 4, e444. doi:10.1038/tp.2014.83 
Roth, T. L., Lubin, F. D., Funk, A. J., & Sweatt, J. D. (2009). Lasting epigenetic influence of 
early-life adversity on the BDNF gene. Biological Psychiatry, 65, 760-769. 
Sabunciyan, S., Aryee, M. J., Irizarry, R. A., Rongione, M., Webster, M. J., Kaufman, W. E., . . . 
GenRED Consortium. (2012). Genome-wide DNA methylation scan in major depressive 
disorder. PLoS ONE, 7(4), e34451. doi:10.1371/journal.pone.0034451 
Santos, F., Hendrich, B., Reik, W., & Dean, W. (2002). Dynamic reprogramming of DNA 
methylation in the early mouse embryo. Developmental Biology, 241(1), 172-182. 
Saveanu, R. V., & Nemeroff, C. B. (2012). Etiology of depression: genetic and environmental 
factors. Psychiatric Clinics of North America, 35(1), 51-71. 
Schadt, E. E. (2009). Molecular networks as sensors and drivers of common human diseases. 
Nature, 461(7261), 218-223. 
Schulz, K., Altman, D., Moher, D., & The CONSORT Group. (2010). CONSORT 2010 
Statement: updated guidelines for reporting parallel group randomised trials. BMC 
Medicine 2010, 8, 18. 
Sheline, Y. I., Mittler, B. L., & Mintun, M. A. (2002). The hippocampus and depression. 
European Psychiatry, 17, 300-305. 
Sheline, Y., Wang, P., Gado, M., Csernansky, J., & Vannier, M. (1996). Hippocampal atrophy in 
recurrent major depression. Proceedings of the National Academy of Sciences USA, 93, 
3908-3913. 
Shi, J., Potash, J. B., Knowles, J. A., Weissman, M. M., Coryell, W., Scheftner, W. A., . . . 
Levinson, D. F. (2011). Genome-wide association study of recurrent early-onset major 
depressive disorder. Molecular Psychiatry, 16(2), 193-201. 
Shyn, S. I., & Hamilton, S. P. (2010). The genetics of major depression: moving beyond the 
monoamine hypothesis. Psychiatric Clinics North America, 33(1), 125-140. 
Silberg, J., Pickles, A., Rutter, M., Hewitt, J., Simonoff, E., Maes, H., . . . Eaves, L. (1999). The 
influence of genetic factors and life stress on depression among adolescent girls. Archives 
of General Psychiatry, 56(3), 225-232. 
Szyf, M., & Bick, J. (2013). DNA methylation: a mechanism for embedding early life 
experiences in the genome. Child Development, 84(1), 49-57. 
Tadic, A., Muller-Engling, L., Schlicht, K. F., Kotsiari, A., Dreimuller, N., Kleimann, A., . . . 
Frieling, H. (2014). Methylation of the promoter of brain-derived neurotrophic factor exon 
 90 
 
 
IV and antidepressant response in major depression. Molecular Psychiatry, 19, 281-283. 
doi:10.1038/mp.2013.58 
Tao-Cheng, J. H., & Zhou, F. C. (1999). Differential polarization of serotonin transporters in 
axons versus soma-dendrites: an immunogold electron microscopy study. Neuroscience, 
94(3), 821-830. 
Tseng, P.-T., Lin, P.-Y., Lee, Y., Hung, C.-F., Lung, F.-W., Chen, C.-S., & Chong, M.-Y. (2014). 
Age-associated decrease in global DNA methylation in patients with major depression. 
Neuropsychiatric Disease and Treatment, 10, 2105-2114. 
Uddin, M., Koenen, K. C., Aiello, A. E., Wildman, D. E., de los Santos, R., & Galea, S. (2011). 
Epigenetic and inflammatory marker profiles associated with depression in a community-
based epidemiologic sample. Psychological Medicine, 41, 997-1007. 
Uddin, M., Sipahi, L., Li, J., & Koenen, K. C. (2013). Sex differences in DNA methylation may 
contribute to risk of PTSD and depression: A review of existing evidence. Depress Anxiety, 
30(12), 1151-1160. 
Unternaehrer, E., Meyer, A. H., Burkhardt, S. C., Dempster, E., Staehli, S., Theill, N., . . . 
Meinlschmidt, G. (2015). Childhood maternal care is associated with DNA methylation of 
the genes for brain-derived neurotrophic factor (BDNF) and oxytocin receptor (OXTR) in 
peripheral blood cells in adult men and women. Stress, 18(4), 451-461. 
van der Knaap, L. J., van Oort, F. V., Verhulst, F. C., Oldehinkel, A. J., & Riese, H. (2015). 
Methylation of NR3C1 and SLC6A4 and internalizing problems. The TRAILS study. 
Journal of Affective Disorders, 180, 97-103. 
van Mil, N. H.-T., Bouwland-Both, M. I., Verbiest, M. M., Rijlaarsdam, J., Hofman, A., Steegers, 
E. A., . . . Tiemeier, H. (2014). DNA methylation profiles at birth and child ADHD 
symptoms. Journal of Psychiatric Research, 49, 51-59. 
Veenema, A. H., & Neumann, I. D. (2008). Central vasopressin and oxytocin release: regulation 
of complex social behaviours. Progress in Brain Research, 170, 261-276. 
Vythilingam, M., Heim, C., Newport, J., Miller, A. H., Anderson, E., Bronen, R., . . . Bremner, J. 
D. (2002). Childhood trauma associated with smaller hippocampal volume in women with 
major depression. The American Journal of Psychiatry, 159(12), 2072-2080. 
Walker, R. M., Christoforou, A. N., McCartney, D. L., Morris, S. W., Kennedy, N. A., Morten, 
P., . . . Porteous, D. J. (2016). DNA methylation in a Scottish family multiply affected by 
bipolar disorder and major depressive disorder. Clinical Epigenetics, 8, 5. 
doi:10.1186/s13148-016-0171-z 
What is Epigenetics. (2013, July 30). A super brief and basic explanation of epigenetics for total 
beginners. Retrieved September 11, 2017, from https://www.whatisepigenetics.com/what-
is-epigenetics/ 
WHO. (1992). The ICD-10 classification of mental and behavioral disorders: clinical 
descriptions and diagnostic guidelines. Geneva: World Health Organization. 
 91 
 
 
Wikipedia. (2016, November 23). Retrieved December 28, 2016, from Gene expression: 
https://en.wikipedia.org/wiki/Gene_expression 
Wikipedia. (2017, August 26). DNA Methylation. Retrieved September 11, 2017, from 
Wikipedia, the free encyclopedia: https://en.wikipedia.org/wiki/DNA_methylation 
Wojdacz, T. K., & Dobrovic, A. (2007). Methylation-sensitive high resolution melting (MS-
HRM): a new approach for sensitive and high-throughput assessment of methylation. 
Nucleic Acids Research, 35, e41. 
Wray, N. R., Pergadia, M. L., Blackwood, D. H., Penninx, B. W., Gordon, S. D., Nyholt, D. 
R., . . . Sullivan, P. F. (2012). Genome-wide association study of major depressive disorder: 
new results, metaanalysis, and lessons learned. Molecular Psychiatry, 17(1), 36-48. 
Wu, H., Coskun, V., Tao, J., Xie, W., W, G., Yoshikawa, K., . . . Sun, Y. E. (2010). Dnmt3a-
dependent nonpromoter DNA methylation facilitates transcription of neurogenic genes. 
Science, 329(5990), 444-448. 
Xu, M., Long, C., Chen, X., Huang, C., Chen, S., & Zhu, B. (2010). Partitioning of histone H3-
H4 tetramers during DNA replication-dependent chromatin assembly. Science, 328(5974), 
94-98. 
ZBTB20 gene. (2017, July 25). Retrieved August 1, 2017, from Genetics Home Reference: 
https://ghr.nlm.nih.gov/gene/ZBTB20#resources 
Zhang, Y., Chang, Z., Chen, J., Ling, Y., Liu, X., Feng, Z., . . . Zhang, C. (2015). Methylation of 
the tryptophan hydroxylase-2 gene is associated with mRNA expression in patients with 
major depression with suicide attempts. Molecular Medicine Reports, 12, 3184-3190. 
Zhao, J., Goldberg, J., Bremner, J. D., & Vaccarino, V. (2013). Association between promoter 
methylation of serotonin transporter gene and depressive symptoms: a monozygotic twin 
study. Psychosomatic Medicine, 75, 523-529. 
Zheleznyakova, G. Y., Cao, H., & Schioth, H. B. (2016). BDNF DNA methylation changes as a 
biomarker of psychiatric disorders: literature review and open access database analysis. 
Behavioral and Brain Functions, 12, 17. 
Zill, P., Baghai, T. C., Schule, C., Born, C., Frustuck, C., Buttner, A., . . . Bondy, B. (2012). DNA 
methylation analysis of the Angiotensin Converting Enzyme (ACE) gene in major 
depression. PLoS ONE, 7(7), e40479. doi:10.1371/journal.pone.0040479 
Zingg, H. H., & Laporte, S. A. (2003). The oxytocin receptor. Trends in Endocrinology and 
Metabolism, 14(5), 222-227. 
 
 
  
 92 
 
 
Appendix 1 Search Strategy 
PubMed 
((((((((depressive disorder [MeSH Terms]) OR major depressive disorder [Text Word]) OR major 
depression [Text Word]) OR unipolar depression [Text Word]) OR depression [Text Word]) OR 
depressed [Text Word]) OR depressive [Text Word])) AND ((((DNA methylation [MeSH Terms]) 
OR methylation [Text Word]) OR epigenetic*[Text Word])) filters: Humans 
 
MEDLINE 
(Mesh (depressive disorder) OR (major depressive disorder) OR (major depression) OR (unipolar 
depression) OR depression OR depressed OR depressive) AND (mesh (DNA methylation) OR 
methylation OR epigenetic*) 
 
Web of Sciences  
#1   TS="DNA methylation" OR TS=methylation OR TS=epigenetic*  
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years 
#2   TS="depressive disorder" OR TS="major depressive disorder" OR TS="major depression" 
OR TS="unipolar depression" OR TS=depression OR TS=depressed OR TS=depressive  
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years 
#3   #2 AND #1 
 
EMBASE  
1 ("DNA methylation" or "methylation" or epigenetic*).mp. [mp=title, abstract, heading word, 
drug trade name, original title, device manufacturer, drug manufacturer, device trade name, 
keyword] 
2 limit 1 to human 
3 1 and 2 
4   ("depressive disorder" or "major depressive disorder" or "major depression" or "unipolar 
depression" or depression or depressed or depressive).mp. [mp=title, abstract, heading word, drug 
trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword] 
5 limit 4 to human 
6 4 and 5 
7 3 and 6 
 
Cochrane Library 
#1 MeSH descriptor: [Depressive Disorder] explode all trees 
#2 "major depressive disorder" or "major depression" or "unipolar depression" or "depressed" 
or "depression” (Word variations have been searched) 
#3 #2 or #1 or "depressive" (Word variations have been searched) 
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#4 MeSH descriptor: [DNA Methylation] explode all trees 
#5 methylation or epigenetic* (Word variations have been searched) 
#6 #4 or #5 
#7 #3 and #6 
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Appendix 3 Characteristics Table 
ID 1 2 3 
First Author Numata Bayles Booij 
Year 2015 2013 2015 
Country Japan Australia Canada 
Age cases: 44.2±15.2; controls: 
42.4±12.3 
cases: 39 ± 2; controls: 42 
± 2 
cases: 40.3 ± 9.5; controls: 
35.3 ± 12.8 
Sample Size 63 (39 discovery and 24 
replication) 
106 69 
Cases 32 (20 discovery and 12 
replication) 
36 (18 males/18 females)  33 (23 females/ 10 males) 
Diagnostic standard DSM-IV DSM-IV DSM-IV, SCID interview 
confirmed, BDI-II 
Controls  31 (19 discovery and 12 
replication) 
70 (47 males/23 females) 36 (21 females/ 15 males) 
Study design discovery-replication 
cohort (case-control) 
case-control case-control 
Cohorts  Hospital-based cases and 
matched controls from 
Japanese 
media advertised 
recruitment  
mental health service of 
hospital 
Biological Sample Peripheral blood blood (leukocytes) peripheral cells (whole 
blood DNA) 
Purification of DNA 
extraction  
Not mentioned not mentioned Not mentioned 
DNA methylation 
methods/ Kits 
Bisulfite conversion EZ 
DNA methylation Kit 
(ZYMO research), 
Infinium Human 
Methylation 450 
Beadchips 
Bisulfite conversion, PCR 
and sequencing; 
EpiTYPER methylation 
analysis 
Bisulfite conversion, 
pyrosequencing; 
PyroMark Q24 Software 
Candidate genes vs. 
genome  
Genome (485,764 CpG 
inlands)  
Two regions in Promoter 
methylation of SLC6A4  
SLC6A4 promoter, 
targeted CpG sites 5–15 
Methylation Validation Next generation 
sequencing (R2=0.81) 
two methodologies not mentioned 
Genotyping No No Yes 
Gene expression Yes No Yes 
Analytical method of 
methylation difference 
Mann-Whitney U test two-way ANOVA linear regression 
Major findings 363 CpG sites 
demonstrated lower DNA 
methylation in MDD 
patients than in controls.  
18 MDD-associated DNA 
methylation markers to 
discriminate cases from 
controls 
No significant differences 
between MDE cases and 
controls in terms of the 
pattern of methylation of 
the SLC6A2 promoter. 
Antidepressant treatment 
did not change the result. 
MDD diagnosis was not 
significantly associated 
with DNA methylation.  
Patients with SSRIs had 
greater methylation levels 
at 2 CpG. 
Category Genome SLC6A4 SLC6A4; treatment 
response 
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ID 4 5 
First Author Carlberg Dell'Osso 
Year 2014 2014 
Country Austria Italy 
Age cases: 46.03 ± 1.07; controls: 31.8 ± 0.55 Age matched 
Sample Size 554 (207 MDD, 59 BD, 278 control) 87 
Cases 207 43 
Diagnostic standard DSM-IV DSM IV 
Controls  278 Age-matched, 44 
Study design case-control case-control 
Cohorts  not mentioned Not mentioned 
Biological Sample peripheral blood mononuclear cells peripheral blood mononuclear cells 
(PBMCs) 
Purification of DNA 
extraction  
PUREGENE DNPurification Kit Not mentioned 
DNA methylation 
methods/ Kits 
Bisulfite convertion, EZ-96 DNA 
Methylation Kit.  Used methylation-
specific quantitativePCR 
bisulfite convertion, PCR and 
sequencing 
Candidate genes vs. 
genome  
BDNF exon I promoter BDNF exon I promoter, 17CpG sites. 
Methylation Validation not mentioned Bisulfite-modified universal 
unmethylated DNA as negative control 
Genotyping Yes No 
Gene expression No No 
Analytical method of 
methylation difference 
Pearson's correlation coefficient test ANOVA followed by Bonferroni's 
post-hoc test 
Major findings BDNF exon I promoter significantly 
increased in MDD.  Anti-depressant 
therapy associated with increase 
methylation. 
Higher level of BDNF DNA 
methylation: MDD statistical 
significance compared with BD-I; 
Overall lithium and valproate tended to 
decrease, even though not 
significantly, DNA methylation level 
at BDNF gene promoter. However, 
mood stabilizers did not seem to affect 
DNA methylation. 
Category BDNF; treatment response BDNF; treatment response 
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ID 6 7 8 
First Author Davies Fuchikami Frodl 
Year 2014 2011 2015 
Country UK & Australia Japan Ireland 
Age Age matched cases: 45.6 ± 12.5; 
controls: 42.3 ± 9.6 
cases: 41.6 ± 10.8; 
controls: 35.6 ± 13.0 
Sample Size 454 - A. 50 twin pairs:  A. 
50 MZ twins [27MZT 
pairs(UK) + 23 pairs(AU)];   
B. replication: 354 age-
matched [118 MDD, 236 
control (female)] 
38 60 
Cases B. replication: 118 MDD 20 (8 males/ 12 females) 25 
Diagnostic standard DSM IV DSM IV DSM  IV 
Controls  B. replication: 236 control 18 (10 males/ 8 females) 35 
Study design A. twin study; B case-control case-control case-control 
Cohorts  UK: TwinsUK Registry.  
AU: Australian Twin 
Registry. 
control recruited by 
advertisement 
Patient: hospital based.  
Control from local 
community 
Biological Sample Whole blood samples peripheral blood peripheral blood 
Purification of DNA 
extraction  
Nucleon Genomic DNA 
Extraction Kit BACC3 
(UK) ;  salt extraction 
method (AU) 
DNeasy Blood &Tissue 
Kits 
Not mentioned 
DNA methylation 
methods/ Kits 
Methylated DNA 
immunoprecipitation 
combined with ultra-deep 
sequencing (MeDIP-seq) 
(enrichment  for methylated 
regions) 
Bisulfite convertion using 
EZ DNA methylation kit 
Bisulfite convertion, 
pyrosequencing, 
PyroMark Q24 
Candidate genes vs. 
genome  
Genome-wide MeDIP-
Sequencing.  4 DMRs for 
replication. 
BDNF gene , 2 CpG 
islands( I and IV) 
SLC6A4 promoter CpG5-
15 
Methylation Validation Not mentioned Not mentioned The mean of methylation 
percentage from sites 5–15 
Genotyping No No No 
Gene expression Yes No No 
Analytical method of 
methylation difference 
linear mixed effect model Hierarchical clustering 
analyses 
Regression analysis 
Major findings Both AU&UK did not 
identify DMR of genome-
wide significance. MDD is 
hypermethylation on coding 
region ZBTB20.  
Meta-analysis:  17 DMRs of 
genome-wide significance 
ZBTB20, AGTPBP1, 
TBC1D8 and CLSTN1 for 
replication. 
Case-control: increased 
methylation. 
Methylation changes do not 
relate to anti-depression use. 
Significant methylation 
difference in CpG I, not 
in IV. 
Diagnosis not significantly 
associated with 
methylation. 
Category Genome; treatment response BDNF SLC6A4 
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ID 9 10 
First Author Iga Januar 
Year 2016 2015 
Country Japan France 
Age cases: 45.0 ± 13.1; controls: 42.2 ± 
12.1 
cases: 72.0 ± 4.5; controls: 71.4 ± 
4.5 
Sample Size 57 1024 
Cases 28 (8 males/ 20 females) 773 
Diagnostic standard DSM IV DSM IV, Late-life depression - 
CES-D⩾16 or current MDD. 
Controls  29 (8 males/ 21 females) 251 
Study design case-control case-control 
Cohorts  both health and control form hospital A longitudinal study of general 
population 
Biological Sample leukocytes Buccal tissue 
Purification of DNA extraction  QIAamp DNA Blood Maxi Kit Not mentioned 
DNA methylation methods/ Kits Bisulfite convertion, 
pyrosequencing, EpiTect Plus DNA 
Bisulfite Kit 
Bisulphite convertion, EZ-96 
DNA 
Methylation-Lightning MagPrep 
Candidate genes vs. genome  5HTT promoter region, 9 CpGs BDNF PROMOTER 1 AND IV 
Methylation Validation The methylation percentage at each 
CpG region was quantified in 
duplicate using PyroMark Q24 
not mentioned 
Genotyping Yes Yes 
Gene expression Yes No 
Analytical method of methylation 
difference 
Unpaired t-test Linear regression 
Major findings Mean methylation level was 
significantly increase in patients 
compared with controls.  No 
significant difference in single CpG 
site.  
Depression at baseline and 
chronic late-life is associated 
with higher BDNF methylation, 
CpG3,4,5. 
Category SLC6A4 BDNF 
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ID 11 12 
First Author Kahl Kang 
Year 2016 2015 
Country German Korea 
Age cases: 41.8 ± 11.1; controls: 43.2 ± 13.1 50.8 ± 9.7 
Sample Size 70 309 at baseline, 244 
followed-up 
Cases 52 (37 of which finished treatment) Baseline: 74 diagnosed with 
depression; Follow-up: 44 
diagnosed 
Diagnostic standard DSM IV DSM IV 
Controls  18 Not applicable 
Study design case-control Longitudinal study, 
followed at 1 year 
Cohorts  Case were inpatients with MDD treated; 
Controls from university announcements 
Hospital based, all women 
with breast cancer 
undergoing breast surgery 
Biological Sample Genomic DNA, frozen EDTA-blood  leukocyte DNA 
Purification of DNA extraction  QIAamp DNA Blood Mini Kit QIAamp DNA Blood Mini 
Kit 
DNA methylation methods/ Kits Bisulfite conversion, PCR and 
sequencing. Sodium-bisulfite using the 
EpiTect Bisulfite Kit); Sequencing was 
performed using a BigDye Terminator 
v3.1 Cycle Sequencing Kit. 
Bisulfite conversion using 
EpiTech Bisulfite Kit, 
Pyrosequencing using the 
PSQ 96M System 
Candidate genes vs. genome  Core promoter regions of GLUT1 and 
GLUT4. 
BDNF CpG1-9 (-612 -- -
463) 
Methylation Validation not mentioned not mentioned 
Genotyping No Yes 
Gene expression No No 
Analytical method of methylation 
difference 
Mixed linear models T-test and multivariate 
logistic regression models 
Major findings Increased methylation of GLUT1 in 
MDD.  Not difference found in GLUT4. 
Higher methylation 
percentage at CpG9 with 
depression, both 1 week and 
1 year, after breast cancer. 
Category Others BDNF 
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ID 13 14 15 
First Author Kang Kang Kaut 
Year 2015 2013 2015 
Country South Korea Korea Netherlands 
Age 72.8 ± 5.9 54.9 ± 14.9 cases: not mentioned; 
controls: 78.8 ± 14.2 
Sample Size 631 without depression at 
baseline (521 of which were 
followed-up) 
108 MDD patients 12 
Cases 86/521 were identified 
depression at follow-up 
Not applicable 6 
Diagnostic standard GMS AGECAT; severity - 
Geriatric Depression Scale 
(GDS) 
DSM IV DSM III 
Controls  Not applicable Not applicable 6 
Study design Longitudinal, followed-up 
for 2 years. 
Longitudinal, Baseline, 
12-week treatment with 
antidepressants.  
Pilot-replcation, 5 
genes selected for 
replication. 
Cohorts  A community-based 
prospective survey of late-
life psychiatric morbidity 
Hospital based Netherlands Brain 
Bank 
Biological Sample Venous blood, leukocyte Leukocytes Post-mortem brain, 
HIP, PFC tissue 
Purification of DNA 
extraction  
QIAamp DNA Blood Mini 
Kit 
QIAamp 
DNA Blood Mini Kit  
Not mentioned 
DNA methylation 
methods/ Kits 
Bisulfite conversion using 
EpiTech Bisulfite Kit, 
Pyrosequencing using the 
PSQ 96M System 
Bisulfite conversion using 
EpiTech Bisulfite Kit, 
Pyrosequencing using the 
PSQ 96M System 
Bisulfite conversion  
with a ZymoResearch 
bisulfite kit and 
Iminium Human 
Methylation 450 K 
bead arrays 
Candidate genes vs. 
genome  
BDNF SLC6A4. −479 and −350, 
7 CpG sites. 
Epigenome-wide.  
Selected genes for 
replication.  
Methylation Validation not mentioned not mentioned Pyrosequencing, 
Pyromark Q24 Kit 
Genotyping Yes No No 
Gene expression No No No 
Analytical method of 
methylation difference 
T-test and multivariate 
logistic regression models 
Association between 
methylation status and 
treatment outcome: 
Pearson's correlation tests 
Mann-Whitney U test 
Major findings Higher BDNF methylation 
was associated with 
depression and severe 
depressive symptoms. 
SLC6A4 methylation 
status as a marker for 
childhood adversities 
among MMD; but was not 
associated with treatment 
outcomes. 
11 genes in 
hippocampus and 20 
genes in prefrontal 
cortex revealed 
differential 
methylation. In 
replication, GRIN2A 
was found 
hypermethylated in 
both tissues and single 
CpG level. 
Category BDNF Treatment response Genome 
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ID 16 17 
First Author Kim Kim 
Year 2013 2013 
Country South Korea South Korea 
Age 64.5 ± 9.5 64.5 ± 9.6 
Sample Size 286 stroke patients at baseline, 222 
of which were followed-up for 1 
year. 
286 stroke patients at baseline (222 
of which were followed-up for 1 
year) 
Cases Poststroke depression (PSD), 80 with 
depression at baseline 
Poststroke depression (PSD); 
baseline: 80 any PSD, 32 major PSD. 
Follow-up: 53 any, 21 major. 
Diagnostic standard DSM IV (depression: major/ minor 
depressive disorder) 
DSM IV (depression: major/ minor 
depressive disorder) 
Controls  Not applicable Not applicable 
Study design Longitudinal, followed-up for 1 year 
after stroke.  
Longitudinal, followed-up for 1 year 
after stroke 
Cohorts  Post-stroke cohort, hospitalized  Post-stroke cohort, hospitalized  
Biological Sample Venous blood, leukocytes Venous blood,  leukocytes 
Purification of DNA extraction  QIAamp DNA Blood Mini Kit QIAamp DNA Blood Mini Kit 
DNA methylation methods/ 
Kits 
Bisulfite conversion using EpiTech 
Bisulfite Kit, Pyrosequencing using 
the PSQ 96M System 
Bisulfite conversion using EpiTech 
Bisulfite Kit, Pyrosequencing using 
the PSQ 96M System 
Candidate genes vs. genome  BDNF promoter region. Between -
694 and -577, 7 CpG cites. 
SLC6A4 promoter region between -
479 and -350, including 7 CpG sites. 
Methylation Validation not mentioned not mentioned 
Genotyping Yes Yes 
Gene expression No No 
Analytical method of 
methylation difference 
Multivariate logistic regression 
model 
Multivariate logistic regression 
model 
Major findings Prevalent, persistent, and incident 
PSD have higher BDNF methylation 
status. CpG site 6 significantly 
associated with incident PSD.  CpG 
1,2,4 higher methylation. 
Higher SLC6A4 methylation status 
was independently associated with 
major PSD at both baseline and 
follow-up. 
  
Category BDNF SLC6A4 
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ID 18 
First Author Kim 
Year 2015 
Country South Korea 
Age 18-85 
Sample Size 969 Acute Coronary Syndrome (711 of which were 
followed-up). At baseline, 378 depressive disorder (255 
of which randomised to a 24-week trial) 
Cases Trail: 127 received escitalopram 
Diagnostic standard DSM IV (depression : major/ minor depressive disorder) 
Controls  Trail: 128 placebo, 123 conventional treatment  
Study design Longitudinal & random trial 
Cohorts  Korean Depression in ACS (K-DEPACS) study, 
hospitalized patients. 
Biological Sample Venous blood, leukocyte DNA 
Purification of DNA extraction  QIAamp DNA Blood Mini Kit 
DNA methylation methods/ Kits Bisulfite conversion using EpiTech Bisulfite Kit, 
Pyrosequencing using the PSQ 96M System 
Candidate genes vs. genome  BDNF exon VI ,  between -612 and -463 
Methylation Validation not mentioned 
Genotyping No 
Gene expression No 
Analytical method of methylation difference T-test and multivariate logistic regression models 
Major findings At baseline higher methylation percentage in MDD 
compared with no depressive. Higher BDNF methylation 
associated with prevalent depressive disorder at baseline 
and follow-up. 
Category BDNF 
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ID 19 
First Author Kimmel 
Year 2016 
Country USA 
Age 30.68 ± 6.32; 33; 32.7 ± 0.018 
Sample Size  3 prospective cohort (two cohorts -women with previous 
diagnoses of mood disorder; one cohort -psychiatrically 
healthy women): 51/61/240, postpartum depression. 
Cases Not applicable 
Diagnostic standard DSM-IV 
Controls  Not applicable 
Study design cohort 
Cohorts  The Women's Mood Disorders Centre, Gene Expression 
Omnibus (GEO), and Franconian Maternal Health 
Evaluation Studies (FRAMES) 
Biological Sample Blood 
Purification of DNA extraction  Not mentioned 
DNA methylation methods/ Kits Bisulfite conversion by EZ DNA Methylation Gold Kit 
and pyrosequencing using PyroMark MD system 
Candidate genes vs. genome  OXTR 
Methylation Validation Not mentioned 
Genotyping Yes 
Gene expression Yes 
Analytical method of methylation difference Linear regression 
Major findings A PPD specific DNA methylation negatively correlates in 
the region with serum estradiol levels. Estradiol levels and 
OXTR DNA methylation exhibited a significant 
interaction to associate with the ratio of allopregnanolone 
to progesterone. 
Category OXTR 
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ID 20 21 
First Author Kleimann Na 
Year 2015 2014 
Country German Korean 
Age 47 ± 16.5 cases: 41.60 ± 11.8; 
controls: 40.72 ± 14.20 
Sample Size 11 patients, treatment-resistant MDD (4 
in remission, 6 in response) 
117 
Cases Not applicable 45 (11 males/ 34 females) 
Diagnostic standard DSM IV DSM IV, Anis I 
diagnosis 
Controls  Not applicable 72 (21 males/51 females) 
Study design Perspective study Case-control 
Cohorts  not mentioned Hospital outpatient 
Biological Sample Whole EDTA blood Peripheral blood 
Purification of DNA extraction  QIAamp DNA Blood Mini Kit EZ DNA Methylation-
Gold kit 
DNA methylation methods/ Kits Bisulfite convertion using EpiTect 
Bisulfite Kit, PCR and sequencing using 
BigDye Terminator Cycle Sequencing 
Kit 
Bisulfite conversion, 
pyrosequencing, using 
PyroMark ID system 
with the Pyro Gold 
reagents kit 
Candidate genes vs. genome  BDNF promoter exon I, IV, VI. NR3C1 promoter, 5 CpG 
sites  
Methylation Validation not mentioned not mentioned 
Genotyping No No 
Gene expression No No 
Analytical method of methylation 
difference 
Mixed linear models Analysis of covariance 
(ANCOVA) 
Major findings Remitters had a significantly lower mean 
promoter methylation rate than non-
remitters, especially exon I. 
MDD had significantly 
lower methylation than 
healthy controls at 2 CPG 
sites (CpG 3,4) 
Category Treatment response NR3C1 
 
  
 110 
 
 
ID 22 23 
First Author Na Nantharat 
Year 2016 2015 
Country Korea Thailand 
Age cases: 42.52 ± 11.42; controls: 40.34 ± 
13.94 
cases: 48.63 ± 8.43; 
controls: 48.00 ± 12.08 
Sample Size 130 62 
Cases 65 (11 males/ 54 females) recurrent 
MDD 
29 (9 males /20 females) 
Diagnostic standard DSM IV, Anis I diagnosis diagnosed by psychiatrists 
Controls  65 (15 males/ 50 females) 33 (7 males /26 females) 
Study design Case-control case-control 
Cohorts  Hospital based hospital based  
Biological Sample Peripheral blood samples Peripheral blood samples 
Purification of DNA extraction  Not mentioned Illustrate  blood genomic 
Prep Mini Spin Kit 
DNA methylation methods/ Kits Bisulfite conversion, pyrosequencing, 
using PyroMark ID system with the 
Pyro Gold reagents kit 
Bisulfite pyrosequencing. 
PyroMark LINE-1 kit 
Candidate genes vs. genome  BDNF promotor region at 4 CpG sites 
(CpG1 = − 675, CpG2 = − 682, CpG3 
= − 686, and CpG4 = − 688) 
NR3C1 promoter, 7 CpG 
sites. 
Methylation Validation not mentioned Sodium bisulfite treatment 
using the EpiTect Bisulfite 
Kit 
Genotyping Yes No 
Gene expression No Yes 
Analytical method of methylation 
difference 
General linear model Unpaired t-test 
Major findings Patients with MDD had significantly 
higher rates of methylation at CpG2 
and CpG4 than healthy controls. No 
difference in naïve or on-medication 
patients. 
Higher methylation levels 
at CpG 7 in MDD in 
female but no in male.  
Category BDNF; treatment response NR3C1 
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ID 24 25 
First Author Okada Philibert 
Year 2014 2008 
Country Japan USA 
Age cases: 40.3 ± 10.3; controls: 40.3 ± 
10.5 
males: 42.4 ± 8.5; females: 38.8 ± 
6.8 
Sample Size 100 192 (96 males /96 females) 
Cases 50 (27 males/ 23 females) Not applicable 
Diagnostic standard DSM IV AAGA-II, DSM IV. Lifetime and 
current MD. 
Controls  50 (27 males/ 23 females) Not applicable 
Study design Case-control. Of 50 patients, 40 
were followed-up for 6 weeks after 
treatment. 
Longitudinal study 
Cohorts  Control recruited by advertisement Adoptees from Iowa Adoption 
Studies (IAS). 
Biological Sample Peripheral blood Lymphoblast cell lines 
Purification of DNA extraction  DNeasy Blood and Tissue Kits DNA was prepared for the cell lines 
using cold protein precipitation 
DNA methylation methods/ Kits Bisulfite conversion using EZ DNA 
methylation kits; analyzed using a 
Mass ARRAY Compact System; 
methylation ratios were calculated 
using EpiTYPER software. 
Bisulfite conversion, methylation 
ratios calculated by using a 
MassARRAY 
Candidate genes vs. genome  SLC6A4 , 81 CpG SLC6A4, 71 CpG residues 
Methylation Validation not mentioned not mentioned 
Genotyping Yes Yes 
Gene expression No Yes 
Analytical method of 
methylation difference 
Mann-Whitney U test for 
methylation differences; Wilcoxon 
signed-rank test for antidepressant 
treatment 
ANOVA 
Major findings Unable to distinguish between 
healthy controls, or between 
unmedicated patients and medicated 
patients No significant difference 
between unmedicated patients and 
healthy controls at any CpG unit. 
Pre-treatment methylation rate 
(CpG3) of SLC6A4 is associated 
with therapeutic responses to 
antidepressants in unmedicated 
patients with MD. 
There is a trend to higher 
methylation with lifetime history of 
major depression, compared with 
alcohol dependence. 
Category SLC6A4; treatment response SLC6A4 
 
 112 
 
 
ID 26 27 
First Author Sabunciyan Tseng 
Year 2012 2014 
Country USA Taiwan 
Age cases: 44.6 ± 10.6; controls: 48.2 ± 
10.5 
Severe MDD patients: 45.9±13.2; 
remitted MDD: 49.2±13.2; controls: 
48.3±11.1 
Sample Size Pilot 65, blood 60,  Replication 29 74 
Cases Pilot 39; blood 30; replication 16 49 (24 severe MDD, 25 remitted 
MDD) 
Diagnostic standard DSM IV DSM IV   
Controls  Pilot 26; blood 30, replication 13 25 
Study design Pilot-validation-replcation (brain, 
blood)  , 17 regions for validation 
Age-gender matched case-control, 4 
compare group 
Cohorts  Donated by the Stanley Medical 
Research Institute 
not mentioned 
Biological Sample Postmortem frontal cortex; 
lymphoblastoid cell lines; 
postmortem brain 
Peripheral leukocytes, 
Purification of DNA extraction  MasterPure DNA Purification kit not specified ("a commercial kit") 
DNA methylation methods/ Kits CHARM assay platform ELISA-based for global DNA 
methylation profiling. MethylFlash 
methylated DNA quantification kit 
(for 5-mc), MethylFlash 
hydroxymethylated DNA 
quantification kit (for 5-hmc) 
Candidate genes vs. genome  Genome-wide. 17 regions for 
validation 
Genome wide, 5-hmc and 5-mc 
levels 
Methylation Validation Bisulfite pyrosequencing: Epitect 
Kit 
not mentioned 
Genotyping No No 
Gene expression Yes No 
Analytical method of 
methylation difference 
T-test Two-tailed t-test 
Major findings PRIMA1 significantly increased 
methylation in MDD in pilot, but not 
in replication. 
Lower levels of 5-hmc and 5-mc in 
severe MDD than controls; no 
difference among severe and 
remitted patient. 
Category Genome Genome 
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ID 28 29 
First Author Zhang Zill 
Year 2015 2012 
Country China German 
Age MDD+suicide 14-71 
(36.8±10.2); MDD 13-70 
(35.3±11.0) 
cases: 21-76 (45.8 ± 14.3); controls: 19-73 
(46.2 ± 14.2) 
Sample Size 125 162 
Cases 50 (23 males /27 females) MDD 
+ suicide 
81 (30 males/ 51 females) 
Diagnostic standard DSM IV DSM IV 
Controls  75 (35 males /40 females) MDD 81 (40 males/ 41 females) 
Study design Case-control Case-control 
Cohorts  Hospital outpatient Cases from inpatients; controls from 
general population 
Biological Sample Venous blood Peripheral leukocytes.  
Purification of DNA 
extraction  
Wizard Genomic DNA 
Purification kit 
Invisorb Blood Giga Kit 
DNA methylation methods/ 
Kits 
Bisulfite conversion, 
methylation-specific PCR 
Bisulfite conversion, PCR and sequencing,  
EpiTect Bisulfite Kit 
Candidate genes vs. genome  TPH2 Angiotensin Converting Enzyme (ACE) 
gene, CpG island -456 to -255, contains 25 
CpG sites, 24 sequencing 
Methylation Validation not mentioned Cycle sequencing: BigDye Terminator 3.1 
Cycle Sequencing Kit 
Genotyping Yes No 
Gene expression Yes No 
Analytical method of 
methylation difference 
Pearson's correlation coefficient 
test and Fisher's exact test 
Pearson's correlation coefficient test 
Major findings The TPH2 promoter was 
methylated in 36.0% of MDD + 
suicide patients, as compared 
with in 13.0% of MDD patients. 
Depressive patients showed a 
hypermethylation pattern at all CpG sites 
compared to healthy controls; 
Statistical significant differences at three 
CpG sites (1, 5, 12) and a trend for 
significance at 5 CpG sites (7, 10, 11, 13, 
21). 
Category others others 
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ID 30 31 32 
First Author Alt Guintivano Bell 
Year 2010 2014 2015 
Country Netherlands USA USA 
Age cases: 70.83 ± 16.04; 
controls: 72.67 ± 12.9 
30.6 Maternal age was matched 
Sample Size 12 93 with history of major 
depression or bipolar 
disorder 
545 
Cases 6, MDD without 
childhood abuse 
Not applicable 269 
Diagnostic standard DSM IV DSM-IV  Edinburgh Postnatal Depression 
Scale (EPDS) 
Controls  6 Not applicable 276 
Study design Matched case-control Longitudinal study; 
Discovery- replication 
Nested matched case-control 
Cohorts  Dutch Brain Bank not mentioned From a longitudinal study 
Biological Sample Post-mortem brain 
tissues 
Blood Whole blood  
Purification of DNA 
extraction  
QIAamp1 DNA Mini kit Not mentioned Not mentioned 
DNA methylation 
methods/ Kits 
Bisulphite conversion, 
pyrosequencing using 
PyroMark ID 
Illumina’s Infinium 
Human Methylation450 
Beadchip Kit 
Bisulfite conversion, 
pyrosequencing using 
PyroMark Gold Q24 
Candidate genes vs. 
genome  
GR promoter Genome wide OXTR (CpG site -934) 
Methylation 
Validation 
not mentioned Bisulfite conversion 
using EZ DNA 
Methylation Gold Kit, 
pyrosequencing using 
PyroMark MD system 
not mentioned 
Genotyping No No Yes 
Gene expression Yes No No 
Analytical method of 
methylation difference 
Mann-Whitney U-test Logistic regression Logistic regression 
Major findings No significant 
difference in 
methylation pattern 
between groups  
CpG methylation levels 
at two loci within the 
HP1BP3 and TTC9B 
genes were identified as 
biomarkers predictive of 
PPD. 
Methylation is not significantly 
associated with postpartum 
depression. 
Category NR3C1 Genome OXTR 
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ID 33 34 35 
First Author Byrne Chagnon Córdova-Palomera 
Year 2013 2015 2015 
Country Australia Canada Spain 
Age 31-63 >=65 Concordant pairs: 22-54 
(42.5±13); discordant pairs: 
20-50 (37±10.9); healthy 
pairs: 19-39 (30.3±7.3) 
Sample Size 24 pairs, 48 individuals  43 17 MZT pairs, 34 
individuals 
Cases 12 MZT pairs discordant for 
MDD  
19 (anxiety and/or 
depression) 
4 concordant & 6 
discordant pairs 
Diagnostic standard DSM IV DSM IV SCIDI-I 
Controls  12 MZT pairs concordant for 
no MDD 
24 7 healthy pairs 
Study design Case-control twin study case control case-control twin study 
Cohorts  Queensland Twin Registry Population-based ESA 
study (Survey on Elders' 
Health) 
General population-
based UB-Twin Registry 
Biological Sample White blood cells Saliva Peripheral blood DNA 
Purification of DNA 
extraction  
not mentioned Qiagen columns (DNA 
mini kit) 
Not mentioned 
DNA methylation 
methods/ Kits 
Bisulphite conversion, 
Illumina Human 
Methylation 450 BeadChip 
Bisulfite conversion, 
pyrosequencing using 
Pyromark 96, except for 
APOE analyzed on 
Illumina Beadchips 
Bisulfite conversion 
using Illumina Infinium 
HumanMethylation450 
Beadchip 
Candidate genes vs. 
genome  
Genome wide BDNF, OXTR, SLC6A4, 
APOE 
Genome wide 
Methylation 
Validation 
Replicate: EZ DNA 
methylation Kit 
not mentioned not mentioned 
Genotyping No Yes Yes 
Gene expression No No No 
Analytical method of 
methylation 
difference 
Two-sample t-test T-test, except for BDNF 
used Wilcoxon-
MannWhitney test 
Ranking analysis 
Major findings No overall difference in 
mean global methylation 
between case and controls; 
the difference in mean 
methylation was significant 
in females within discordant 
pairs, but not in male. 
BDNF & OXTR showed 
greater methylation in 
cases compared with 
controls; no difference 
with APOE and SLC6A4. 
Hypomethylation in 
WDR26 gene associated 
with a lifetime diagnosis 
of depression.  
Category Genome BDNF; SLC6A4; OXTR;  
others 
Genome 
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ID 36 37 
First Author Haghighi Haghighi 
Year 2015 2014 
Country USA USA 
Age Cases: 35.1 ± 11.8; controls: 36.9 
± 13.3 
cases: 47±17; controls: 52±17 
Sample Size 120 53 
Cases 61 25 depressed-suicide 
Diagnostic standard SCID-I & SCID-I non-patient 
version 
DSM IV 
Controls  59 28 
Study design Case-control Case-control 
Cohorts  not mentioned not mentioned 
Biological Sample Buffy coat Orbital ventral prefrontal cortex  
Purification of DNA 
extraction  
QIAamp DNA Blood Mini Kit Not mentioned 
DNA methylation 
methods/ Kits 
Bisulfite conversion by EpiTect 
Bisulfite Kit, pyrosequencing 
using PyroMark Q96 MD 
Bisulfite conversion using Illumina 
Infinium HumanMethylation27 
BeadChip 
Candidate genes vs. 
genome  
Main human LC-PUFA 
biosynthetic genes: Fads1, 
Fads2, ELovl5 
Genome-wide, 20493 CpG sites.  
Methylation Validation not mentioned Bisufite pyrosequencing: EpiTect 
Bisulfite kit; Selected sites validation 
(Eya2, Megf11, Lmna, Glud1, Erbb3, 
Slc18a2) 
Genotyping No No 
Gene expression No No 
Analytical method of 
methylation difference 
ANCOVA models ANOVA 
Major findings  MDD patients showed a lower 
methylation in Fads 2, but higher 
at  Elovl5.  
Increased age-related DNA 
methylation perturbations in 
prefrontal cortex in major depression 
suicide compared with nonpsychiatric 
controls. 
Category others Genome 
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ID 38 39 40 
First Author Kaminsky Melas Reiner 
Year 2014 2013 2015 
Country USA Sweden German 
Age not mentioned Cases 23-74; 
controls 21-74 
cases: 19-49; controls: 20-
52 
Sample Size not mentioned MAOA 174 85 
Cases Not applicable MAOA 82  43 female (42 MD, 
Dysthymia 1) 
Diagnostic standard DSM-IV DSM IV SCID-I & SCID-II 
Controls  not applicable MAOA 92 42 
Study design Longitudinal Case-control Case-control 
Cohorts  not mentioned From a population-
based longitudinal 
study 
Inpatients from medical 
center; controls from flyers 
& posters 
Biological Sample Whole blood Saliva Leukocyte DNA 
Purification of DNA 
extraction  
Not mentioned Not mentioned QIAamp DNA Blood Mini 
Kit 
DNA methylation 
methods/ Kits 
not mentioned Bisulfite-converted 
using EZ-96 DNA 
Methylation-Gold 
Kit, PCR and 
sequencing, 
EpiTyper software 
Bisulfite conversion using 
EpiTect Bisulfite Kit, PCR 
and sequencing using 
BigDye Terminator v3.1 
Cycle Sequencing Kit 
Candidate genes vs. 
genome  
HP1BP3 and TTC9B MAOA OXTR exon 1 and 2 
Methylation Validation not mentioned not mentioned not mentioned 
Genotyping No Yes Yes 
Gene expression No No No 
Analytical method of 
methylation difference 
not mentioned Non-parametric 
statistical analyses 
Linear mixed effect model 
Major findings HP1BP3 and TTC9B 
predicted PPD with an area 
under the receiver operator 
characteristic curve (AUC) of 
0.87. In a replication analysis, 
these biomarkers also 
functioned to segregate PPD 
status in women with 
depression during the 
antenatal period; however the 
prediction was in the opposite 
direction. 
Overall MAOA 
methylation levels 
were decreased in 
depressed females 
compared to 
controls.  
Depressed female patients 
had decreased OXTR 
exon1 DNA methylation 
compared to non-depressed 
women.  
Category others others OXTR 
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ID 41 42 
First Author Domschke Domschke 
Year 2014 2015 
Country German German 
Age 47.7±1.7 47.7±1.7 
Sample Size 94 MDD patients 94 MDD patients 
Cases Not applicable Not applicable 
Diagnostic standard CSID-I, BDI, and GAF CSID-I, HAM-D-21, BDI, and 
GAF 
Controls  Not applicable Not applicable 
Study design Cohort Cohort 
Cohorts  MDD patients MDD patients treated at the 
University 
Biological Sample Whole blood Whole blood 
Purification of DNA extraction  FlexiGene DNA Kit FlexiGene DNA Kit 
DNA methylation methods/ 
Kits 
Sodium bisulfite converted using 
EZ-96 DNA methylation Kit, PCR 
and sequencing using Big Dye 
Terminator 
Sodium bisulfite converted using 
EZ-96 DNA methylation Kit, PCR 
and sequencing using Big Dye 
Terminator 
Candidate genes vs. genome  9 CpG sites in the 5-HTT 
transcriptional control region 
upstream of exon 1A 
43 MAO-A CpG sites 
Methylation Validation As a control, commercially 
available fully methylated and fully 
non-methylated DNA were used in 
all experiments 
As a control, commercially 
available fully methylated and 
fully non-methylated DNA was 
used in all experiments 
Genotyping Yes Yes 
Gene expression No No 
Analytical method of 
methylation difference 
Linear regression Linear regression 
Major findings Hypomethylation of the 5-HTT 
transcriptional control region might 
impair antidepressant treatment 
response in Caucasian patients with 
MDD 
It is not suggested that MAO-A 
DNA methylation major influence 
on antidepressant treatment 
response. However, the CpG-
specific MAO-A gene 
hypomethylation might drive 
impaired antidepressant treatment 
response in females 
Category Treatment response Treatment response 
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ID 43 44 
First Author Cordova-Palomera Choi 
Year 2015 2015 
Country Spain Korea 
Age 22-65 Cases: 41.9±11.3; controls: 
41.2±13.9 
Sample Size 34 (17 MZ twin pairs) 113 
Cases Not applicable 60 
Diagnostic standard Brief Symptom Inventory 
(BSI) 
Hamilton Depression Rating 
Scale (HDRS-17), confirmed by 
SCID-I 
Controls  Not applicable 53 
Study design Twin study (zygosity of 
the pairs was examined) 
Case-control 
Cohorts  General population Patients from the outpatient 
psychiatric clinic; controls from 
community 
Biological Sample Peripheral blood Peripheral blood samples 
Purification of DNA 
extraction  
Not mentioned Not mentioned 
DNA methylation 
methods/ Kits 
Bisulfite conversion, bead 
array using The Illumina 
Infinium 
HumanMethylation450 
(450K) BeadChip 
Bisulfite conversion, 
pyrosequencing was performed 
on a PyroMark ID system using 
the Pyro Gold reagents kit 
Candidate genes vs. 
genome  
DEPDC7 BDNF promotor region at 4 CpG 
sites (− 675, − 682, − 686, and − 
688) 
Methylation Validation Bisulfate pyrosequencing 
& replication in MDD 
post-mortem cerebellum 
samples 
not mentioned 
Genotyping Yes No 
Gene expression No No 
Analytical method of 
methylation difference 
Linear regression model Two-sample t-test 
Major findings A hypomethylation of 
cg09090376 in a co-twin 
would associated with an 
increase in his/her 
depressive symptom score 
No significant differences in the 
BDNF DNA methylation status at 
the 4 CpG sites between MDD 
patients and healthy controls. 
Category others BDNF 
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ID 45 46 
First Author Hohne Khulan 
Year 2015 2014 
Country German Finland (Helsinki) 
Age 30-42 (34.35 ± 3.43) Cases: 64.0±2.9; controls: 
62.9±2.5 
Sample Size 116 166 
Cases 61 83 Men with early-life stress 
(ELS) 
Diagnostic standard Munich version of the Composite 
International Diagnostic Interview (M-
CIDI) 
Beck Depression Inventory 
(BDI) and BDI II 
Controls  55 83 Matched controls 
Study design Case-control Case control cohort 
Cohorts  From EDSP study - community sample From the Helsinki Birth 
Cohort Study (HBCS) 
Biological Sample Peripheral blood cells Peripheral blood 
Purification of DNA extraction  Puregene whole blood DNA-extraction 
kit 
QIAamp DNA Blood Maxi 
Kit 
DNA methylation methods/ Kits Bisulfite conversion, PCR and 
sequencing using EpiTYPER assay 
Bisulphite conversion, EZ 
DNA methylation kit, bead 
array using illumina 
methylation 450k beadchip 
and infinium chemistry 
Candidate genes vs. genome  Intro 7 of the KFBP5 gene (chr6:35, 
666, 288-35, 666, 763, hg18) 
Genome-wide 
Methylation Validation not mentioned Pyrosequencing using 
PyroMark Q24Gold reagents 
on a PyroMark Q24 
Pyrosequencer 
Genotyping Yes No 
Gene expression Yes No 
Analytical method of methylation 
difference 
Two-way ANCOVA Linear modelling using 
Limma and methyAnalysis 
package and t-tests 
Major findings Subjects with the TT genotype and a 
life-time history of MD had a 10% 
higher DNA methylation rate than 
healthy controls with the same FKBP5 
genotype. 
Hypomethylation was 
identified in association with 
depressive symptoms. 
Category others Genome 
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ID 47 48 
First Author Melas Olsson 
Year 2015 2010 
Country Sweden Australia 
Age not mentioned Adolocsents 
Sample Size 44 150 (83 males /67 females) 
Cases 17 25 
Diagnostic standard DSM, MDI CIS-R (clinical interview 
schedule - revised) 
Controls  27 125 
Study design Case control Case control 
Cohorts  From PART study Population representative 
sample form VAHCS 
Biological Sample Saliva Buccal cell 
Purification of DNA extraction  Not mentioned Not mentioned 
DNA methylation methods/ Kits Bisulfite-converted using EZ-96 DNA 
Methylation-Gold Kit, PCR and 
sequencing, EpiTyper software 
Bisulfite conversion, 
Sequenom MassARRAY 
EpiTyping 
Candidate genes vs. genome  MAOA, 7 CpG sites 799 bp CpG island 3' of the 
5HTT promoter 
Methylation Validation not mentioned Not mentioned 
Genotyping No Yes 
Gene expression No Yes 
Analytical method of methylation 
difference 
Linear regression; t-test for gender 
difference 
Logistic regression 
Major findings Subjects with a history of depression 
were hypomethylated compared to 
controls. Depressed females were 
hypomethylated, but no significant 
association in males; females were 
hypermethylated at the MAOA region 
compared to males. 
No association between 
depressive symptoms and 
either buccal cell 5HTT 
methylation or 5HTTLPR. 
Category others SLC6A4 
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ID 49 
First Author van der Knaap 
Year 2015 
Country Dutch 
Age 16.2±0.7 
Sample Size 954 
Cases Not applicable 
Diagnostic standard CIDI according to DSM-IV 
Controls  Not applicable 
Study design Cross-sectional and prospective cohort 
Cohorts  Adolescents from TRAILS - population-based 
Biological Sample Whole-blood samples 
Purification of DNA extraction  Not mentioned 
DNA methylation methods/ Kits Methylation levels analyzed using EpiTYPER method; 
bisulfite conversion using EZ-96 DNA Methylation 
Kit, followed by PCR 
Candidate genes vs. genome  NR3C1 & SLC6A4 
Methylation Validation Not mentioned 
Genotyping Yes 
Gene expression No 
Analytical method of methylation difference Logistic regression for diagnosis and linear regression 
for symptom scores 
Major findings NR3C1 methylation levels at NR3C1_1 were 
positively associated with the risk of a depressive 
disorder, and depressive symptom scores at follow-up, 
but became non-significant when accounting for the 
scores at baseline. SLC6A4 methylation levels were 
not associated with depression diagnosis, but were 
positively associated with depressive symptom scores 
at follow-up, and remained significant when 
accounting for the scores at baseline.  
Category NR3C1; SLC6A4 
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ID 50 
First Author Zhao 
Year 2013 
Country USA 
Age 55.1±2.8 
Sample Size 84 Monozygotic twin pairs (43 pairs were discordant for 
MDD) 
Cases Not applicable 
Diagnostic standard Beck Depression Inventory II (BDI II), Life and Current Major 
Depression by DSM-III-R 
Controls  Not applicable 
Study design Twin study 
Cohorts  Emory Twin Studies drawn from Vietnam Era Twin Registry 
Biological Sample Peripheral blood leucocytes 
Purification of DNA extraction  Not mentioned 
DNA methylation methods/ Kits Bisulfite conversion using EZ DNA methylation kit, 
pyrosequencing using PSQ96 HS System 
Candidate genes vs. genome  20 CpG dinucleotides in the promoter region of the SLC6A4 from -
213 to -69; 5-HTTLPR as confounder 
Methylation Validation Pyrosequencing assay on duplicate samples; Each experiment 
included non-CpG cytosines as internal controls; 
Unmethylated and methylated DNA as controls were added in 
each run.  
Genotyping Yes 
Gene expression No 
Analytical method of methylation difference Linear regression 
Major findings Variation in methylation level within the promoter region of 
the SLC6A4 is associated with variation in depressive 
symptoms. A 10% increase in mean DNA methylation level 
was associated with 4.4 increase in the difference in BDI 
scores. 
Category SLC6A4 
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ID 51 52 
First Author Bustamante Tadic 
Year 2016 2014 
Country USA Not mentioned 
Age cases: 49.6±10.6; controls: 50.3±13.8 44.9±12.7 
Sample Size 147 adults 39 MDD patients 
Cases 65 Not applicable 
Diagnostic standard Patient Health Questionnaire (PHQ-9) 
consistent with DSM-IV 
Hamilton Depression Rating 
Scale-21 
Controls  82 Not applicable 
Study design Case-control Cohort 
Cohorts  From Detroit Neighborhood Health 
Study 
Hospital patients treated for 
MDD 
Biological Sample Whole blood via venipuncture Whole blood 
Purification of DNA extraction  QIAamp DNA Blood Mini Kit & Life 
Sciences's Quickgene DNA Whole 
Blood Kit 
QIAamp DNA Blood Mini Kit; 
BioMek NX liquid handling 
system 
DNA methylation methods/ Kits Bisulfite conversion using EpiTect 
Bisulfite Kit, pyrosequencing using 
PyroMark Q24 Assay Design Software 
Bisulfite conversion, PCR and 
sequencing using BigDye 
Terminator v3.1 Cycle 
Sequencing Kit 
Candidate genes vs. genome  13 CpG sites within the promoter 
region of NR3C1 
13 CpG sites within the BDNF 
exon IV promoter 
Methylation Validation Pyrosequencing using PyroMark Q24 
Assay Design Software 2.0 
not mentioned 
Genotyping No No 
Gene expression Yes Yes 
Analytical method of methylation 
difference 
Independent samples t-test Linear mixed effect model 
Major findings MDD was not associated with DNA 
methylation in CpG sites 1-4 following 
FDR adjustment. DNA methylation 
was significantly lower over CpG sites 
5-13 in those with vs. without MDD. 
Antidepressant treatment did 
not significantly affect the 
methylation at BDNF promoter 
IV. 
Category NR3C1 Treatment response 
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ID 53 54 
First Author Nagy Oh 
Year 2015 2015 
Country Canada Australia, The Netherlands, UK; and 
Canada 
Age cases: 41.0±2.6; controls: 41.3±5.9 18-75 
Sample Size 121 260 
Cases 76 subjects who died by suicide 
with MDD 
133 (30 for prefrontal cortex; 103 for 
peripheral blood from MZ twins) 
Diagnostic standard DSM-IV DSM-IV 
Controls  45 subjects who died in accidents 
without axis I disorders 
127 (30 for prefrontal cortex; 97 for 
peripheral blood from MZ twins) 
Study design Case-control Case-control 
Cohorts  Brain samples obtained from 
Douglas-Bell Canada Brain Bank 
MZ twins from Australia, the 
Netherlands, and the UK; Prefrontal 
cortex samples from SMRI and QSBB 
Biological Sample Brain tissue Peripheral blood from monozygotic 
twins; brain prefrontal cortex, and 
germline (sperm) samples 
Purification of DNA 
extraction  
Qiangen QIAamp Not mentioned 
DNA methylation methods/ 
Kits 
Bisulfite converted using EpiTect 
Bisulfite kit, PCR and sequencing 
Bisulfite conversion, pyrosequencing 
using Gold Q96 Reagents and Pyromark 
Q24 
Candidate genes vs. genome  Genome wide Genome wide 
Methylation Validation High-resolution melting and 
bisulfite Sanger sequencing 
not mentioned 
Genotyping No No 
Gene expression Yes No 
Analytical method of 
methylation difference 
Mixed model regression and 
pairwise comparisons 
not mentioned 
Major findings Significant differences (decrease) 
in the methylation patterns 
specific to astrocytic dysfunction 
associated with depressive 
psychopathology 
Hypermethylated loci in the white blood 
cells of MDD twins; while the brain and 
the sperm showed higher proportions of 
hypomethylated regions in MDD patients 
compared with controls. 
Category Genome Genome 
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ID 55 
First Author Uddin 
Year 2011 
Country USA 
Age cases: 43.5±11.9; controls: 46.2±18.7 
Sample Size 100 
Cases 33 
Diagnostic standard Patient Health Questionnaire (PHQ-9) 
Controls  67 
Study design Case-control 
Cohorts  Subset of participants in the Detroit Neighborhood 
Health Study (DNHS) - community sample 
Biological Sample Whole blood 
Purification of DNA extraction  Not mentioned 
DNA methylation methods/ Kits Bisulfite conversion using EZ-96 DNA Methylation Kit, 
bead array using humanmethylation 27 (HM 27) DNA 
analysis beadchip 
Candidate genes vs. genome  Genome wide 
Methylation Validation Four technical replicates were included - duplicate 
samples of two randomly selected individuals and 
duplicate samples of the control human methylated and 
unmethylated DNA. 
Genotyping No 
Gene expression Yes 
Analytical method of methylation difference Functional annotation cluster analyses 
Major findings Uniquely unmethylated gene sets distinguished between 
those with versus without lifetime depression. Some 
processes (e.g. brain development, tryptophan 
metabolism) showed increased methylation in those 
with depression, whereas others (e.g. lipoprotein) 
showed decreased methylation. 
Category Genome 
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ID 56 57 
First Author Walker Osborne 
Year 2016 2016 
Country Scotland USA 
Age not mentioned 30.7 ± 6.3; 33; 32.7 ± 0.018 
Sample Size 29 291 
Cases Affected carriers of the linked 
haplotype (ALH=10; BD=5, 
MDD=5) 
51 High risk women 
Diagnostic standard Not mentioned Beck Depression Inventory and the 
Edinburgh Postnatal Depression Scale 
Controls  Unaffected carriers of the linked 
haplotype (ULH=10); unaffected, 
non-haplotype-carring married-in 
controls (Mis=9) 
240 Women without previous 
psychiatric diagnosis 
Study design Case-control Case-control 
Cohorts  Members of a large family multiply 
affected by BD and MDD 
From two prospective cohorts 
designed to study PPD and two 
cohorts where DNA was taken long 
after pregnancy. 
Biological Sample Blood Blood 
Purification of DNA 
extraction  
Nucleon BACC2 Genomic DNA 
Extraction Kit 
Not mentioned 
DNA methylation methods/ 
Kits 
Sodium bisulphite using the EZ-96 
DNA Methylation Kit, bead array 
using the Infinium 
HumanMethylation450 BeadChip 
Illumina Human Methylation 450 
(HM450) bead array  for 51 women 
with mood disorders (existing data); 
Bisulfite conversion pyrosequencing 
using PyroMark MD system for the 
rest of samples 
Candidate genes vs. genome  Genome wide Genome wide 
Methylation Validation not mentioned not mentioned 
Genotyping No No 
Gene expression Yes Yes 
Analytical method of 
methylation difference 
T-test Linear regression 
Major findings Nominally significant differences in 
DNA methylation were observed. 
For N=51, first trimester antenatal 
gene expression levels of HP1BP3 
and TTC9B predicted PPD status. For 
N=240, DNA methylation variations 
could predict PPD status.  
Category Genome Genome 
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CHAPTER 5 – PREDICTORS OF FUNCTIONAL IMPROVEMENT IN CHILDREN AND 
ADOLESCENTS AT A PUBLICALLY FUNDED SPECIALIST OUTPATIENT CLINIC 
 
A version of this chapter as a manuscript entitled “Predictors of functional improvement 
in children and adolescents at a publicly funded specialist outpatient treatment clinic in a 
Canadian Prairie City” authored by Li, Muzi; D'Arcy, Carl; Meng, Xiangfei, has been submitted 
online to Child and Adolescent Mental Health for publication review. 
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5.1 Abstract 
Objectives. Children’s mental health problems substantially impact their daily functioning. For 
children and adolescents we (1) document the impact of mental health treatment on functioning, 
and (2) identify predictors of functional improvement. 
Methods. Clinic anonymized data from a regional publicly funded specialist outpatient treatment 
clinic (N=645 children, ages 6-11 and 682 adolescents, ages 12-17) were analyzed. Outcome was 
assessed with the Child and Adolescent Functional Assessment Scale (CAFAS) - a global 
measure of impairment/functioning with eight domain subscales. Non-parametric tests were used 
to compare median scores at baseline and exit. Logistic regression was used to examine 
predictors of improvement. Comparisons between children and youth were conducted. A typical 
treatment cycle involves 8-12 sessions. 
Results. CAFAS Total Scores at exit showed a significant decrease from initial scores for both 
age groups, indicating that client functioning had improved. Initial level of dysfunction, length of 
treatment and the presence of pervasiveness of behavioural impairment (PBI) were shared 
predictors for functional improvement among in both age groups. Primary presenting problem, 
caregiver support and area of residence were only associated with outcome among children.  
Conclusion. Our findings clearly indicate that current mental health treatment significantly 
improved overall functioning in children and adolescents. Clients with a high initial level of 
dysfunction and PBI require longer treatment to reach an acceptable level of functioning. 
Shortening the length of treatment cycles may improve the efficiency of resource use but will be 
detrimental to some clients. Personalized treatment should be tailored to the specific 
characteristics and needs of clients. 
Key words: CAFAS, functional improvement, child and adolescent, outpatient treatment  
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5.2 Introduction 
Children’s mental health problems substantially impact their functioning in various 
aspects of life, especially social and cognitive development. Children with mental health issues 
tend to have a lower self-worth, negative feelings, poor performance in school, and be involved 
in unhealthy lifestyle later. Good mental health is as important as good physical health, and is 
essential for the individuals themselves and people surrounding them (Kids Mental Health, 
2015). 
Outpatient psychiatric treatment, as the most common form of treatment for children and 
adolescents, has been consistently found to be positive on psychiatric symptoms (Angold, 
Costello, Burns, Erkanli, & Farmer, 2000; Burns, Hoagwood, & Mrazek, 1999; Waddell, 
McEwan, Shepherd, Offord, & Hua, 2005). It contains a large number of therapeutic approaches, 
including individual and group psychotherapy, school-based services, therapeutic foster care, and 
focused family-support programs (Kazdin, & Weisz, 1998). A systematic review identified 
outpatient treatment as either “well-established” or “probably efficacious” treatment for such 
mental disorders as disruptive behaviour disorders, anxiety disorders, and autism (Burns etc., 
1999). A significant dose-response relationship was also found between the number of treatment 
sessions received and improvement in symptoms at follow-up. Eight or more sessions was 
suggested as being required to produce such positive effects (Angold etc., 2000). 
Studies have documented that the Child and Adolescent Functional Assessment Scale 
(CAFAS) is a useful tool for assessing degree of impairment in functioning (Boydell, Barwick, 
Ferguson, & Haines, 2005; Hodges, 2000). It is used to assess functioning of children and 
adolescents entering and exiting from the mental health care. It consists eight subscales: School, 
Home, Community, Behaviour Toward Others, Mood/Emotions, Self-Harm, Substance Use, and 
Thinking. Change in scores on CAFAS subscales is informative as it is important to know 
whether clients improve generally as well as in specific domains when exiting from treatment 
(Rohr, Bartlett, & Duncan, 2014). Complementary scales allow the assessment of caregiver 
resources, Family/Social Support and Material Needs subscales are used to examine the extent to 
which the clients’ functioning was disrupted due to limitations in the family’s psychosocial 
resources and caregiving ability. Having an impaired caregiving environment can decrease the 
probability of successful treatment outcomes (Xue, Hodges, & Wotring, 2004). 
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It is important to allow clinicians and health managers to know their clients, the 
effectiveness of their services in improving client functioning, and the factors that may affect the 
effectiveness of their services. It is also important to understand special needs for children and 
youth separately since they are at different development stages. Parents or caregivers play a large 
role in children’s life during their development of behaviours, social skills, cognition, and 
emotions that can affect their life-long health. Similarly, the transition from childhood to 
adulthood can further subject adolescents to a variety of psychological and social pressures. They 
experience puberty with both physical and emotional changes, including hair, breasts, 
establishing identity, etc. 
Studies have reported the wide use of the CAFAS scale in clinical settings, for instance, a 
province wide Ontario (Canada) study found a high reliability in the use of the scale in health 
practitioners 1 and 3-years after training (Barwick, Boydell, Cunningham & Ferguson, 2014). 
Another study of the scale indicated its usefulness in case formulation and in tracking changes in 
functioning over time (Boydell et al., 2005). However, little research can be found on whether 
different social-demographic and clinical characteristics are associated with changes in clients’ 
functioning (Walrath, Mandell, & Leaf, 2001). Knowledge of the predicators of functional 
change are important for clinicians, decision-makers, and administrators as they need to know 
what determinants are associated with better functioning improvements and apply personalized 
care towards clients’ needs improving mental health outcomes for all.  
This study aims to fill the information gap by answering the following questions: (1) 
were the CAFAS subscales good indicators for clients’ overall functioning impairment? (2) 
What, if any, changes occurred by the time clients exited treatment? (3) What factors were 
associated with improvement in client functioning? And, (4) are there any difference between 
children and youth in answers to the previous questions? 
These issues are explored using clinical data from a publicly funded specialized provider 
of a range of outpatient mental health treatment services for children and youth in a mid-sized 
Canadian prairie city. 
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5.3 Methods 
5.3.1 Context 
Though federally mandated, provincial governments in Canada take the responsibility of 
most health services delivered within their provinces with the services provided varying 
somewhat from province to province. These services include almost all hospital and physician 
services, prescription drug subsidies, a significant proportion of nursing home, community care 
services and preventive public health services. Saskatchewan is a prairie province in Canada. 
These public funded health services are available at no direct cost to the clients. Saskatoon is a 
city in central Saskatchewan. It is the largest city in the province with a population of 222,189 in 
2011. The Saskatoon Health Region (SHR) is the largest health region in the province, and about 
30% of the province’s population resides within the region’s geography. SHR is an integrated 
health delivery agency providing a comprehensive range of services and programs including 
hospital, long-term care, public health, home care, mental health and addition services, and 
prenatal and palliative care. In 2015 it served approximately 342,362 residents in urban and rural 
areas in central Saskatchewan (Saskatoon Health Region, 2015). 
Child and Youth Mental Health and Addictions Services (CYMHAS) is the major agency 
in the Saskatoon Health Region involved in the provision of a continuum of outpatient treatment 
services to children and youth (and their families) who require mental health treatment. Children 
and adolescents are generally referred for assessment and treatment from a variety of sources: 
parents, schools, health professionals, mental health centres, departments of juvenile justice, and 
social services. The common and over-arching treatments include Cognitive Behavioural 
Therapy, exposure therapies, play therapy, parent education, behavioural therapy, pet therapy, art 
therapy, and neuro-sequential model of therapeutics. Treatment modalities vary between 
clinicians and depend on the clients’ presenting concerns. 
The Child and Adolescent Functional Assessment Scale (CAFAS) was widely used as a 
functioning assessment tool within the CYMHAS during the study period. In general, the 
prototypical treatment cycle (episode) at the time was conceived as using the CAFAS at: an 
initial assessment, a 3-month assessment, a 9-month assessment, followed by an exit assessment. 
Some me patients can and do terminate treatment earlier than anticipated, whereas others 
continue the treatment over a longer time period. The CAFAS assessments are conducted by 
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social workers, counsellors, psychologists, etc. These clinicians do not prescribe medications. 
5.3.2 Population Studied - Data Source  
We analysed data for all those CYMHAS clients aged 6 to 17 years old, and enrolled for 
treatment between 2011 and 2014 for their first treatment episode (cycle). Those with incomplete 
records of initial and exit assessments were excluded from this study.  
The data was extracted and anonymised from individual client clinical (CAFAS) and 
administrative (Administrative and Management Information System, AMIS) data files. 
5.3.2.1 CAFAS 
The Child and Adolescent Functional Assessment Scale (CAFAS) consists of eight 
subscales (School, Home, Community, Behaviour Toward Others, Mood/Emotions, Self-Harm, 
Substance Use, and Thinking) and two caregiver resources sub-scales (Family/Social Support 
and Material Needs). Each of subscales is scored 0 to 30, indicating minimal/none to severe 
impairment. Higher scores indicated greater impairment. A Total Score is summed up by the 
scores from the eight subscales. The Total Score was further divided into five levels of 
dysfunction: 1 (scored 0 to 10) – no impairment; 2 (scored 20 to 40) – outpatient treatment; 3 
(scored 50 to 90) – additional services beyond outpatient care; 4 (scored 100 to 130) – more 
intensive than outpatient care and/or multiple sources of supportive care; and, 5 (scored 140 and 
above) – intensive treatment. 
5.3.2.2 AMIS 
CYMHAS’s AMIS – Administrative and Management Information System contains 
detail socio-demographic and some clinical data. It was matched with CAFAS data via clients’ 
unique identification number. However, due to a large proportion of missing values in youth age 
group, AMIS predictors were only used in the analysis of predictors of functioning and changes 
in functioning for the child age group.  
5.3.3 Measures 
5.3.3.1 Outcome 
We defined our outcome as the improvement in level of dysfunction between intake and 
exit, which was calculated by the following formula and coded as a dichotomous variable (1 = 
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with improvement, 0 = without improvement): 
Improvement in level of dysfunction = level of dysfunction at intake – level of dysfunction at exit 
5.3.3.2 Predictors 
Social demographic variables. Majority of the social demographic variables were 
retrieved from AMIS including information on living arrangement, area of residence, number of 
addresses, referral source, and parental involvement in capacity development. Information on age 
and gender was available and retrieved from the CAFAS dataset. 
Clinical variables. Information on primary presenting problem and number of presenting 
problems were obtained from the AMIS dataset. The CAFAS dataset provided client information 
on initial and exit CAFAS Total Scores and sub-scales scores, length of stay in treatment, number 
of episodes (treatment cycles), Pervasive Behavioural Impairment (PBI), which was defined as 
moderately or severely impaired on all three relevant subscales: School, Home, and Behaviour 
Towards Others (scored 30 or 20), caregiver resources – family/social support which assesses the 
extent to which the client’s functioning was disrupted due to limitations in the family’s 
psychosocial resources, and caregiver resources – material needs, which examined whether the 
client’s needs exceed the caregiver’s ability to provide. 
5.3.4 Statistical Analysis 
All the analyses were conducted separately for each age group – child (aged 6-11 years) 
and youth (aged 12-17). Children and youth are experiencing different developmental stages both 
mentally and physically, thus their mental health treatment needs are different. The cut-off point 
of age group is based on the definition of children and youth from the Centres for Disease 
Control and Prevention (CDC) (CDC, 2015). 
Descriptive analyses were used to understand clients’ characteristics. Confirmatory factor 
analyses (CFAs) were applied to test whether and to what extent the eight subscales were 
consistently predicting the overall level of dysfunction. Because the subscale variables were 
ordinal, CFAs were conducted using robust maximum likelihood estimation with the Satorra and 
Bentler (S-B) scaled chi-squared tests (Satorra, & Bentler, 1994). This adjustment for non-
normality also allowed us to obtain robust results for standard errors, p-values, confidence 
intervals, and goodness-of-fit statistics. Model fitting was evaluated by using the following fit 
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statistics: S-B chi-square, comparative fit index (CFI), Tucker Lewis Index (TLI), root mean 
square error of approximation (RMSEA), Akaike information criterion (AIC), and Bayesian 
Information Criterion (BIC). By convention, higher CFI and TLI values (≥ 0.90), and lower chi-
square values, RMSEA (≤ 0.08), AIC, and BIC values indicate better fit (Hu, & Bentler, 1998, 
1999).    
Because the subscale and total scores showed non-normality, non-parametric tests were 
used to gauge the changes in total and each subscale score and their significances. Higher 
CAFAS scores indicate more severe impairment. More negative differences were expected when 
comparing initial and exit scores. Asymptotic significances were used unless there were less than 
a total of 25 positive and negative differences, in which cases exact significances were 
employed. 
Multivariable logistic regressions were used to examine determinants associated with 
functioning improvement. Again, the goodness of fit was tested. Due to the large proportion of 
missing values (approximately 85%), AMIS variables were not included in the model for youth 
group and were analysed separately using chi-square tests. For the purpose of comparison of 
factors between children and youth, the model for child age group was assessed in two ways: 
AMIS variables included and not included. We used Stata 14 software (StataCorp, 2015) for all 
the analyses.  
5.4 Results 
5.4.1 Sample Description 
A total number of 1,327 children (645) and youth (682) met inclusion criteria and their 
data were included in the analysis. Table 5-1 presents the socio-demographic and clinical 
characteristics of the clients. Overall, the majority of the subjects lived in the West or Southwest 
of Saskatoon, lived with family of origin with one stable address, were referred by health 
professionals, families or guardians, or schools, had only one treatment episode (cycle), had 
mostly behavioural concerns or anxiety, received services for 15 months or less, did not have 
issues with regard to both caregiver resources (family support and material needs) and PBI, and 
had a Total Score of  90 or less at intake, indicating minimal to moderate level of dysfunction. 
Their caregivers were not involved in any parental capacity developmental programs.  
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Table 5-1 Population characteristics by age group (total number of cases may vary due to 
missing values) 
 Child (6–11 
years) 
Adolescent (12–17 
years) 
Total 
Categorical variables n Percent n Percent n Percent 
Gender 
Male 
Female 
 
392 
253 
 
60.8% 
39.2% 
 
296 
386 
 
43.4% 
56.6% 
 
688 
639 
 
51.8% 
48.2% 
Area of residence 
Northeast 
East Centre 
South 
Southwest 
North 
West 
Rural & Prince Albert 
 
67 
57 
71 
108 
80 
129 
65 
 
11.6% 
9.9% 
12.3% 
18.7% 
13.9% 
22.4% 
11.3% 
 
11 
15 
13 
11 
12 
30 
9 
 
10.9% 
14.9% 
12.9% 
10.9% 
11.9% 
29.7% 
8.9% 
 
78 
72 
84 
119 
92 
159 
74 
 
11.5% 
10.6% 
12.4% 
17.6% 
13.6% 
23.5% 
10.9% 
Number of addresses 
1 
2 
3+ 
 
456 
95 
26 
 
79.0% 
16.5% 
4.5% 
 
77 
12 
12 
 
76.2% 
11.9% 
11.9% 
 
533 
107 
38 
 
78.6% 
15.8% 
5.6% 
Living arrangement 
Family of origin 
Foster homes & other 
Not provided 
 
549 
39 
47 
 
86.5% 
6.2% 
7.4% 
 
99 
9 
8 
 
85.3% 
7.8% 
6.9% 
 
648 
48 
55 
 
86.3% 
6.4% 
7.3% 
Primary presenting problem 
Aggressive behavior 
Anxiety 
Relationship difficulties 
Cognitive difficulties 
Behavioral concern 
Traumatic events 
Depression 
Other 
 
59 
137 
33 
37 
176 
64 
44 
15 
 
10.4% 
24.2% 
5.8% 
6.5% 
31.2% 
11.3% 
7.8% 
2.7% 
 
12 
30 
4 
4 
28 
13 
13 
0 
 
11.5% 
28.8% 
3.8% 
3.8% 
26.9% 
12.5% 
12.5% 
0.0% 
 
71 
167 
37 
41 
204 
77 
57 
15 
 
10.6% 
25.0% 
5.5% 
6.1% 
30.5% 
11.5% 
8.5% 
2.2% 
Number of problems 
1 
2 
3+ 
 
195 
164 
206 
 
34.5% 
29.0% 
36.5% 
 
22 
38 
44 
 
21.2% 
36.5% 
42.3% 
 
217 
202 
250 
 
32.4% 
30.2% 
37.4% 
Referral source 
Professionals 
Client family/guardian 
Justice 
School 
Other 
 
204 
290 
12 
115 
14 
 
32.1% 
45.7% 
1.9% 
18.1% 
2.2% 
 
38 
55 
3 
16 
4 
 
32.8% 
47.4% 
2.6% 
13.8% 
3.4% 
 
242 
345 
15 
131 
18 
 
32.2% 
45.9% 
2.0% 
17.4% 
2.4% 
Initial total score 
Low (0 – 40) 
Medium (50 – 90) 
High (100+) 
 
354 
235 
56 
 
54.9% 
36.4% 
8.7% 
 
237 
318 
127 
 
34.8% 
46.6% 
18.6% 
 
591 
553 
183 
 
44.5% 
41.7% 
13.8% 
 PBI 
No 
Yes 
 
569 
76 
 
88.2% 
11.8% 
 
626 
56 
 
91.8% 
8.2% 
 
1,195 
132 
 
90.1% 
9.9% 
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 Child (6–11 
years) 
Adolescent (12–17 
years) 
Total 
Categorical variables n Percent n Percent n Percent 
Length of stay (month) 
0-3 
3-6 
6-9 
9-12 
12-15 
15-18 
18-21 
21-24 
24+ 
 
104 
128 
136 
77 
75 
41 
34 
22 
28 
 
16.1% 
19.8% 
21.1% 
11.9% 
11.6% 
6.4% 
5.3% 
3.4% 
4.3% 
 
242 
109 
185 
45 
52 
10 
21 
4 
14 
 
35.5% 
16.0% 
27.1% 
6.6% 
7.6% 
1.5% 
3.1% 
0.6% 
2.1% 
 
346 
237 
321 
122 
127 
51 
55 
26 
42 
 
26.1% 
17.9% 
24.2% 
9.2% 
9.6% 
3.8% 
4.1% 
2.0% 
3.2% 
Caregiver resources – Family 
support 
Minimal (0) 
Mild (10) 
Moderate (20) to Severe (30) 
 
 
386 
129 
102 
 
 
62.6% 
20.9% 
16.5% 
 
 
300 
173 
115 
 
 
51.0% 
29.4% 
19.6% 
 
 
686 
302 
217 
 
 
56.9% 
25.1% 
18.0% 
Caregiver resources – Material 
needs 
Minimal (0) 
Mild (10) 
Moderate (20) to Severe (30) 
 
 
570 
34 
10 
 
 
92.8% 
5.5% 
1.6% 
 
 
547 
34 
7 
 
 
93.0% 
5.8% 
1.2% 
 
 
1,117 
68 
17 
 
 
92.9% 
5.7% 
1.4% 
Number of treatment episodes 
1 
2 
3+ 
 
524 
100 
21 
 
81.2% 
15.5% 
3.3% 
 
565 
108 
9 
 
82.8% 
15.8% 
1.3% 
 
1,089 
208 
30 
 
82.1% 
15.7% 
2.3% 
Parental capacity development 
No 
Yes 
 
 
526 
109 
 
 
82.8% 
17.2% 
 
 
102 
14 
 
 
87.9% 
12.1% 
 
 
628 
123 
 
 
83.6% 
16.4% 
SD, Standard Deviation; PBI, Pervasive Behavioral Impairment 
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5.4.2 Contribution of CAFAS subscale scores to overall level of dysfunction at intake 
Figure 5-1 shows the relationship of subscales and level of dysfunction for children and 
adolescents. While all eight subscales were positively and significantly predicting children’s 
overall level of dysfunction. There was no statistically significant relationship for ‘Mood’ and 
‘Thinking Problem’ domains among adolescents. ‘School’, ‘Home’, and ‘Behaviour Towards 
Others’ subscales were top three domains that had the strongest impact to the overall level of 
dysfunction in both groups. ‘Mood’, ‘Self-Harm’, and ‘Substance Use’ subscales had the least 
impact on overall dysfunction score among children. ‘Substance Use’ subscale also had a 
relatively low association with youth’s level of dysfunction compared with other significant 
subscales. It is noteworthy that ‘Self-Harm’ subscale negatively predicted the overall level of 
dysfunction in youth.  
5.4.3 Difference in CAFAS Total Score between Initial and Exit Assessment 
Figure 5-2 graphs the differences in the distribution of Total Score at initial assessment 
and at exit for child and adolescent client populations separately. Clearly evidence is that 
substantial improvement has occurred for the majority of clients in both age groups. However, it 
is also evident that there is still a number of clients that remain substantially dysfunctional after a 
single treatment episode. It is also obvious that those with higher initial Total Score have a 
greater potential for improvement.   
CAFAS defines a clinically meaningful and reliable difference in Total Score 
(dysfunction) as a reduction in Total Score of 20 or more points. A client has to have score 20 or 
more at intake to be included in the analysis, 583 (out of 645) children and 645 adolescents (out 
of 682) qualified. Of those, 52% of children and 56% of adolescents were deemed to have made 
a clinically significant and meaningful change in functioning. 
  
  
 
 
Figure 5-1 Confirmatory factor analysis by age group 
 
CAFAS Subscales
School
Home
Community
Behavior 
Towards Others
Mood
Self-Harm
Substance Use
Thinking 
Problem
Child Group 
Level of 
Dysfunction 
Adolescent 
Group 
Level of 
Dysfunction 
0.89**
* 
*p<0.05; **p<0.01; ***p<0.001 
0.63**
* 
1
3
9
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Figure 5-2 Area graph of the distribution of initial and exit CAFAS Total Scores for both child 
and adolescent age groups 
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5.4.4 Difference in Total and Subscale Scores of CAFAS between Initial and Exit 
Assessments 
Non-parametric tests (sign tests) were used to compare the differences in total and 
subscale scores between initial and exit assessment for both children and adolescents (see Table 
5-2). The total score and seven of the eight subscale (except ‘Substance Use’) scores at exit 
elicited a statistically significant median decline in functioning impairment compared to initial 
assessment scores among children. ‘School’, ‘Home’, ‘Behaviour Towards Others’, and ‘Mood’ 
subscales showed more improvement. The exact significance test was used for ‘Substance Use’ 
due to the small number of negative and positive differences, and the p-value was 0.25. 
For adolescents, the total score and all the subscale scores at exit demonstrated a 
significant median decrease in functioning impairment, compared to initial assessment scores. 
‘Mood’ and ‘Self-Harm’ subscales declined more than other subscales.  
5.4.5. Predictors of Improvement in Level of Dysfunction among Children with All AMIS 
Variables Included In the Model 
There were 76.7% (495/645) children with completed records for all variables included in 
the model. Clients who had medium to high initial total score, no initial PBI, stayed 12 month or 
longer for the treatment, had a diagnosis of anxiety, relationship difficulties, and depression as 
primary presenting problems, and who lived in the north and northeast of Saskatoon and rural 
areas and Prince Albert (a neighbouring city) were more likely to have improvement in level of 
dysfunction (Table 5-3). 
 
  
  
 
 
Table 5-2 Median differences, total and subscale scores from entry to exit for children and adolescents (N=1,327) 
 Children (6-11 years, n=645) Adolescent (12-17 years, n=682) 
Negative 
differences 1 
(better) 
Positive 
differences 2 
(worse) 
Ties 3 Z score Negative 
difference 1 
(better) 
Positive 
difference 2 
(worse) 
Ties 3 Z score 
Total score 389 57 199 -15.7*** 457 96 129 -15.3*** 
School subscale 205 40 400 -10.5*** 187 63 432 -7.8*** 
Home subscale 207 23 415 -12.1*** 198 61 423 -8.5*** 
Community subscale 24 9 612 -2.4* 72 23 587 -4.9*** 
Behavior subscale 233 32 380 -12.3*** 168 49 465 -8.0*** 
Mood subscale 247 31 367 -12.9*** 301 47 334 -13.6*** 
Self-Harm subscale 60 10 575 -5.9*** 211 16 455 -12.9*** 
Substance subscale 3 0 642 0.250 a 83 49 550 -2.9** 
Thinking subscale 27 8 610 -3.0** 59 27 596 -3.3** 
1 Exit score < initial score; 2 Exit score > initial score; 3 Exit score = initial score; a Exact sign test was used 
*p-value<0.05; **p-value<0.01; ***p-value<0.001 
 
 
1
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Table 5-3 Comparison of predictors for improvement in level of dysfunction by age group 
 Child (AMIS 
variables included 
in the model) 
Child (Amis variables excluded) Adolescent (Amis variables 
excluded) 
Logistic regression 
Variable Categories OR (95% CI) OR (95% CI) OR (95% CI) 
Initial total 
score 
Low (0 – 40) 
Medium (50 – 90) 
High (100+) 
1 
4.3 (2.7 – 7.0)*** 
9.9 (3.1 – 31.9)*** 
1 
3.7 (2.5 – 5.4)*** 
5.8 (2.4 – 14.1)*** 
1 
2.4 (1.6 – 3.5)*** 
7.2 (3.5 – 14.9)*** 
Initial PBI Yes 
No 
1 
3.8 (1.5 – 9.7)** 
1 
1.6 (0.8 – 3.4) 
1 
3.1 (1.3 – 7.4)** 
Length of stay 
(month) 
0-3 
3-6 
6-9 
9-12 
12-15 
15-18 
18-21 
21-24 
24+ 
1 
2.0 (1.0 – 4.0) 
1.8 (0.9 – 3.6) 
2.1 (0.9 – 4.6) 
4.3 (1.9 – 9.5)*** 
4.4 (1.6 – 12.1)** 
4.0 (1.4 – 12.0)* 
1.9 (0.6 – 6.5) 
4.2 (1.4 – 13.1)* 
1 
1.5 (0.8 – 2.6) 
2.0 (1.1 – 3.6)* 
2.6 (1.3 – 5.1)** 
4.3 (2.2 – 8.5)*** 
4.4 (1.9 – 9.9)*** 
5.1 (2.1 – 12.8)*** 
1.6 (0.6 – 4.4) 
3.8 (1.5 – 9.9)** 
1 
1.4 (0.8 – 2.4) 
1.9 (1.2 – 2.9)** 
1.8 (0.9 – 3.6) 
2.6 (1.3 – 5.1)** 
6.9 (1.2 – 40.9)* 
5.6 (1.5 – 20.5)* 
1.2 (0.2 – 9.3) 
1.8 (0.5 – 6.1) 
Caregiver 
resources – 
Family support 
Minimal (0) 
Mild (10) 
Moderate (20) to 
Severe (30) 
1 
0.7 (0.4 – 1.1) 
1.0 (0.6 – 1.9) 
1 
0.5 (0.4 – 0.9)** 
0.6 (0.4 – 1.0) 
1 
0.9 (0.6 – 1.3) 
0.6 (0.4 – 1.0) 
Number of 
address 
1 
2 
3 or more 
1 
1.6 (0.9 – 2.8) 
1.7 (0.6 – 5.1) 
  
Primary 
presenting 
problem 
Behavioural concern 
Aggressive behaviour 
Anxiety 
Relationship difficulties 
Cognitive difficulties 
Traumatic events 
1 
2.0 (1.0 – 4.2) 
2.5 (1.4 – 4.4)** 
4.0 (1.6 – 10.0)** 
1.5 (0.6 – 3.6) 
1.4 (0.6 – 3.0) 
  
1
4
3
 
  
 
 
 Child (AMIS 
variables included 
in the model) 
Child (Amis variables excluded) Adolescent (Amis variables 
excluded) 
Depression 
Other 
3.1 (1.3 – 7.1)* 
1.7 (0.5 – 6.2) 
   Chi-square test 
   Not 
improved 
Improved Total Not 
improved 
Improved Total 
Area of 
residence 
West 
Northeast 
East Centre 
South 
Southwest 
North 
Rural & Prince Albert 
1 
2.4 (1.1 – 4.9)* 
1.7 (0.8 – 3.8) 
1.9 (1.0 – 3.9) 
1.1 (0.6 – 2.1) 
2.2 (1.1 – 4.5)* 
3.0 (1.4 – 6.6)** 
76 (58.9%) 
33 (49.3%) 
29 (50.9%) 
34 (47.9%) 
74 (68.5%) 
39 (48.8%) 
26 (40.0%) 
53 (41.1%) 
34 (50.7%) 
28 (49.1%) 
37 (52.1%) 
34 (31.5%) 
41 (51.2%) 
39 (60.0%) 
129 (100%) 
67 (100%) 
57 (100%) 
71 (100%) 
108 (100%) 
80 (100%) 
65 (100%) 
   
   Chi-square value: 18.3**    
PBI, Pervasive Behavioural Impairment; OR, odds ratio; CI, Confidence Interval; *p<0.05; **p<0.01; ***p<0.001 
 
  
1
4
4
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5.4.6 Comparison of Predictors between Children and Adolescents with AMIS Variables 
Analysed Separately 
Due to a large proportion of missing values of AMIS variables in the adolescent group, 
AMIS variables were excluded from model building process and were analysed separately by 
using chi-square tests. For the purpose of comparison, a model was also built for children 
without AMIS variables. In the regression models, 95.7% (617/645) of children and 85.8% 
(585/682) of adolescents with completed records of CAFAS variables were included in the 
analysis. Initial total score and length of stay were associated with the improvement in level of 
dysfunction for both groups, while initial PBI showed significant association only in the youth 
group and caregiver family support only in the children group. Children living in North, 
Northeast, South, and rural of Saskatoon and Prince Albert were more likely to improve their 
level of dysfunction at exit, whereas no significant differences were identified among 
adolescents. 
5.4.7 Comparison of predictors in children with and without AMIS variables included in 
the model 
The predictors of improvement in level of dysfunction were analysed via two different 
methods for children – including and not including AMIS variables in the model. Both methods 
indicated that initial total score, length of stay, and area of residence were significantly 
associated with the improvement in level of dysfunction. Initial PBI and primary presenting 
problem did not show significant impacts in the model without AMIS variables and separate chi-
square tests, respectively. Children had mild impairment on their caregiver family support initial 
score (10), were more likely to have a decreased level of dysfunction compared to those who had 
a minimal score (0) in the model with CAFAS variables only. 
5.5 Discussion 
This study evaluated the structure of the CAFAS as a tool assessing client functioning is a 
 146 
 
 
variety of aspects of life , examined the effectiveness of treatment offered by the Saskatoon 
Mental Health and Addiction Services, and identified the determinants of the desirable outcome. 
The CAFAS subscales values generally well predicted the overall level of dysfunction for both 
children and adolescents. The total and most of the subscales scores (except the ‘Substance Use’ 
in child group which as low to begin with) at exit significantly decreased compared to their 
initial scores, which means client functioning had been improved by the time they exited  
treatment. Common and unique characteristics were associated with functional improvements for 
both children and adolescents.  
Our finding is consistent with a report in which statistically significant declines in scores 
were observed for most of the subscales, while the ‘Substance Use’ subscale did not show 
significant results for either age groups (Rohr et al., 2014). A similar finding was also observed 
in children with serious emotional disturbances, indicating that significant functional 
improvement was found from baseline to 6-month assessment (Walrath et al., 2001). 
CAFAS scores have been reported as significant predicators of treatment and service 
utilization (Hodges & Wong, 1997; Bates, Furlong, & Green, 2006). Bates et al. (2001) in his 
review also pointed out the merit of the CAFAS used as a tool for making treatment eligibility 
decisions and documenting the outcomes.  
Pervasiveness of behavioural impairment (PBI) is one of the shared predictors for 
improvements in functioning among children and adolescents. This finding fits with the existing 
literatures. Pervasive behavioural problems was the strongest predictor of poor outcome for 
‘School’ and ‘Home’ domains, and social interactions (Xue et al., 2004). Loeber (1982) also 
demonstrated that cross-setting consistency was associated with greater stability of problems. 
Notably, we did not find the difference between children and adolescents with regard to 
their initial total score, PBI, and length of stay in treatment as predictors of improvement. The 
significance levels of ‘length of stay’ categories across the three models generally shows that the 
 147 
 
 
association between the improvement in level of dysfunction and length of stay was getting 
stronger with the increase of length of stay to a specific point in time (around 18-21 months) (see 
Table 3). However, staying longer than that in the treatment did not play a role in achieving a 
better outcome. 
Caregiver resources (family support), primary presenting problem, and area of residence 
were unique factors related to the improvement in functioning in the child age group. Children’s 
mental and psychological development may rely more on parents and caregivers than the 
adolescent age group do. Family’s psychosocial resources (family support), living environment 
and social economic status (reflected by area of residence) play greater roles in children’s mental 
health and their recovery from dysfunction in comparison to adolescents. 
5.5.1 Strengths and Limitations 
Although this is a prospective case cohort study using standardized assessment of 
functioning, few limitations should be noted. Firstly, our analysis was limited to clients’ first 
treatment cycle. We did not report on the predictors or effectiveness of treatment in subsequent 
treatment cycles. Secondly, data analysed here were limited to the variables already collected for 
standard administrative and clinical purposes. As a result we did not have enough information to 
include ethnicity and number of services/visits in the analysis. Nor did we have access to the data 
on whether or not these clients came back for subsequent treatment of similar problems or new 
emerging problems. Thirdly, the CAFAS was not administered to all clients with behavioural 
consults and children under 6 years old not attending school. Clients younger than 6 years old 
were generally not administered by the CAFAS. It was estimated that the CAFAS is administer 
to approximately 75-80% of all clients seen by Saskatoon Child and Youth Mental Health and 
Addictions Services. Finally, the analysis concerning predictors of functioning only dealt with 
clients who had completed their first treatment cycle (episode) using their initial and exit 
assessment records, which means in-process improvements were not considered (e.g. 3-month 
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and/or 9-month assessment). Also, there is potential selection bias in terms of only analyzing 
data on clients who stayed in treatment. We do not have information on those who left program 
with incomplete record. 
5.6 Conclusion 
Our findings provide robust evidence clearly indicating that current child and adolescent 
mental health services effectively improved clients’ functioning. Treatment does make a 
difference. Clients with a high level of dysfunction at intake and pervasive behavioural problems 
needed a longer period for treatment in order to reach favourable outcome. Shortening the length 
of each treatment cycle may improve the efficiency of resource use but at the expense of clients 
that need more time to achieve a more optimal functional improvement. Personalized treatment 
services is what is required. Further studies on predictors of functioning improvement using 
CAFAS data are warranted.  
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CHAPTER 6 – STIMULANT USE AND DEVELOPMENT OF BIPOLAR AFFECTIVE 
DISORDER: A 10-YEAR OUTCOME STUDY USING ADMINISTRATIVE HEALTH CARE 
DATA FILES OF REGULAR PRACTICE SETTINGS 
 
A version of this chapter will be submitted to an ADHD journal for publication review. 
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6.1 Abstract 
Introduction. There has been controversy concerning the use of stimulant medications, a 
standard treatment for attention deficit hyperactivity disorder (ADHD), and the development of 
bipolar affective disorder (BPAD). Previous studies on the subject have had various limitations 
suggesting a need for prospective, longitudinal investigations to better understand the 
relationship between stimulant use, ADHD, and development of BPAD. In regular practice does 
the treatment of ADHD patients with stimulants lead to BPAD?  
Method. Health administrative data for the Canadian province of Saskatchewan were 
used for a prospective cohort study. All children and adolescents aged 5 to 17 years of age who 
were diagnosed and treated for ADHD with stimulant medications during 1989-1990 comprised 
the inception cohort. These exposures were followed-up for 10 years to determine BPAD 
occurrence, and were matched with two age-gender-region of residence comparisons. A total of 
1,918 exposures and comparisons comprised the cohorts. Analyses used Penalized Maximum 
Likelihood Estimation.  
Results. Prescription of stimulants for ADHD was a significant risk factor of BPAD in 
unconditional analysis (OR 2.67, 95% CI 1.66-4.35). However, stimulant use became to be a 
protective factor for BPAD after adjusting for comorbid psychiatric disorders (OR 0.48, 95% CI 
0.24-0.98). 
Conclusion. The findings reflect the impact of the nature of the initial disease on further 
disease progression. This study, consistent with some previous research, indicates that stimulant 
use by itself does not lead to the development of BPAD but rather the severity of the initial 
disease is an indicator of future disease trajectory.  
 
Key words (3): ADHD treatment, stimulant medication, bipolar affective disorder 
(BPAD) 
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6.2 Introduction 
Prescription of psychotropic medications to treat psychiatric disorders in children and 
adolescents has steadily increased (Zito, et al., 2003) (Alessi-Severini, Biscontri, Collins, Sareen, 
& Enns, 2012). Anti-depressants and anti-psychotics are the most commonly used for pediatric 
population (Merikangas, He, Rapoport, Vitiello, & Olfson, 2013). 
Most recently, the dispensing of psychotropic drugs for mental health disorders has 
increased in North America. From 2010 to 2013 in Canada, prescription of anti-psychotics to 
children and adolescents increased 33% (from 34 to 45 prescriptions per 1000) and that of anti-
depressants raised 63% (from 34 to 55 per 1000) (Arora, et al., 2016). In Saskatchewan the 
prescription of anti-depressants for children and adolescents increased from 5.9 per 1,000 in 
1983 to 15.4 per 1,000 in 2007 (Meng, D’Arcy & Tempier, 2014). The number of prescriptions 
dispensed for depression also increased in adolescents from 2005 to 2014 in the United States 
(Mojtabai, Olfson, & Han, 2016). 
6.2.1 ADHD as A Common Mental Health Issue and Its Comorbidity 
Attention-deficit/hyperactivity disorder (ADHD) is one of the most common mental 
health disorders in children and adolescents, and is characterized by inattention, hyperactivity 
and impulsivity (Phelan, 1993) (Barkley, 1998). Diagnosis of ADHD can result in a range of 
adverse effects. Children with ADHD, compared with controls, are more impaired in reading, 
arithmetic achievement, repeating grades, needing extra help etc. Their family environments 
were also more impaired in terms of cohesion and conflict (Biederman et al., 1996a). 
Affective and conduct disorders are the most common comorbid diagnosis with ADHD 
(Cuffe, et al., 2001) (Thapar, Harrington, & McGuffin, 2001). Biederman et al. comprehensively 
reviewed comorbidity from a 4-year follow-up study and found that remission rates were higher 
for children with major depression, multiple anxiety disorders and conduct disorder (Biederman 
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et al., 1996b). In addition, the occurrence of anxiety disorders, major depression, bipolar 
disorder, and substance abuse disorders all increased from baseline to the end of the 4-year 
follow-up (Biederman et al., 1996a). 
Various studies have reported that children and adolescents with ADHD are at higher risk 
of subsequently developing Bipolar Affective Disorder (BPAD), and children with comorbidity 
of ADHD and BPAD appear to have an earlier onset of other illness compared to their 
counterparts who are not comorbid (Barkley, 1998; Faraone, Biederman, Wozniak, Mundy, 
Mennin, & O’Donnell, 1997). It also found that among a group of children who were all 
diagnosed with bipolar disorder on the basis of the presence of elation or grandiosity, prepubertal 
children who had ADHD along with BPAD, were significantly younger than those without 
comorbid ADHD (Geller, et al., 2000). 
6.2.2 Bipolar Affective Disorder (BPAD) 
Bipolar affective disorder (BPAD) is a serious psychiatric illness that is thought to occur 
in approximately 1% of children (Lewinsohn, klein, & Seeley, 1995). Those who develop 
Bipolar Disorder as children and young adolescents frequently have the low recovery and high 
relapse rates characteristic of adults with a severe form of the disorder (Geller, et al., 2001).  
Young individuals with BPAD often struggle with significant psychiatric co-morbidity, frequent 
suicide attempts, and poor family, peer, and educational functioning (Reichart, Nolen, Wals, & 
Hillegers, 2000). 
6.2.3 Stimulant Use and Concerns of Its Iatrogenic Effects 
Stimulant medications are prescribed primarily for the treatment of ADHD. The short-
term efficacy of stimulant medications (methylphenidate, dextroamphetamine and magnesium 
pemoline) in the treatment of ADHD has been well established (Sadock & Sadock, 1999) 
(Barkley, 1998) (Robin, 1998). Stimulant medication has been shown to have a robust and 
positive effect on academic performance in school, short term outcomes, ADHD symptoms and 
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quality of life, even though long-term studies with controls are warranted (Craig, Davies, 
Schibuk, Weiss, & Hechtman, 2015). 
However, stimulant use has been fraught with controversy both within professional 
circles and the public arena due to the possibility of iatrogenic effects. DelBello et al. (2001) 
have confirmed that prior treatment with stimulants is related to earlier age of onset of BPAD 
independent of ADHD.  It has also hypothesized that the very low rates of childhood bipolar 
disorder in The Netherlands is related to the low rates in that country of prescribing of stimulants 
and antidepressants to children (Reichart, Nolen, Wals, & Hillegers, 2000). 
On the other hand, more recent studies found that stimulant treatment in children and 
adolescents offers protection against the development of a range of psychiatric problems 
(Rasmussen, Palmstierna, & Levander, 2015) (Jain, Jain, & Islam, 2011). Biederman, 
Monuteaux, Spencer, Wilens, & Faraone (2009) in their longitudinal study reported that ADHD 
patients who received stimulant treatment were significantly less likely to subsequently develop 
depressive, disruptive behavior and anxiety disorders compared with those who were not treated 
with stimulants. 
The limits of previous studies on this topic have led to the need for prospective, 
longitudinal investigations in “real word settings” to better understand the relationship between 
stimulant use, ADHD, and development of BPAD. The purpose of this study is to determine 
whether there is an increased diagnosis of BPAD in children and adolescent treated with 
stimulants for ADHD and comorbidities in regular practice settings. 
6.3 Method 
6.3.1 Context 
Though federally mandated, provincial governments in Canada take the responsibility of 
most health services delivered within their provinces with the services provided varying 
somewhat from province to province. These services include almost all hospital and physician 
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services, prescription drug subsidies, a significant proportion of nursing home, and public health 
(Marchildon & O'Fee, 2007). There is a single payer for these health services. Saskatchewan is a 
prairie province in Canada. The Saskatchewan Health Care data files which record basic 
administrative, basic clinical and payment for services, were used for this study. These data files 
are a unique and comprehensive source of data on health care utilization of the population. 
Through the use of a unique identifier, they also allow for the tracking of the health utilization of 
individuals over time.  The value of these data files for epidemiological research has been well 
recognized (Rawson, D'Arcy, & Blackburn, 1992) (Strand & Downey, 1994).  These data files 
have been used for a range of important epidemiological studies (Spitzer, et al., 1992). 
Data from the Physician Services data file which tracks fee-for-service physician 
utilization and diagnoses; the Mental Health Services data file which tracks the use of 
provincially funded direct mental health services; the Hospital Services data file which tracks 
hospital stays and length of stay; and the Prescription Drug data file which tracks prescription 
drug usage used in this study. Linkage between the data files allowed for the development of 
individual patient profile through time.  A dummy-identified linked health use dataset was 
released for research purposes. 
6.3.2 Study Design 
This is a prospective cohort study which consist of all children and adolescents aged 5 to 
17 years of age who were diagnosed and treated for ADHD and/or prescribed a stimulant 
medication during the two year period January 1, 1989 to December 31, 1990. 
This exposure group was then followed up for a further ten years to assess the outcome of 
treatment for ADHD, particularly focusing on the occurrence of Bipolar Mood Disorder.  The 
follow-up period was from inception into the cohort to ten years or December 31, 2000. 
An age-gender-residence (Regional Health Authority - RHA) matched comparison group 
was also be picked.  Two comparisons were selected for each exposed subject.  Each comparison 
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was age-gender-RHA matched to each exposed subject but had not had a diagnosis or treatment 
for ADHD and had not been prescribed a stimulant medication during the inception and follow-
up period.  Those comparisons who during the follow-up period were diagnosed with ADHD 
and/or prescribed a stimulant were deleted from the study. 
6.3.3 Study Population 
A total number of 1,393 ADHD subjects and 2,786 matched comparisons were initially 
enrolled. Surprisingly, a significant number of those diagnosed with ADHD did not have a 
stimulant medication registered as being dispensed to them (753/1,393; 54.1%). In this study, we 
were only interested in subjects who were both diagnosed ADHD and prescribed and dispensed 
a stimulant medications during inception period, which is 45.9% (640/1,393) of all ADHD cases. 
Same matching strategies were applied to generate a subpopulation of exposures and 
comparisons for ADHD and stimulant use for this study. The inclusion criteria for exposures are 
a diagnosis of ADHD (DSM III-R 314.01) in the Physician Services or the Mental Health 
Services data files and prescription and dispensed a stimulant medication (methylphenidate, 
dextroamphetamine, or magnesium pemoline) in the Prescription Drug data file, during the 
period January 1, 1989 to December 31, 1990. 
Comparisons were age-gender-region matched individuals who received treatment during 
the inception inception period but were not prescribed stimulants during the period of the study 
from 1989 to 2000. Figure 6-1 shows a flowchart of the subject selection process. 
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Figure 6- 1 Flowchart of subject selection 
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6.3.4 Statistical Analysis 
Descriptive analyses were employed to understand demographic characteristics of the 
study population. 
Inference analyses were also conducted by using Penalized Maximum Likelihood 
Estimation (the Firth Method) which was designed for analyzing rare events with logistic 
regression (Williams, 2016). Two regression models were fitted: (1) Association between 
stimulant use, individual diagnosis of mental illnesses, and diagnosis of BPAD; (2) whether 
stimulant use and comorbidity of other psychiatric diagnoses with ADHD would increase the risk 
of diagnosis of BPAD. 
Variables in inference analyses were mainly the diagnoses of psychiatric disorders and 
prescriptions of psychotropic medications. The outcome variable was bipolar diagnosis (yes/no). 
Predictor variables in the first model were all dichotomous (yes/no), including ADHD diagnosis, 
conduct/anti-social diagnosis, other depression diagnosis, substance abuse, anti-depressant 
prescription, mood stabilizer prescription, anti-psychotic prescription, and other psychotropic 
prescription. The variable “comorbid ADHD” replaced individual comorbid diagnosis of mental 
illness in the second model and were coded into four categories: no diagnosis, ADHD only, other 
diagnosis without ADHD, and ADHD comorbid. 
6.4 Results 
6.4.1 Characteristics of Study Population 
A total number of 1,918 children and adolescents were included in the analysis. Of 
which, 640 (33.4%) had at least one stimulant prescription (exposure group), and 1,278 (66.6%) 
had no prescription stimulant medicines (comparison group) during the inception and follow-up 
period.  
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Table 6-1 presents the socio-demographic and clinical characteristics of the study population. 
Age, gender, and region of residence were proportionally distributed among subjects with and 
without stimulant use due to matching. The majority of the subjects had no diagnosis of BPAD, 
other depression, and substance abuse or prescription of psychotropic medications (anti-
depressant, mood stabilizer, anti-psychotic, or other psychotropic medications except stimulants) 
in exposure and comparison groups, respectively. However, more exposures (428/640, 66.9%) 
had been diagnosed conduct/anti-social disorder, while most comparisons had not (1,168/1,278, 
91.4%). Subjects prescribed stimulants were more likely to be diagnosed psychiatric disorders 
and be prescribed psychotropic medications. 
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Table 6-1 Characteristics of study population by exposure of stimulant use 
 No stimulant 
(n=1,278) 
Stimulant use 
(n=640) 
Total 
(N=1,918) 
P-
valuea 
Scale variables (Mean ± SD) 
Age at index (year) 9.7 ± 2.7 9.6 ± 2.7 9.7 ± 2.7 0.961b 
Categorical variables (n, %) 
Gender 
Male 
Female 
 
1,112 (87.0%) 
166 (13.0%) 
 
557 (87.0%) 
83 (13.0%) 
 
1,669 (87.0%) 
249 (13.0%) 
0.990 
Regional Health Authority (RHA) 
Sun County 
Five Hills 
Cypress 
Regina Qu’Appelle 
Sunrise 
Saskatoon 
Heartland 
Kelsey Trail 
Parkland 
Prairie North 
Mamawetan Churchill River 
Keewatin Yatthe 
 
54 (4.2%) 
51 (4.0%) 
26 (2.0%) 
148 (11.6%) 
29 (2.3%) 
716 (56.0%) 
76 (6.0%) 
36 (2.8%) 
92 (7.2%) 
38 (3.0%) 
2 (0.2%) 
10 (0.8%) 
 
27 (4.2%) 
26 (4.1%) 
13 (2.0%) 
74 (11.6%) 
15 (2.3%) 
358 (55.9%) 
38 (5.9%) 
18 (2.8%) 
46 (7.2%) 
19 (3.0%) 
1 (0.2%) 
5 (0.8%) 
 
81 (4.2%) 
77 (4.0%) 
39 (2.0%) 
222 (11.6%) 
44 (2.3%) 
1,074 (56.0%) 
114 (5.9%) 
54 (2.8%) 
138 (7.2%) 
57 (3.0%) 
3 (0.2%) 
15 (0.8%) 
1.000c 
Any ADHD diagnosis 
No 
Yes 
 
969 (75.8%) 
309 (24.2%) 
 
0 (0.0%) 
640 (100.0%) 
 
969 (50.5%) 
949 (49.5%) 
0.000c 
Death 
No death recorded 
Death recorded 
 
1,271 (99.5%) 
7 (0.6%) 
 
635 (99.2%) 
5 (0.8%) 
 
1,906 (99.4%) 
12 (0.6%) 
0.549c 
Any bipolar diagnosis 
No 
Yes 
 
1,248 (97.7%) 
30 (2.4%) 
 
601 (93.9%) 
39 (6.1%) 
 
1,849 (96.4%) 
69 (3.6%) 
0.000 
Any conduct/anti-social diagnosis 
No 
Yes 
 
1,168 (91.4%) 
110 (8.6%) 
 
212 (33.1%) 
428 (66.9%) 
 
1,380 (72.0%) 
538 (28.1%) 
0.000 
Any other depression diagnosis 
No 
Yes 
 
1,031 (80.7%) 
247 (19.3%) 
 
348 (54.4%) 
292 (45.6%) 
 
1,379 (71.9%) 
539 (28.1%) 
0.000 
Any substance abuse 
No 
Yes 
 
1,222 (95.6%) 
56 (4.4%) 
 
558 (87.2%) 
82 (12.8%) 
 
1,780 (92.8%) 
138 (7.2%) 
0.000 
Any anti-depressant prescription 
No 
Yes 
 
1,168 (91.4%) 
110 (8.6%) 
 
473 (73.9%) 
167 (26.1%) 
 
1,641 (85.6%) 
277 (14.4%) 
0.000 
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 No stimulant 
(n=1,278) 
Stimulant use 
(n=640) 
Total 
(N=1,918) 
P-
valuea 
Any mood stabilizer prescription 
No 
Yes 
 
1,240 (97.0%) 
38 (3.0%) 
 
573 (89.5%) 
67 (10.5%) 
 
1,813 (94.5%) 
105 (5.5%) 
0.000 
Any anti-psychotic prescription 
No 
Yes 
 
1,251 (97.9%) 
27 (2.1%) 
 
544 (85.0%) 
96 (15.0%) 
 
1,759 (93.6%) 
123 (6.4%) 
0.000 
Any other psychotropic 
prescription 
No 
Yes 
 
 
1,151 (90.1%) 
127 (9.9%) 
 
 
431 (67.3%) 
209 (32.7%) 
 
 
1,582 (82.5%) 
336 (17.5%) 
0.000 
ADHD and comorbidity 
No diagnosis 
ADHD only 
Other diagnosis without ADHD 
ADHD comorbid 
 
792 (62.0%) 
162 (12.7%) 
177 (13.9%) 
147 (11.5%) 
 
0 (0.0%) 
132 (20.6%) 
0 (0.0%) 
508 (79.4%) 
 
792 (41.3%) 
294 (15.3%) 
177 (9.2%) 
655 (34.2%) 
0.000c 
a Chi-square test was employed unless noted; b 2-tailed t-test; c Fisher’s exact test 
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Table 6-2 Predictors for diagnosis of Bipolar Affective Disorder 
Variable Unadjusted Model 1 Model 2 
OR (95% CI) OR (95% CI) OR (95% CI) 
Stimulant prescription 
Yes 
No 
 
2.67 (1.66-4.35)*** 
Reference 
 
0.57 (0.28-1.16) 
Reference 
 
0.48 (0.24-0.98)* 
Reference 
ADHD diagnosis 
Yes 
No 
 
4.94 (2.66-9.16)*** 
Reference 
 
1.48 (0.63-3.46) 
Reference 
N/A 
 
Other depression 
Yes 
No 
 
20.74 (10.04-42.81)*** 
Reference 
 
7.78 (3.52-17.22)*** 
Reference 
N/A 
 
Conduct/anti-social disorder 
Yes 
No 
 
3.72 (2.29-6.05)*** 
Reference 
n.s. N/A 
 
Substance abuse 
Yes 
No 
 
6.05 (3.50-10.46)*** 
Reference 
n.s. N/A 
 
Comorbidity 
ADHD only 
Other diagnosis without ADHD 
ADHD comorbid 
No diagnosis 
 
0.73 (0.12-4.47) 
6.30 (2.07-19.16)** 
13.49 (5.59-32.59)*** 
Reference 
N/A 
 
 
0.45 (0.07-3.05) 
2.63 (0.78-8.82) 
4.76 (1.60-14.23)** 
Reference 
Anti-depressant prescription 
Yes 
No 
 
17.13 (10.05-29.20)*** 
Reference 
 
4.02 (2.17-7.44)*** 
Reference 
 
5.17 (2.77-9.64)*** 
Reference 
Mood stabilizer prescription 
Yes 
No 
 
32.28 (19.00-54.83)*** 
Reference 
 
8.89 (4.79-16.52)*** 
Reference 
 
10.33 (5.56-19.20)*** 
Reference 
Anti-psychotic prescription 
Yes 
No 
 
13.53 (8.06-22.71)*** 
Reference 
 
2.65 (1.36-5.16)** 
Reference 
 
2.47 (1.27-4.80)** 
Reference 
Other psychotropic prescription 
Yes 
No 
 
3.65 (2.24-5.96)*** 
Reference 
n.s. n.s. 
OR, odds ratio; CI, confidence interval; n.s., not significant; *p<0.05; **p<0.01; ***p<0.001 
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6.4.2 Predictors for Diagnosis of Bipolar Affective Disorder (BPAD) 
In unconditional analysis, any psychiatric diagnoses significantly predicted the 
occurrence of BPAD (Table 6-2). The odds ratios (ORs) were: ADHD [OR 4.94, 95% confidence 
interval (CI) 2.66-9.16], other depression (OR 20.74, 95% CI 10.04-42.81), conduct/anti-social 
disorder (OR 3.72, 95% CI 2.29-6.05), and substance abuse (OR 6.05, 95% CI 3.50-10.46). It 
also shows that subjects diagnosed with psychiatric disorders without ADHD (OR 6.30, 95% CI 
2.07-19.16) and comorbid with ADHD (OR 13.49, 95% CI 5.59-32.59) were more likely to 
develop BPAD compared with those without any psychiatric diagnosis. 
Prescription of any psychotropic drugs, including stimulants, were also risk factors of 
development of BPAD. The odds ratios (ORs) were: stimulant (OR 2.67, 95% CI 1.66-4.35), 
anti-depressant (OR 17.13, 95% CI 10.05-29.20), mood stabilizer (OR 32.28, 95% CI 19.00-
54.83), anti-psychotics (OR 13.53, 95% CI 8.06-22.71), and other psychotropic medication (OR 
3.65, 95% CI 2.24-5.96). 
Two regression models were fitted to explore the association between stimulant use and 
the occurrence of BPAD: individual diagnoses of psychiatric disorders were included in Model 1; 
and these individual diagnoses were recoded and replaced by comorbidity in Model 2. 
Prescriptions of psychotropic medications were included in both models. 
In Model 1, stimulant use appeared to be a protective but non-significant factor for BPAD 
(OR 0.57, 95% CI 0.28-1.16) and the diagnosis of ADHD was a non-significant risk factor for 
BPAD (OR 1.18, 95% CI 0.63-3.46). The subjects with diagnosis of ‘other depression’ were 
almost 8 times more likely to develop BPAD compared with those without that diagnosis (OR 
7.78, 95% CI 3.52-17.22). The prescription of anti-depressant (OR 4.02, 95% CI 2.17-7.44), 
mood stabilizer (OR 8.89, 95% CI 4.79-16.52), and anti-psychotics (OR 2.65, 95% CI 1.36-5.16) 
also predicted BPAD. These associations were diminished compared with those in unconditional 
analysis due to the adjustment for all diagnoses of psychiatric disorders and psychotropic 
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prescriptions. Diagnosis of conduct/anti-social disorder, substance abuse, and ‘other 
psychotropic’ medications were not significantly related to BPAD. 
The redefined comorbid ADHD variable included in Model 2 showed that the subjects 
with comorbid ADHD were approximately 5 times more likely to develop BPAD than those 
without any psychiatric diagnosis (OR 4.76, 95% CI 1.60-14.23). In addition, prescription of 
stimulants demonstrated a protective effect on the future development of BPAD (OR 0.48, 95% 
CI 0.24-0.98). The prescription of anti-depressants (OR 5.17, 95% CI 2.77-9.64), mood 
stabilizers (OR 10.33, 95% CI 5.56-19.20), and anti-psychotics (OR 2.47, 95% CI 1.27-4.80) still 
positively predicted BPAD. 
6.5 Discussion 
Our study used population-based provincial administrative health care data files to 
investigate the association between prescription of stimulant medications for ADHD and 
subsequent onset of BPAD. We found that stimulant prescription had protective effects on the 
development of BPAD. In contrast, subjects with ADHD and comorbid for other psychiatric 
disorders and those prescribed anti-depressant, mood stabilizer, and anti-psychotic medications 
were at much greater risk of subsequently developing BPAD. 
6.5.1 Stimulant Use and BPAD 
Prescription of stimulants for ADHD was shown as a significant risk factor of BPAD in 
unconditional analysis. This is consistent with some studies indicating that prior treatment with 
stimulants is related to earlier onset of BPAD independent of ADHD (DelBello, et al., 2001). 
With adjustment for several specific psychiatric diagnoses and other psychotropic 
medications, stimulant use tended to be a protective factor for BPAD, although the association 
was not significant. However, this protective effect became significant when the redefined 
comorbid psychiatric disorder variable and the use of other psychotropic medications were taken 
into account. This is consistent with more recent studies among children and adolescents with 
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ADHD that showed stimulant treatment offers protection against the development of BPAD 
(Biederman, Monuteaus, Spencer, Wilens, & Faraone, 2009) (Gibson, 2009). 
6.5.2 ADHD and Comorbidity 
In unconditional analysis, the diagnosis of ADHD was found to be a risk factor of the 
development of BPAD but not when it was adjusted for the diagnosis of other psychiatric 
disorders and the dispensing of non-stimulant psychotropic medication. Our finding in 
unconditional analysis is consistent with previous studies (West, et al., 1995; DelBello, et al., 
2001). 
In model building, we found that subjects with ADHD and comorbid with other mental 
disorders were almost 5 times more likely to develop BPAD compared with those without any 
psychiatric diagnosis. Biederman, Newcorn, & Sprich (1991) proposed that “attention deficit 
hyperactivity disorder is most likely a group of conditions with potentially different etiologic and 
modifying risk factors and different outcomes rather than a single homogeneous clinical entity”. 
It was also claimed in a longitudinal study that children with comorbid diagnosis of ADHD and 
conduct disorder or major depression at baseline were more likely to develop bipolar disorder 
than those with ADHD alone and normal controls (Biederman et al., 1996a). 
We propose that ADHD is more likely to be persistent when it is comorbid with other 
psychiatric disorders. It has been confirmed that when combined with conduct problems, ADHD 
is a more severe genetic variant (Thapar, Harrington, & McGuffin, 2001). A longitudinal twin 
study was conducted and indicated that children with persistent ADHD had more mental health 
issues, including generalized anxiety disorder, major depressive episode, conduct disorder, and 
marijuana dependence (Agnew-Blais, et al., 2016). 
6.5.3 ADHD and Prescription of Other Psychotropic Medications 
Besides the prescription of stimulants, we found that use of other psychotropic 
medications, such as anti-depressant, mood stabilizer, and anti-psychotic, were also associated 
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with BPAD. These prescription drugs can be used for treatment of corresponding disorders or 
comorbidities, or can also be alternative options for better outcomes if symptoms of bipolar 
disorders have shown up. 
Many authors have called attention to the difficulty of distinguishing between ADHD and 
BPAD in children and adolescents (West, McElroy, Strakowski, Keck, & McConville, 1995) 
(Faraone S. V., Biederman, Mennin, & Russell, 1998) (Wozniak, Biederman, & Richards, 2001). 
This might be important, because it has been found that symptoms of ADHD were stabilized 
only in subjects whose mania was well treated (Wozniak, Biederman, & Richards, 2001) 
(Spencer, et al., 2001). Biederman, Russell, Soriano, Wozniak, & Faraone (1998) discovered no 
disadvantage to the use of adjunctive medication, such as selective serotonin reuptake inhibitors 
(SSRIs) and stimulants, to treat comorbid symptoms, but children did better if they received a 
mood stabilizer than an antidepressant or stimulant when symptoms of mania were present. 
6.5.4 Strengths and Limitations 
This study should be considered in light of several strengths and limitations. The first 
strength is that a large number of population exposure group from regular practice settings were 
analyzed. Second, the exposures and matched comparisons were followed-up for 10 years, which 
is sufficient for a longitudinal study on mental health outcomes to reasonably expect the 
occurrence of an outcome in question and to examine the association between the exposure and 
outcome, if it exists. 
Some limitations also need to be noted. First, limited information was provided from 
administrative data files. For example, only age, gender, and region of residence were recorded 
as socio-demographic characteristics. Additionally, since we do not have information on clients 
who were lost of follow-up leading to the possibility of some  selection bias. 
More details are needed to better understand the relationship between stimulant use and 
bipolar disorder, and to explore socio-demographic determinants of the outcome. More detailed 
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clinical information is also desired, such as diagnosis and severity of ADHD, number of 
hospital/physician’s visits, and number of comorbidity. These can be helpful describing the 
population under study, severity of disease, and identifying a dose-response relationship. Second, 
diagnoses can vary between general practitioners and specialists. One-time diagnosis or 
prescription might be the least severe cases, but can also be an error judgement. In this patient 
population, approximately 7.6% (55/728) were prescribed stimulant medications only once. 
Finally, Penalized Maximum Likelihood Estimation for logistic regression was applied for 
analysis due to low number of outcome events.  As a result, statistical model diagnosis was not 
available to examine the degree of model fit. 
6.6 Conclusion 
This study using administrative health data from everyday practice provides robust 
evidence that stimulant use in children and adolescents appears to be protective against the future 
development of bipolar disorder. In contrast, anti-depressant, mood stabilizer, and anti-psychotic 
use and the additional diagnoses of depression and comorbid ADHD are predictive of BPAD. 
The findings no doubt reflect the impact of the nature of the initial disease on further 
disease progression. Given the current controversies regarding the use of stimulant medications 
in children, this study indicates that stimulant use by itself does not lead to the development of 
BPAD but rather the severity of the initial disease itself and comorbidity serve as an indicator of 
the development of future disease.  
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CHAPTER 7 – CONCLUSION AND POLICY AND PROGRAM IMPLICATIONS 
Mental illness is a leading cause of disability in Canada (Mental Health Commission of 
Canada, 2014; Lim, Jacobs, Ohinmaa, Schopflocher, & Dewa, 2008). They account for nearly a 
quarter (23%) of Years of Life Lost (YLL) due to disability and 13% of YLL due to disability 
and premature mortality in Canada. It is estimated that 1 in 5 Canadians experiences a mental 
health or addiction problem every year (Smetanin, et al., 2011). 
Mental illness also causes a heavy economic burden. The costs in Canada were estimated 
at $51 billion per year, which included health care costs, lost productivity, and reductions in 
health-related quality of life (Lim, Jacobs, Ohinmaa, Schopflocher, & Dewa, 2008; Smetanin, et 
al., 2011). People with mental illness and addictions are more likely to suffer from comorbidity 
of other mental or chronic health conditions (Scott, et al., 2011). Conversely, depression and 
anxiety disorders may be a concomitant consequence of the burden of chronic diseases or 
conditions, such as long-term medical conditions and coronary heart disease (Patten, 2001; 
Frasure-Smith & Lesperance, 2005). 
In order to reduce the burden of mental and behavioral disorders, the World Health 
Organization (WHO, 2001) suggested that a public health approach would be the most 
appropriate method to respond to the multifaceted etiology, widespread stigma and 
discrimination, and significant treatment gap across the world. There are a number of actions that 
can be achieved, such as formulating policies, assuring universal access to mental health services 
(including health promotion and prevention), ensuring adequate care and protection of human 
rights, promoting healthy lifestyles and reducing risk factors, as well as enhancing research into 
the causes of mental disorders, the development of effective treatment, and the evaluation of 
mental health systems, etc. (WHO, 2001). 
The core of public health is the prevention of disease, particularly primary and secondary 
prevention. In order to prevent and intervene in the development of mental illness, knowledge of 
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its nature – risk factors, course and outcome – is needed. Prevention should not be harmful or 
iatrogenic. The treatment of some psychiatric conditions and population groups have been 
considered as carrying significant risks for iatrogenesis. 
Why Study Children and Adolescents? It is reported that 70% of mental health problems 
have their onset during childhood or adolescence (Government of Canada, 2006). Young people 
aged 15 to 24 are more likely to experience mental illness and/or substance abuse than any other 
age group (Pearson, Janz, & Ali, Statistics Canada Catalogue no.82-624-X, 2015). The usage of 
health services for mental illness among children and adolescents increased from 1996/97 to 
2009/10. In addition, a life course epidemiology links adult health and disease risk to physical or 
social exposures during gestation, childhood, adolescence, earlier in adult life, or across 
generations. Early life conditions and experiences, such as poverty, adverse experience, and poor 
early growth, may make individuals more susceptible to developing adult risk factors and/or 
chronic diseases. Therefore, the life course strategies for prevention of chronic conditions 
suggest intervening as early as possible before damage and disability set in (Factor-Litvak & 
Susser, A life course approach to chronic disease epidemiology, 2004). 
The primary goal of this thesis is to contribute to our understanding of mental health 
issues in children and adolescents by applying various epidemiological methods and data sources 
to provide a possible basis for future health prevention planning and policy decision-making. In 
this context, this thesis explores in separate chapters research targeting on primary and secondary 
prevention and potential iatrogenic effects on psychoactive medication use in children 
adolescents. Finally, the implications of this research for mental health policy and intervention in 
children and adolescents’ mental illness/health are identified. 
7.1 Major Findings of This Thesis 
At the primary prevention level in Chapter 3 of this thesis using systematic review and 
meta-analysis methods examined relationship between early childhood maltreatment and the 
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latter onset of depression and anxiety disorders and the potential for disease reduction if 
exposure to such risk factors was decreased. While the literature supports a strong relationship 
between childhood maltreatment and mental illness, most studies were cross-sectional and/or use 
recall to assess maltreatment and are thus prone to temporality and recall bias. In addition, 
research on the potential prospective impact of maltreatment reduction on the incidence of 
psychiatric disorders is scarce. Electronic databases and grey literature from 1990 to 2014 were 
searched for English-language cohort studies with criteria for depression and/or anxiety and non-
recall measurement of childhood maltreatment. Systematic review with meta-analysis 
synthesized the results. Study quality, heterogeneity, and publication bias were examined. Initial 
screening of titles and abstracts resulted in 199 papers being reviewed. Eight high-quality articles 
met eligibility criteria. Population attributable fractions (PAFs) estimated potential preventive 
impact. Physical abuse, sexual abuse, and neglect were found to all significantly increase the risk 
for depression and anxiety. The pooled odds ratio (OR) between any type of maltreatment and 
depression was 2.03 [95% confidence interval (CI) 1.37–3.01] and 2.70 (95% CI 2.10–3.47) for 
anxiety. For specific types of maltreatment and depression or anxiety disorders, the ORs were: 
physical abuse (OR 2.00, 95% CI 1.25–3.19), sexual abuse (OR 2.66, 95% CI 1.88–3.75), and 
neglect (OR 1.74, 95% CI 1.35–2.23). PAFs suggest that over one-half of global depression and 
anxiety cases are potentially attributable to self-reported childhood maltreatment. A 10–25% 
reduction in maltreatment could potentially prevent 31.4–80.3 million depression and anxiety 
cases worldwide. PAFs also suggest that over one-third of Canadian depression and anxiety cases 
are potentially attributable to childhood maltreatment. A large number of cases could potentially 
be prevented by reducing the exposure to maltreatment. This review provides robust evidence of 
childhood maltreatment increasing the risk for depression and anxiety, and reinforces the need 
for effective programs and policies to reduce its occurrence. 
Chapter 4 of this thesis also targeting primary prevention explores that epigenetic 
changes, especially DNA methylation changes that are generally associated with depression.  
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Studies have consistently found that genetic and psychosocial environment substantially 
contribute to the risk of depression (Saveanu & Nemeroff, 2012; Silberg, et al., 1999; Rice, 
Harold, & Thapar, 2001), although inconsistent findings were identified in different subgroups of 
candidate genes (e.g. BDNF, SLC6A4, NR3C1, OXTR, and others) and genome-wide studies. 
However, replications of these research findings have been hampered by phenotypic and genetic 
heterogeneities, even in large-scale genome wide association studies (Lewis, et al., 2010; Shi, et 
al., 2011; Akula, et al., 2010; Muglia, et al., 2010). It is now generally accepted that the 
pathogenesis of depression not only includes genetic, psycho-socio environmental factors, their 
interactions, but also involves epigenetic modifications, especially with altered DNA 
methylations, which have been identified as an etiological and diagnostic biomarker for many 
mental disorders in a number of studies (Dempster, et al., 2011; Fuchikami, et al., 2011; Walker, 
et al., 2016; Kaminsky, et al., 2012). Both genetic and environmental factors can affect the extent 
of DNA methylation. It may also integrate the impact of both genetic and environmental factors 
in the potential downstream functional outcomes on a phenotype (Lienert, et al., 2011; Schadt, 
2009).  
Gene expression and epigenetics. A number of gene have been putatively linked to major 
depression. A gene is a string of DNA encoding information and hiding in a cell’s nucleus. Gene 
expression refers to the process of synthesizing the information in a gene to produce functional 
gene products which can be proteins or non-proteins, such as transfer RNA (tRNA) or small 
nuclear RNA (snRNA). Gene expression consists from several steps, including transcription, 
RNA splicing, translation, and post-translational modification. Genes are expressed by being 
transcribed into message RNA (mRNA), and then be translated into protein via tRNA 
(Wikipedia, 2016). 
The regulation of gene expression is crucial to an organism’s development. It ensures the 
genetic information in DNA is properly interpreted and allows the genotype to give rise to 
organism’s phenotype. Genes can interact with and respond to organism’s environment. External 
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environmental factors or endocrine signals (Nguyen, Nioi, & Pickett, 2009) may cause 
modification of regulatory proteins (Paul, 2008) and intracellular signals (Los, Maddika, Erb, & 
Schulze-Osthoff, 2009), then further affect regulation of gene expression. 
Epigenetics refers to the external changes in a chromosome, which affects transcription 
and gene expression, and alters heritable phenotype. Epigenetic modifications of gene expression 
include alterations in DNA methylation – the addition of a methyl group which prevents certain 
genes from being expressed, and histone modifications (Dalton, Kolshus, & McLoughlin, 2014; 
Rettner, 2013; Ennis, 2014). Histones are proteins that DNA wraps around. Modifications that 
squeeze DNA tightly make the DNA cannot be “read” by the cell; on the contrary, relaxed 
histones can make the DNA accessible to be “read” (Rettner, 2013). Epigenetic modifications 
can be potentially caused by many outside stimulus from chemicals to lifestyle factors, such as 
Bisphenol A (BPA), exercise, and child abuse and other forms of early trauma (Ennis, 2014). 
DNA methylation is the most studied epigenetic modification, and can change the activity 
(turning genes “on” or “off”) of a DNA segment without change in the DNA’s sequence (Dalton, 
Kolshus, & McLoughlin, 2014). 
A number of systematic reviews on susceptible genes and gene by environment 
interactions provide a comprehensive list of putative genetic and environmental risk factors for 
major depressive disorder (MDD) (Levinson, 2006; Lohoff, 2010; Shyn & Hamilton, 2010; 
Saveanu & Nemeroff, 2012; Cohen-Woods, Craig, & McGuffin, 2013; Dunn, et al., 2015). 
However, there has been little compilation of our knowledge of DNA methylation and 
depression. Furthermore, there has been no comprehensive review of epigenetic studies in 
depression critically exploring experimental methodologies and verification of laboratory testing 
in humans, which may significantly affect the accuracy and validity of results.  
To fill this information gap, and provide critical update on the latest findings of DNA 
methylation in depression, we aimed to: 1) systematically synthesize major findings on DNA 
 177 
 
 
methylation and depression; 2) compare similarities and differences across different studies, 
including experimental and laboratory factors and statistical analyses, which might partially 
explain some inconsistencies of results; and, 3) comment on the challenges and opportunities for 
future studies. 
Electronic databases and grey literatures up to June 2016 were searched for English-
language studies with clear criteria for diagnosis of depression. Fifty-seven articles met our 
eligibility criteria and were included in this review along with a summary of study 
characteristics. We grouped the findings into etiological and treatment studies according to the 
following genomic attributes: (1) BDNF; (2) SLC6A4; (3) NR3C1; (4) OXTR; (5) other candidate 
genes; (6) genome-wide; and, (7) treatment response. Majority of the studies were recently 
published and from developed countries. Whole blood and saliva samples were the most studied 
common tissues. Bisulfite conversion, along with pyrosequencing, was widely used to test DNA 
methylation level across all studies. High heterogeneity existed among the studies in terms of 
experimental and statistical methodologies and study designs. Given such heterogeneity it is 
recommended that a systematic review without meta-analysis be undertaken. Inconsistent 
findings were identified in each study subgroup. Majority of the studies on BDNF (10/11) and 
nearly half of studies on SLC6A4 (5/11) showed that an increased DNA methylation was 
associated with depression. Significant (with both hyper- and hypo-methylation) and 
insignificant relationships were found in all other subgroups. However, this review generally 
supports the finding that DNA methylation changes are associated with depression. It is 
suggested that more longitudinal studies using standardized experimental and laboratory 
methodologies are needed in future epigenetic studies to enable more systematic comparisons 
and quantitative synthesis. 
In Chapter 5 the effect of early treatment of mental health and emotional problems in 
children and adolescent mental health problems in a publicly funded mental health treatment 
services is examined. Children and adolescents’ mental health problems substantially impact 
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their daily functioning. We sought to: (1) understand the impact of treatment in public mental 
health services had on functional improvement; (2) identify predictors of functional 
improvement in the various domains of children and youths’ lives; and (3) make suggestions 
regarding improving the effectiveness of services. 
Clinical data from the Child and Youth Mental Health and Addictions Services of 
the Saskatoon Health Region (N=645 children and 682 youths) for the year 2011-2014 
were examined. The outcome measure used was the established Child and Adolescent 
Functional Assessment Scale (CAFAS) - a global measure of impairment/functioning with 
eight domain subscales. Non-parametric tests were used to compare median scores at 
baseline and exit. Logistic regression models were fitted to examine predictors of 
improvement. Comparisons between children and youth were conducted. 
CAFAS Total Scores at exit form treatment showed a significant decrease from 
initial scores for both the child and adolescent age groups, indicating that client functioning 
had improved. Initial levels of dysfunction, length of treatment and pervasiveness of 
behavioural impairment (PBI) were shared predictors for functional improvement among 
all clients. Primary presenting problem, caregiver support and area of residence (west side 
of the City of Saskatoon) were associated with the outcome among children only.  
Our findings clearly indicate that current mental health services significantly 
improved child and adolescent functioning for most but not all clients. However, those 
with an initial high level of dysfunction and high PBI score require more treatment to reach 
an appropriate outcome. Shortening the length of each treatment cycle may improve the 
efficiency of resource use but can be detrimental to some clients. Personalized treatment 
should be tailored to the specific characteristics and needs of clients. 
Finally, in Chapter 6 the question of whether the use of stimulants to treat Attention 
Deficit and Hyperactivity Disorder (ADHD) has iatrogenic results in the development of 
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Bipolar Affective Disorder (BPAD) is examined in a 10-year outcome study using 
administrative health care data files of physicians in regular practice settings in the 
Province of Saskatchewan. There has been controversy in the literature concerning the use 
of stimulant medications, a standard treatment for ADHD, and the development of BPAD. 
Previous studies on the subject have had various limitations suggesting a need for 
prospective, longitudinal investigations of everyday practice to better understand the 
relationship between stimulant use, ADHD, and development of BPAD. In regular practice, 
does the treatment of ADHD patients with stimulants lead to BPAD?  
Health administrative data for the Canadian province of Saskatchewan were used for a 
prospective cohort study. All children and adolescents aged 5 to 17 years of age who were 
diagnosed and treated for ADHD with stimulant medications during 1989-1990 comprised the 
inception cohort. These exposure subjects were followed-up for 10 years to determine BPAD 
occurrence, and were matched with two age-gender-region of residence comparisons. A total of 
1,918 exposures and comparisons comprised the cohorts analyses used Penalized Maximum 
Likelihood Estimation.  
It was found that prescription of stimulants for ADHD was a significant risk factor of 
BPAD in unconditional analysis (OR 2.67, 95% CI 1.66-4.35). However, it became to be a 
protective factor for BPAD after adjusting for comorbidity of psychiatric disorders, particularly 
co-morbid depression. (OR 0.48, 95% CI 0.24-0.98). 
The study finding suggest findings that it is the impact of the nature of the initial disease 
rather than the use of stimulants that leads to progression of some initial exposure to Bipolar 
Disorder. This study, consistent with some previous research, indicates that stimulant use by 
itself does not lead to the development of BPAD but rather the severity of the initial disease is an 
indicator of future disease trajectory.  
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7.2 Policy Implications and Future Research 
The two systematic reviews in this thesis reveal the association between childhood 
maltreatment and epigenetics and the development of depression and/or anxiety. They reinforce 
the importance of life course strategies for prevention and the need for effective programs and 
policies to reduce the occurrence of mental illnesses. Pregnancy and early life experience and 
environment, which may lead to epigenetic changes, play an essential role in lifetime mental 
wellbeing. Decreasing the amount of maltreatment and other adverse experience in childhood 
and during pregnancy should be the target for mental illness prevention and mental health 
promotion. 
This thesis also indicates that current child and adolescent mental health services 
effectively improved most clients’ functioning. Severity of mental problems can affect the 
effectiveness of treatment. Shortening the length of each treatment cycle may improve the 
efficiency of resource use but at the expense of clients that need more time to achieve a more 
optimal functional improvement. Personalized treatment services are required to meet clients’ 
specific needs and maximize the cost effectiveness of services. 
Given the current controversies regarding the use of stimulant medications in children, 
this thesis indicates that stimulant use in children and adolescents appears to be protective 
against the future development of bipolar disorder. However, the severity of the initial disease 
itself and comorbidity serve as an indicator of the development of future disease. 
From a research perspective future epidemiological studies should be more linked to 
epigenetics and adopt longitudinal study designs to trace the change overtime. To allow for a 
systematic comparison of studies, an agreed upon consistent set of standards involving a 
minimum set for items for the execution and reporting of epigenetic studies is warranted. 
7.3 Conclusion  
There are four take-way messages from this research are that: 
 181 
 
 
1) Early childhood maltreatment is a significant causal factor in the development of future 
depression and anxiety, and that the incidence of depression and anxiety could be 
significantly reduced by reducing the prevalence of various types of childhood mal treatment. 
2) Alterations in gene expression (epigenetic events) can lead to increased risk of depression. 
Such epigenetic events can be the result of in utero exposure of fetus to a variety of negative 
stressors. 
3) Early treatment of mental health problems in children and adolescents is beneficial in 
increasing their positive functioning in and across life domains. Early intervention is likely to 
change the trajectory of disease progression. 
4) Stimulant medication used to treat children and adolescents for ADHD does not have 
negative (iatrogenic) effects leading to an increased risk of developing BPAD. 
The clear public health message is that early reduction in risk factor exposure in utero 
and in childhood and adolescence and the early treatment of mental health problems has a very 
positive effect in reducing the onset and further development of psychiatric disease and mental 
health problems. 
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